Altamira Therapeutics (CYTOF) 20-F 10 Apr 24 2023 FY Annual report (foreign) Financial data

Document And Entity Information

Document And Entity Information - shares	12 Months Ended
	Dec. 31, 2023	Apr. 05, 2024
Document Information Line Items
Entity Registrant Name	ALTAMIRA THERAPEUTICS LTD.
Trading Symbol	CYTO
Document Type	20-F
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		1,477,785
Amendment Flag	false
Entity Central Index Key	0001601936
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Entity Emerging Growth Company	false
Entity Shell Company	false
ICFR Auditor Attestation Flag	false
Document Registration Statement	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	001-36582
Entity Incorporation, State or Country Code	D0
Entity Address, Address Line One	Clarendon House
Entity Address, Address Line Two	2 Church Street
Entity Address, City or Town	Hamilton
Entity Address, Postal Zip Code	HM11
Entity Address, Country	BM
Title of 12(b) Security	Common Shares, par value USD 0.002 per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Document Financial Statement Error Correction [Flag]	false
Document Accounting Standard	International Financial Reporting Standards
Auditor Firm ID	1235
Auditor Name	Roland Mueller
Auditor Location	Zurich, Switzerland
Business Contact
Document Information Line Items
Entity Address, Address Line One	Clarendon House
Entity Address, Address Line Two	2 Church Street
Entity Address, City or Town	Hamilton HM11
Entity Address, Postal Zip Code	HM11
Entity Address, Country	BM
Contact Personnel Name	Thomas Meyer
City Area Code	+1 (441)
Local Phone Number	295 59 50

Consolidated Statement of Profi

Consolidated Statement of Profit or Loss and Other Comprehensive Income/(Loss)	12 Months Ended
	Dec. 31, 2023 CHF (SFr) SFr / shares	Dec. 31, 2022 CHF (SFr) SFr / shares	Dec. 31, 2021 CHF (SFr) SFr / shares
Income Statement [Abstract]
Other operating income	SFr 255,589	SFr 9,327
Research and development	(3,035,413)	(14,621,570)	(3,202,505)
General and administrative	(3,136,275)	(3,401,676)	(3,668,845)
Operating loss	(5,916,099)	(18,013,919)	(6,871,350)
Finance income	354,093	565,399	79,236
Finance expense	(1,668,475)	(1,211,042)	(14,112)
Share of loss of an associate	(39,557)
Loss before tax	(7,270,038)	(18,659,562)	(6,806,226)
Income tax gain/(loss)		7,919	117,945
Net loss from continuing operations	(7,270,038)	(18,651,643)	(6,688,281)
Discontinued operations:
Profit/(loss) after tax from discontinued operations	3,400,865	(7,876,768)	(10,370,162)
Net loss attributable to owners of the Company	(3,869,173)	(26,528,411)	(17,058,443)
Other comprehensive income/(loss):
Remeasurements of defined benefit liability, net of taxes of CHF 0	31,163	441,277	264,984
Items that are or may be reclassified to profit or loss
Foreign currency translation differences, net of taxes of CHF 0	208,848	61,046	772
Share of other comprehensive income of an associate	6,869
Other comprehensive income/(loss), net of taxes of CHF 0	246,880	502,323	265,756
Total comprehensive loss attributable to owners of the Company	SFr (3,622,293)	SFr (26,026,088)	SFr (16,792,687)
Loss per share
Basic loss per share (in Francs per share and Dollars per share) | SFr / shares	SFr (7.88)	SFr (582.58)	SFr (515.11)
Basic loss per share from continuing operations (in Francs per share and Dollars per share) | SFr / shares	SFr (14.8)	SFr (409.6)	SFr (201.97)

Consolidated Statement of Pro_2

Consolidated Statement of Profit or Loss and Other Comprehensive Income/(Loss) (Parentheticals) - CHF (SFr)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Remeasurements of defined benefit liability, net of taxes	SFr 0	SFr 0	SFr 0
Foreign currency translation differences, tax	0	0	0
Other comprehensive income/(loss), net	SFr 0	SFr 0	SFr 0
Diluted loss per share (in Francs per share) (in Francs per share)	SFr (7.88)	SFr (582.58)	SFr (515.11)
Diluted loss per share from continuing operations (in Francs per share)	SFr (14.80)	SFr (409.60)	SFr (201.97)

Consolidated Statement of Finan

Consolidated Statement of Financial Position	Dec. 31, 2023 CHF (SFr)	Dec. 31, 2022 CHF (SFr)
Non-current assets
Property and equipment	SFr 1	SFr 1
Right-of-use assets	80,110	445,827
Intangible assets	3,893,681	3,893,681
Other non-current financial assets	80,001	194,263
Investment in an associate	2,417,312
Total non-current assets	6,471,105	4,533,772
Current assets
Inventories		11,644
Trade receivables		6,525
Other receivables	74,823	755,987
Prepayments	283,832	709,266
Derivative financial instruments	247,090	270,176
Cash and cash equivalents	617,409	15,395
Total current assets	1,223,154	1,768,993
Total assets	7,694,259	6,302,765
Equity
Share capital	2,646	236,011
Share premium	20,102,873	192,622,406
Other reserves	4,399,200	258,044
Accumulated deficit	(18,046,002)	(201,431,272)
Total shareholders’ (deficit)/equity attributable to owners of the Company	6,458,717	(8,314,811)
Non-current liabilities
Non-current lease liabilities		343,629
Employee benefit liability	346,628	336,206
Deferred income		932,200
Deferred tax liabilities		125,870
Total non-current liabilities	346,628	1,737,905
Current liabilities
Loan		5,869,797
Current lease liabilities	99,659	117,856
Trade and other payables	440,414	4,914,404
Accrued expenses	348,841	1,977,614
Total current liabilities	888,914	12,879,671
Total liabilities	1,235,542	14,617,576
Total equity and liabilities	SFr 7,694,259	SFr 6,302,765

Consolidated Statement of Chang

Consolidated Statement of Changes in Equity - CHF (SFr)	Share Capital	Share Premium	Loans with Warrants Equity Component	Foreign Currency Translation Reserve	Accumulated Deficit	Total
Beginning Balance at Dec. 31, 2020	SFr 114,172	SFr 177,230,300		SFr 61,297	SFr (160,635,879)	SFr 16,769,890
Net loss					(17,058,443)	(17,058,443)
Other comprehensive income / (loss)				772	264,984	265,756
Total comprehensive loss				772	(16,793,459)	(16,792,687)
Capital increase / Exercise of warrants	20,822	7,083,869				7,104,691
Transaction costs		(156,817)				(156,817)
Conversion of loan	5,168	1,366,087				1,371,255
Share based/Asset purchase	7,735	2,447,081			1,078,800	3,533,616
Share based payments	1,746	540,956			663,601	1,206,303
Ending Balance at Dec. 31, 2021	149,643	188,511,476		62,069	(175,686,937)	13,036,251
Net loss					(26,528,411)	(26,528,411)
Other comprehensive income / (loss)				61,046	441,277	502,323
Total comprehensive loss				61,046	(26,087,134)	(26,026,088)
Capital increase / Exercise of warrants	86,368	4,146,425				4,232,793
Transaction costs		(35,495)				(35,495)
Recognition of equity component of loans with warrants			134,929			134,929
Share based payments					342,799	342,799
Ending Balance at Dec. 31, 2022	236,011	192,622,406	134,929	123,115	(201,431,272)	(8,314,811)
Net loss					(3,869,173)	(3,869,173)
Other comprehensive income / (loss)				215,717	31,163	246,880
Total comprehensive loss				215,717	(3,838,010)	(3,622,293)
Capital increase / Exercise of warrants	486,587	5,035,157				5,521,744
Proceeds from public offering	1,052,546	3,391,899				4,444,445
Proceeds from exercise of warrants	143	540,891				541,034
Transaction costs		(809,378)				(809,378)
Conversion of convertible loan	1,131,043	6,887,993				8,019,036
Reclassification equity component on conversion or repayment		469,151	(475,842)			(6,691)
Recognition of equity component of loans with warrants			475,842			475,842
Value of warrants and prefunded warrants		(4,086,688)	4,086,688
Fair value change of warrants					(8,376)	(8,376)
Reduction of share capital	(2,903,684)	2,903,684
Reduction of share premium		(186,852,242)			186,852,242
Transfer to profit or loss				(161,249)		(161,249)
Share based payments					379,414	379,414
Ending Balance at Dec. 31, 2023	SFr 2,646	SFr 20,102,873	SFr 4,221,617	SFr 177,583	SFr (18,046,002)	SFr 6,458,717

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - CHF (SFr)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities
Net loss	SFr (3,869,173)	SFr (26,528,411)	SFr (17,058,443)
Adjustments for:
Depreciation	119,304	118,887	76,357
Impairment of intangible assets		12,397,148	1,529,929
Share in result of an associate	39,557
Gain on disposal of discontinued operations	(5,205,535)
Deferred income		932,200
Unrealized foreign currency exchange loss/(gain), net	180,349	(46,087)	(279,329)
Net interest expense	1,007,690	891,651	174,593
Share based payments	379,414	342,799	1,206,303
Transaction costs		1,137
Employee benefits	41,585	109,164	65,927
Revaluation loss/(gain) derivative financial instruments	166,192	(451,131)	410,918
(Gain)/loss on modification of financial instruments	(29,461)
Income tax loss/(gain)	(99,847)	(10,329)	21,620
Total	(7,269,925)	(12,242,972)	(13,852,125)
Changes in:
Inventories	(319,821)	827,577	(839,221)
Trade and other receivables	14,062	(103,601)	(340,119)
Prepayments	197,011	856,429	(1,297,537)
Trade and other payables	(3,299,680)	1,263,196	2,937,019
Accrued expenses	(832,711)	716,140	(280,755)
Net cash used in operating activities	(11,511,064)	(8,683,231)	(13,672,738)
Cash flows from investing activities
Purchase of intangibles		(2,142,806)	(3,325,952)
Cash received from other non-current financial assets	10,040		(179,104)
Investment in an associate	(490,000)
Interest received	505	969
Disposal of subsidiaries	1,924,324
Net cash from / used in investing activities	1,444,869	(2,141,837)	(3,505,056)
Cash flows from financing activities
Proceeds from offerings and warrant exercises	10,507,223	3,962,618	6,842,940
Transaction costs	(786,292)	(35,496)	(156,817)
Proceeds from loans	2,500,000	6,038,627
Repayment of loan	(1,335,562)		(50,000)
Repayment of lease liabilities	(115,413)	(114,251)	(18,700)
Interest paid	(148,341)	(19,503)	(3,699)
Net cash from financing activities	10,621,615	9,831,995	6,613,724
Net increase / (decrease) in cash and cash equivalents	555,420	(993,073)	(10,564,070)
Cash and cash equivalents at beginning of the period	15,395	984,191	11,258,870
Net effect of currency translation on cash	46,594	24,277	289,391
Cash and cash equivalents at end of the period	SFr 617,409	SFr 15,395	SFr 984,191

Reporting Entity

Reporting Entity	12 Months Ended
	Dec. 31, 2023
Reporting Entity [Abstract]
Reporting entity	1. Reporting entity Altamira Therapeutics Ltd. (the “Company”) is an exempted company incorporated under the laws of Bermuda. The Company began its operations as a corporation organized in accordance with Swiss law and domiciled in Switzerland under the name Auris Medical Holding AG (“Auris Medical (Switzerland)”). Following shareholder approval at an extraordinary general meeting of shareholders held on March 8, 2019 and upon the issuance of a certificate of continuance by the Registrar of Companies in Bermuda on March 18, 2019, the Company discontinued as a Swiss company and, pursuant to Article 163 of the Swiss Federal Act on Private International Law and pursuant to Section 132C of the Companies Act 1981 of Bermuda (the “Companies Act”), continued existence under the Companies Act as a Bermuda company with the name “Auris Medical Holding Ltd.” (the “Redomestication”). On March 18, 2019, the common shares of the Company began trading on the Nasdaq Capital Market under the trading symbol “EARS”. The Company’s registered office is located at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda. On July 21, 2021, the Company changed its name to Altamira Therapeutics Ltd. Since July 26, 2021, the Company’s common shares are traded under the trading symbol “CYTO”. On December 13, 2023, the Company effected a one-for-twenty reverse share split (the “2023 Reverse Share Split”) of the Company’s issued and outstanding common shares. Unless indicated or the context otherwise requires, all per share amounts and numbers of common shares in this report have been retrospectively adjusted for the 2023 Reverse Share Split, as if such 2023 Reverse Share Split occurred on the first day of the periods presented. These consolidated financial statements comprise the Company and its subsidiaries (together referred to as the “Company” and individually as “Company entities”). The Company is the ultimate parent of the following Company entities: ● Auris Medical AG, Basel, Switzerland (100%) with a nominal share capital of CHF 2,500,000 ● Otolanum AG, Zug, Switzerland (100%) with a nominal share capital of CHF 100,000 ● Altamira Therapeutics AG, Zug, Switzerland (100%), with a nominal share capital of CHF 100,000 ● Altamira Medica AG, Zug, Switzerland (49%), with a nominal share capital of CHF 3,000,000 1) ● Altamira Therapeutics, Inc., Newark, Delaware, United States (100%) with a nominal share capital of $100 ● Auris Medical Ltd., Dublin, Ireland (100%) with a nominal share capital of EUR 100 ● Auris Medical Pty Ltd, Melbourne, Australia (49%), with a nominal share capital of AUD 100 1) 1) On November 21, 2023, the Company divested partially its Bentrio® business by selling a 51% stake in Altamira Medica AG, Zug, Switzerland, and its 100% subsidiary Auris Medical Pty Ltd, Melbourne, Australia. After the sale, the retained 49% stake is accounted for as investment in an associate using the equity method. Altamira is a preclinical-stage biopharmaceutical company developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (OligoPhore™ / SemaPhore™ platforms). It currently has two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. The versatile delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies through out-licensing. In 2023 the Company took a first step in its repositioning around the RNA delivery business by spinning off a 51% stake in Altamira Medica AG, which manufactures and markets Bentrio®, an OTC nasal spray for allergic rhinitis. The Company intends to partner / divest also its AM-125 program, a nasal spray for vertigo (post Phase 2), as well as its early- to late-stage clinical development programs in tinnitus and hearing loss.

Basis of Preparation

Basis of Preparation	12 Months Ended
	Dec. 31, 2023
Basis of Preparation [Abstract]
Basis of preparation	2. Basis of preparation Statement of compliance These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (“IFRS”). These consolidated financial statements were approved by the Board of Directors and the Audit Committee of the Company on April 3, 2024. Basis of measurement The consolidated financial statements are prepared on the historical cost basis, except for the revaluation to fair value of certain financial liabilities. Historical cost is generally based on the fair value of the consideration given in exchange for goods and services. The principal accounting policies adopted are set out below. In addition, for financial reporting purposes, fair value measurements are categorized into Level 1, 2 or 3 based on the degree to which the inputs to the fair value measurements are observable and the significance of the inputs to the fair value measurement in its entirety, which are described as follows: ● Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date ● Level 2 inputs are inputs, other than quoted prices included within Level 1, that are observable for the asset or liability, either directly or indirectly; and ● Level 3 inputs are unobservable inputs for the asset or liability. Functional and reporting currency These consolidated financial statements are presented in Swiss Francs (“CHF”), which is the Company’s functional (“functional currency”) and the Company’s reporting currency. Going Concern We have incurred recurring losses and negative cash flows from operations since inception and we expect to generate losses from operations for the foreseeable future primarily due to incurring research and development costs for our potential product candidates. We expect our research and development expenses to remain significant as we advance or initiate the pre-clinical and clinical development of our OligoPhore™/SemaPhore™ platforms, AM-401, AM-411 or any other product candidate. We expect our total additional cash need in 2024 to be in the range of CHF 6.5 to 7.5 million, which represents a substantial reduction compared to 2023 as we have completed the clinical development of Bentrio®, partially divested our Bentrio® business and significantly reduced headcount and expense levels. The Board of Directors have considered the cash flow forecasts and the funding requirements of the business and continues to explore and pursue various funding opportunities, including licensing revenues and capital raises. Following the partial spin-off of the Bentrio® business, the Company intends to partner or divest also its inner therapeutic assets, notably the AM-125 development program, in order to focus on the development of its OligoPhore™/SemaPhore™ RNA delivery platform and the AM-401 and AM-411 flagship programs. The Board of Directors considers it feasible to generate CHF 8 to 10 million in funding within 12 months from the reporting date. At the date of issuing these financial statements, such plans have not yet been realized. Our assumptions may prove to be wrong, and we may have to use our capital resources sooner than we currently expect. As is often the case with drug development companies, the ability of the consolidated entity to continue its development activities as a going concern is dependent upon it deriving sufficient cash from investors, from licensing and partnering activities, in particular the intended divestiture or partnering of the Company’s legacy assets in the fields of inner ear therapeutics and OTC consumer health products, and from other sources of revenue such as grant funding. To the extent that we will be unable to generate sufficient cash proceeds from the planned divestiture or partnering of our legacy assets or other partnering activities, we will need substantial additional financing to meet our funding requirements. While Management and the Board of Directors continue to apply best efforts to evaluate available options, there is no guarantee that any transaction can be realized or that such transaction would generate sufficient funds to finance operations for twelve months from the issuance of these financial statements. These factors raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements have been prepared on a going concern basis, which contemplates the continuity of normal activities and realization of assets and settlement of liabilities in the normal course of business. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The lack of a going concern assessment may negatively affect the valuation of the Company’s investments in its subsidiaries and result in a revaluation of these holdings. The Board of Directors will need to consider the interests of our creditors and take appropriate action to restructure the business if it appears that we are insolvent or likely to become insolvent. If additional capital is not available when required, the Company may need to delay or curtail its operations until such funding is received. Various internal and external factors will affect whether and when the Company’s product candidates can be out-licensed, The length of time and cost of developing these product candidates and/or failure of them at any stage of the development process will materially affect the Company’s financial condition and future operations. Such matters are not fully within the control of the Company and thus all associated outcomes are uncertain. We also expect to continue to incur additional costs associated with operating as a public company. Additional funds may not be available on a timely basis, on favorable terms, or at all, and such funds, if raised, may not be sufficient to enable us to continue to implement our long-term business strategy. If we are not able to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts, which could materially harm our business, prospects, financial condition and operating results. This could then result in bankruptcy, or the liquidation of the Company. 2023 Reverse Share Split The Company effected the 2023 Reverse Share Split of its common shares at a ratio of 1-for-20 on December 13, 2023. No fractional common shares were issued as fractional common shares were settled in cash. Impacted amounts and share information included in the consolidated financial statements and notes thereto have been adjusted for the reverse share split as if such reverse share split occurred on the first day of the periods presented. Certain amounts in the notes to the consolidated financial statements may be slightly different than previously reported due to rounding of fractional shares as a result of the reverse share split. Use of estimates and judgments The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions of accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Information about judgments made in applying accounting policies that have the most significant effects on the amounts recognized in the consolidated financial statements are described below. Income taxes As disclosed in Note 25 the Company has significant tax losses in Switzerland. These tax losses represent potential value to the Company to the extent that the Company is able to create taxable profits in Switzerland prior to expiry of such losses. Tax losses may be used within 7 years from the year the losses arose. The Company also has tax losses in the United States, 80% of which may be used for an unlimited period of time, or for a shorter time period in accordance with prevailing state law. At December 31, 2023, the Company has not recorded any deferred tax assets in relation to these tax losses (December 31, 2022: CHF 41,430), Deferred tax assets on tax losses are only considered to the extent that they offset taxable temporary differences within the same entity. The key factors which have influenced management in arriving at this evaluation are the fact that the business is still in a development phase and the Company has not yet a history of making profits. Should management’s assessment of the likelihood of future taxable profits change, a deferred tax asset will be recorded. Income tax gain reflects the reassessment of deferred tax assets and liabilities booked in the 2023 fiscal year. Development expenditures The project stage forms the basis for the decision as to whether costs incurred for the Company’s development projects can be capitalized. We do not capitalize clinical development expenditures until the Company obtains regulatory approval (i.e. approval to commercially use the product), as this is considered to be essentially the first point in time where it becomes probable that future revenues can be generated. Up to 2022, direct development expenditures for the Company’s intranasal betahistine program for the treatment of vertigo (AM-125) were capitalized as the development is primarily focused on the delivery route and formulation and not the drug itself (already an approved generic) and aims to demonstrate higher bioavailability through intranasal delivery. All capitalized direct development expenditures were impaired as of December 31, 2022 based on the impairment test performed under IFRS. No development costs were capitalized in 2023. As of each reporting date, the Company estimates the level of service performed by the vendors and the associated costs incurred for the services performed. As part of the process of preparing the Company’s financial statements, the Company is required to estimate its accrued expenses. This process involves reviewing contracts, identifying services that have been performed on the Company’s behalf and estimating the level of service performed and the associated cost incurred for the service when it has not yet been invoiced or otherwise notified of the actual cost. Employee benefits The Company maintains a pension plan for all employees in Switzerland through payments to a legally independent collective foundation. This pension plan qualifies under IFRS as defined benefit pension plan. The Company’s net obligation in respect of defined benefit plans is calculated by estimating the amount of future benefit that employees have earned in return for their service in the current and prior periods, discounting that amount and deducting the fair value of any plan assets. The Company makes relevant actuarial assumptions with regard to the discount rate, future salary increases and life expectancy. Research and Development and Accrued Expenses The Company records the costs associated with research, nonclinical and clinical trials, and manufacturing process development as incurred. These costs are a significant component of the Company’s research and development expenses, with a substantial portion of the Company’s on-going research and development activities being conducted by third party service providers, including contract research and manufacturing organizations. The Company accrues for expenses resulting from obligations under agreements with contract research organizations (“CROs”), contract manufacturing organizations (“CMOs”), and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accrued expenses are recorded based on estimates of services received and efforts expended pursuant to agreements established with CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. The Company makes significant judgments and estimates in determining the accrued expense balance in each reporting period. In the event advance payments are made to a CRO, CMO, or outside service provider, the payments will be recorded as prepayments which will be expensed as the contracted services are performed. Inputs, such as the services performed, the number of patients enrolled, or the trial duration, may vary from the Company’s estimates. As actual costs become known, the Company adjusts its prepayments and accrued expenses.

Material Accounting Policies

Material Accounting Policies	12 Months Ended
	Dec. 31, 2023
Significant Accounting Policies [Abstract]
Material accounting policies	3. Material accounting policies The accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements, unless otherwise indicated. Basis of consolidation Subsidiaries Subsidiaries are entities controlled by the Company. The Company controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases. Transactions eliminated on consolidation All inter-company balances, transactions and unrealized gains on transactions have been eliminated in consolidation. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred. Segment reporting A segment is a distinguishable component of the Company that engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses that relate to transactions with any of the Company’s other components. The Chief Executive Officer is determined to be the Company’s Chief Operating Decision Maker (“CODM”). The CODM assesses the performance and allocates the resources of the Company as a whole, as all of the Company’s activities are focusing on the development of therapeutics for important unmet medical needs. Financial information is only available for the Company as a whole. Therefore, management considers there is only one operating segment under the requirements of IFRS 8, Operating Segments. Foreign currency Foreign currency transactions Items included in the financial statements of Company entities are measured using the currency of the primary economic environment in which the entity operates. Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in profit or loss. Non-monetary items that are measured based on historical cost in a foreign currency are not re-translated. Foreign operations Assets and liabilities of Company entities whose functional currency is other than CHF are included in the consolidation by translating the assets and liabilities into the reporting currency at the exchange rates applicable at the end of the reporting period. Income and expenses are translated at average exchange rates (unless this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transaction). These foreign currency translation differences are recognized in Other Comprehensive income/(loss) and presented in the foreign currency translation reserve in equity. When a foreign operation is disposed of such that control is lost, the cumulative amount in the translation reserve related to that foreign operation is reclassified to profit or loss as part of the gain or loss on disposal. Closing rates for the most significant foreign currencies relative to CHF: Geographical Reporting December 31, December 31, Currency area entities 2023 2022 CHF Swiss Franc Switzerland 5 1.0000 1.0000 USD Dollar United States 1 0.8451 0.9251 EUR Euro Europe 1 0.9287 0.9901 AUD Dollar Australia 1 0.5735 0.6305 Average exchange rates for the year for the most significant foreign currencies relative to CHF: Geographical Reporting Currency area entities 2023 2022 CHF Swiss Franc Switzerland 5 1.0000 1.0000 USD Dollar United States 1 0.8985 0.9550 EUR Euro Europe 1 0.9721 1.0050 AUD Dollar Australia 1 0.5971 0.6629 Property and equipment Property and equipment is measured at historical costs less accumulated depreciation and any accumulated impairment losses. Historical costs include expenditures that are directly attributable to the acquisition of the items. When parts of an item of tangible assets have different useful lives, they are accounted for as separate tangible asset items (major components). Depreciation is calculated on a straight-line basis over the expected useful life of the individual asset. The applicable estimated useful lives are as follows: Production equipment 5 years Office furniture and electronic data processing equipment (“EDP”) 3 years Subsequent costs are included in the asset’s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. The carrying amount of the replaced part is derecognized. All other repairs and maintenance are charged to profit or loss during the financial period in which they are incurred. Depreciation methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate. When an asset is reviewed for impairment, the asset’s carrying amount may be written down immediately to its recoverable amount, provided the asset’s carrying amount is greater than its estimated recoverable amount. Management assesses the recoverable amount by assessing the higher of its fair value less costs to sell or its value in use. Cost and accumulated depreciation related to assets retired or otherwise disposed are removed from the accounts at the time of retirement or disposal and any resulting gain or loss is included in profit or loss in the period of disposition. Intangible assets Research and development Expenditures on the Company’s research programs are not capitalized, they are expensed when incurred. Expenditures on the Company’s development programs are generally not capitalized except if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development and to use or sell the asset. For the development projects of the Company, these criteria are generally only met when regulatory approval for commercialization is obtained. For the AM-125 program for the treatment of vertigo it was the Company’s assessment up to 2022 that the criteria mentioned above were met and therefore direct development expenditures were capitalized for AM-125 in 2021 and 2022, including intellectual property-related costs for the prosecution and registration of patents. As of December 31, 2022, all capitalized direct development costs related to AM-125 were impaired based on the impairment test performed under IFRS. The impairment was recognized as an R&D expense in 2022. Licenses, intellectual property and data rights Intellectual property rights that are acquired by the Company are capitalized as intangible assets if they are controlled by the Company, are separately identifiable and are expected to generate future economic benefits, even if uncertainty exists as to whether the research and development will ultimately result in a marketable product. Consequently, upfront and milestone payments to third parties for the exclusive use of pharmaceutical compounds in specified areas of treatment are recognized as intangible assets. Measurement Intangible assets acquired that have finite useful lives are measured at cost less accumulated amortization and any accumulated impairment losses. Subsequent expenditure Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditure, including expenditure on internally generated goodwill and brands, is recognized in profit or loss as incurred. Amortization All licenses of the Company have finite lives. Amortization will commence once the Company’s intangible assets are available for use which will be the case after regulatory approvals are obtained and the related products are available for use. Amortization of licenses is calculated on a straight-line basis over the period of the expected benefit or until the license expires, whichever is shorter. The estimated useful life is 10 years or the remaining term of patent protection. The Company assesses at each statement of financial position date whether intangible assets which are not yet ready for use are impaired. Impairment of non-financial assets Property and equipment and intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. For the purpose of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (cash-generating units). An impairment loss is recognized as the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs to sell or value in use. Impairment losses are recognized in profit or loss. Assets that were previously impaired are reviewed for possible reversal of the impairment at each reporting date. Any increase in the carrying amount of an asset will be based on the depreciated historical costs had the initial impairment not been recognized. Asset purchase On June 1, 2021, we acquired 100% of the share capital of privately held Trasir Therapeutics Inc. (“Trasir”) through the merger of our subsidiary Auris Medical Inc. with and into Trasir (the “Merger”), with Trasir surviving the merger as the surviving entity. Trasir was subsequently renamed Altamira Therapeutics, Inc. and redomiciled in Dover, Delaware. Founded in 2014, Trasir has been a pioneer in the development of nanoparticles for extrahepatic oligonucleotide delivery. The purchase price for Trasir comprised: (i) 1,911 non-registered common shares of the Company, par value CHF 4.00 per share, calculated based on a value of $2,500,000 divided by the average closing price of the Common Shares on the 15 trading days preceding the closing date (the “Reference Price”, which amounted to $1,308 per Common Share); (ii) contingent on the occurrence of positive results from a subsequent post-closing scientific study led by Trasir (“Positive Results”), $1,500,000 of common shares of the Company to be calculated based on the average closing price of the common shares on the 15 trading days preceding the occurrence of Positive Results; and (iii) $210,000 for expenses incurred by certain selling Trasir shareholders paid in $180,000 in cash and 23 non-registered common shares based on the Reference Price. Trasir’s main asset is an exclusive license agreement (the “License Agreement”) with Washington University located in St. Louis, Missouri (“WU”). Pursuant to the License Agreement, WU granted Trasir an exclusive, worldwide, royalty-bearing license (with the right to sublicense) during the term of the License Agreement under certain patent rights owned or controlled by WU to research, develop, make, have made, sell, offer for sale, use and import pharmaceutical products covered under such patent rights for all fields of use. Such licensed products may include “silencing RNA” (siRNAs) pharmaceutical preparations formulated in combination with Trasir’s proprietary delivery technologies. In consideration for such worldwide, exclusive license, the Company (through its acquisition of Trasir, described above) will be obligated to pay WU: annual license maintenance fees in the low five figures through first commercial sale; pre-clinical and clinical regulatory milestones; sales milestones; and a low single digit royalty based on annual net sales of licensed products worldwide for at least the applicable patent term or period of marketing exclusivity, whichever is longer, but in no case less than a minimum royalty term of 12 years; and a percentage share (in the double digits) of sublicensing revenues received by the Company in connection with licensed products. Such regulatory and sales milestones may total up to an aggregate of $4,375,000. In the event the Company fails to meet certain regulatory diligence milestones, WU will have the right to terminate the license. The acquisition of Trasir was treated as an asset acquisition because substantially all the fair value is concentrated in a single identifiable asset, the License Agreement with WU. The acquisition of the license is settled to a large extent in exchange for a variable number of the Company’s publicly listed shares. IFRS 2 “Share-based payments” was applied. With regards to the contingent part of the purchase price as mentioned under (ii) above, a downward adjustment of CHF 269,700 to the estimated fair value was made to reflect the possibility of not meeting the condition of Positive Results. As of December 31, 2022 and December 31, 2023, the total carrying amount of the license acquired amounted to CHF 3,893,681, including directly attributable transaction costs of CHF 198,246. Leases The Company assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Company recognizes lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets. Right-of-use assets The Company recognizes right-of-use assets at the commencement date of the lease. Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurements of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date. Unless the Company is reasonably certain to obtain ownership of the leased asset at the end of the lease term, the recognized right-of-use assets are depreciated on a straight-line basis over the shorter of its estimated useful life and the lease term. Right-of-use assets are subject to impairment. Lease liabilities At the commencement date of the lease, the Company recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Company and payments of penalties for terminating a lease, if the lease term reflects the Company exercising the option to terminate. The variable lease payments that do not depend on an index or a rate are recognized as expense in the period during which the event or condition that triggers the payment occurs. In calculating the present value of lease payments, the Company uses the incremental borrowing rate at the lease commencement date if the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accumulation of interest and reduced by the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change in the assessment to purchase the underlying asset. Short-term leases and leases of low-value assets The Company applies the short-term lease recognition exemption to its short-term leases. It also applies the lease of low-value assets recognition exemption to leases that are considered of low value (i.e. below CHF 5,000). Lease payments on short-term leases and leases of low-value assets are recognized as expense over the lease term. Associates Where the Company has the power to participate in (but not control) the financial and operating policy decisions of another entity, it is classified as an associate. Associates are initially recognized in the consolidated statement of financial position at cost. An investment in an associate that represents the retained interest in a former subsidiary is recognized at its fair value at the date when control is lost. Subsequently associates are accounted for using the equity method, where the Company’s share of post-acquisition profits and losses and other comprehensive income is recognized in the consolidated statement of profit and loss and other comprehensive income (except for losses in excess of the Company’s investment in the associate unless there is an obligation to make good on those losses). Profits and losses arising on transactions between the Company and its associates are recognized only to the extent of unrelated investors’ interests in the associate. The investor’s share in the associate’s profits and losses resulting from these transactions is eliminated against the carrying value of the associate. Any premium paid for an associate above the fair value of the Company’s share of the identifiable assets, liabilities and contingent liabilities acquired is capitalized and included in the carrying amount of the associate. Where there is objective evidence that the investment in an associate has been impaired the carrying amount of the investment is tested for impairment in the same way as other non-financial assets. Inventories Inventories are stated at the lower of cost and net realizable value. Cost comprises direct materials and, where applicable, direct labor costs and those overheads that have been incurred in bringing the inventories to their present location and condition. Cost is calculated using the first-in, first-out method. Net realizable value represents the estimated selling price less all estimated costs of completion and costs to be incurred in marketing, selling and distribution. Discontinued operations A discontinued operation is a component of the Company’s business that represents a separate major line of business or geographical area of operations or is a subsidiary acquired exclusively with a view to resale, that has been disposed of, has been abandoned or that meets the criteria to be classified as held for sale. Discontinued operations are presented in the consolidated statement of comprehensive income/(loss) as a single line which comprises the post-tax profit or loss of the discontinued operation along with the post-tax gain or loss recognized on the re-measurement to fair value less costs to sell or on disposal of the assets or disposal Companies constituting discontinued operations. When an operation is classified as a discontinued operation, the comparative statement of profit or loss is re-presented as if the operation had been discontinued from the start of the comparative year. The objective is to provide the users of the financial statements with the most useful information to evaluate the financial effects of discontinued operations. Transactions between continuing and discontinued operations are presented as part of the respective continuing or discontinued operations. For the divested Bentrio business, this approach best reflects the continuance of the relationship. However, intragroup transactions between continuing and discontinued operations are eliminated in the financial statements as a whole. Financial instruments The Company classifies its financial assets in the following categories: loans and receivables based on the expected loss model. The classification depends on the nature and purpose of the financial assets and is determined at the time of initial recognition. Recognition and derecognition of non-derivative financial assets and liabilities The Company initially recognizes loans and receivables and debt securities issued on the date when they are originated. All other financial assets and financial liabilities are initially recognized on the trade date. The Company derecognizes a financial asset when the contractual rights to the cash flows from the asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred, or it neither transfers nor retains substantially all of the risks and rewards of ownership and does not retain control over the transferred asset. Any interest in such derecognized financial assets that is created or retained by the Company is recognized as a separate asset or liability. The Company derecognizes a financial liability when its contractual obligations are discharged, cancelled, or expired. Financial assets and financial liabilities are offset and the net amount presented in the statement of financial position when, and only when, the Company has a legal right to offset the amounts and intends either to settle them on a net basis or to realize the asset and settle the liability simultaneously. Non-derivative financial assets and liabilities—measurement Loans and receivable These are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. Loans and receivables are initially recognized at fair value plus any directly attributable transaction costs. Subsequent to initial recognition, they are measured at amortized cost using the effective interest method, less expected losses. Cash and cash equivalents The Company considers all short-term, highly liquid investments that are readily convertible into known amounts of cash and which are subject to an insignificant risk of changes in value with original maturities of three months or less at the date of the purchase to be cash equivalents. Non-derivative financial liabilities—measurement Non-derivative financial liabilities are initially recognized at fair value less any directly attributable transaction costs. Subsequent to initial recognition, these liabilities are measured at amortized cost using the effective interest method. Convertible loans In a convertible loan classified as a hybrid contract containing a host and a separated embedded derivative, both classified as liability, the carrying amount of the host contract at initial recognition is the difference between the carrying amount of the hybrid contract and the fair value of the embedded derivative. Transaction costs that relate to the issue of the convertible loan are allocated to the host and embedded derivative in proportion to the allocation of the gross proceeds. Transaction costs relating to the embedded derivative are immediately recognized in profit and loss. Transaction costs relating to the host contract are included in the carrying amount of the liability. The host contract is then subsequently measured at amortized cost, using the effective interest method. Share capital All shares of the Company are registered shares and classified as part of shareholders’ equity. Incremental costs directly attributable to the issue of the Company’s shares, net of any tax effects, are recognized as a deduction from equity. The warrants are classified as a financial liability at fair value through profit or loss and the cost allocated to the liability component will be immediately expensed to the income statement. The Company has not paid any dividends since its inception and does not anticipate paying dividends in the foreseeable future. Impairment of non-derivative financial assets Financial assets are assessed at each reporting date to determine whether there is objective evidence of impairment. Objective evidence that financial assets are impaired includes: ● default or delinquency by a debtor; ● indications that a debtor or issuer will enter bankruptcy; ● adverse changes in the payment status of borrowers or issuers; ● the disappearance of an active market for a security; or ● observable data indicating that there is measurable decrease in expected cash flows from a Company of financial assets. Financial assets measured at amortized cost The Company considers evidence of impairment for these assets at an individual asset level. An impairment loss is calculated as the difference between an asset’s carrying amount and the present value of the estimated future cash flows discounted at the asset’s original effective interest rate. Losses are recognized in profit or loss and reflected in an allowance account. When the Company considers that there are no realistic prospects of recovery of the asset, the relevant amounts are written off. If the amount of impairment loss subsequently decreases and the decrease can be related objectively to an event occurring after the impairment was recognized, then the previously recognized impairment loss is reversed through profit or loss. Derivative Financial Instruments Derivative financial instruments (assets) are accounted as the cost to obtain the rights from a third party to issue shares under the purchase agreement. The fair value calculation of the derivative financial instrument (asset) is adjusted on the utilization of the asset based on total dollar amount of the purchase agreement. At each period-end, relative to the portion of shares sold under the contract, a portion of the option value is derecognized to equity. Derivative financial instruments (liabilities) are accounted at fair value and changes in fair value are shown as profit or loss. The fair value calculation of the derivative financial instruments is based on the Black-Scholes option pricing model. Assumptions are made for volatility and the risk-free rate in order to estimate the fair value of the instrument. Transaction cost related to derivative financial instruments are recorded through profit and loss. Embedded Derivatives Derivatives may be embedded in another contractual arrangement. The Company accounts for an embedded derivative separately from the host contract when: - The host contract is not an asset in the scope of IFRS 9 - The host contract is not itself carried at fair value through profit and loss (FVPL) - The terms of the Embedded Derivative would meet the definition of a derivative if they were contained in a separate contract - The economic characteristics and risks of the embedded derivative are not closely related to the economic characteristics and risks of the host The separated embedded derivative in the 2022 FiveT convertible loan was initially measured at fair value by an independent consultant applying a simulation-based valuation approach. On December 31, 2022, the embedded derivative was measured based on the Black-Scholes option pricing model, resulting in a fair value of zero. Assumptions are made for volatility, risk free rate and other features of the instrument. All changes in the fair value of embedded derivatives were recognized in profit and loss. The 2023 FiveT convertible loan was classified as a compound financial instrument containing a host liability and two equity components (conversion right and warrants). The fair value of the liability component was determined first by discounting the future cash flows at the rate of interest that would apply to an identical financial instrument without these features. The equity components were measured at the residual amount, by deducting the amount calculated for the liability component from the fair value of the instrument as a whole. The residual amount was allocated to the two equity components based on their relative fair values. The host liability was subsequently measured at amortized cost, using the effective interest rate method. Income tax Income tax expense comprises current and deferred tax. It is recognized in profit or loss except to the extent that it relates to a business combination, or items recognized directly in equity or in Other Comprehensive Income. Current tax Current tax comprises the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to tax payable or receivable in respect of previous years. It is measured using tax rates enacted or substantively enacted at the reporting date. Deferred tax Deferred income tax is recognized, using the balance sheet liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred tax is not recognized for: ● temporary differences on the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit or loss; ● temporary differences related to investments in subsidiaries to the extent that the Company is able to control the timing of the reversal of the temporary differences and it is probable that they will not reverse in the foreseeable future; and ● taxable temporary differences arising on the initial recognition of goodwill. Deferred income tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled. Deferred income tax assets are recognized to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized. Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off tax assets against tax liabilities and when they relate to income taxes levied by the same taxation authority and the Company intends to settle its tax assets and liabilities on a net basis. Employee benefits The Company maintains a pension plan for all employees in Switzerland through payments to a legally independent collective foundation. This pension plan qualifies under IFRS as defined benefit pension plan. There are no pension plans for the subsidiaries in Ireland, Australia and the United States. The Company’s net obligation in respect of defined benefit plans is calculated by estimating the amount of future benefit that employees have earned in return for their service in the current and prior periods, discounting that amount and deducting the fair value of any plan assets. The recognized asset is limited to the present value of economic benefits available in the form of any future refunds from the plan or reductions in future contributions to the plan. In order to calculate the present value of economic benefits, consideration is given to any minimum funding requirements. Remeasurements of the net defined benefit liability, which comprise actuarial gains and losses, the return on plan assets (excluding interest) and the effect of the asset ceiling (if any, excluding interest), are recognized immediately in Other Comprehensive Income. Past service costs, including curtailment gains or losses, are recognized immediately in general and administrative expenses within the operating results. Settlement gains or losses are recognized in general and administrative expenses within the operating results. The Company determines the net interest expense (income) on the net defined benefit liability (asset) for the period by applying the discount rate used to measure the defined benefit obligation at the beginning of the annual period or in case of any significant events between measurement dates to the then-net defined benefit liability (asset), taking into account any changes in the net defined benefit liability (asset) during the period as a result of contributions and benefit payments. Net interest expense and other expenses related to defined benefit plans are recognized in profit or loss. Share-based compensation The Company maintains a share-based payment plan in the form of a stock option plan for its employees, members of the Board of Directors as well as key service providers. Stock options are granted at the Board’s discretion without any contractual or recurring obligations. The share-based compensation plans qualify as equity settled plans. The grant-date fair value of share-based payment awards granted to employees is recognized as an expense, with a corresponding increase in equity, over the period that the

New Standards, Amendments and I

New Standards, Amendments and Interpretations Adopted by the Company	12 Months Ended
	Dec. 31, 2023
New Standards, Amendments and Interpretations Adopted by the Company [Abstract]
New standards, amendments and interpretations adopted by the Company	4. New standards, amendments and interpretations adopted by the Company In 2023, the following revised standards have been adopted: IFRS 17 Insurance contracts IAS 1 Amendments to IAS 1 and IFRS practice Statement 2, Disclosure of Accounting Policies IAS 8 Amendments to IAS 8, Definition of Accounting Estimates IAS 12 Amendments to IAS 12, Deferred tax related to Assets and Liabilities arising from a Single Transaction IAS 12 Amendment to IAS 12, International Tax Reform – Pillar Two Model Rules Adoption has not had a material impact on the amounts reported in these financial statements but may impact the accounting for future transactions and arrangements. A number of new standards, amendments to standards and interpretations are effective for annual periods beginning after January 1, 2024, and have not been applied in preparing these consolidated financial statements. Planned application Effective by the Standard/Interpretation Impact date Company New standards, interpretations or amendments IFRS 16 Amendments to IFRS 16, Liability in a Sale and Leaseback 1) January 1, FY 2024 2024 IAS 1 Amendments to IAS 1, Classification of Liabilities as Current or Non-current 1) January 1, FY 2024 2024 IAS 1 Amendments to IAS 1, Non-current liabilities with covenants 1) January 1, FY 2024 2024 IAS 7 Amendments to IAS 7, Supplier finance agreements 1) January 1, FY 2024 2024 IAS 21 Amendments to IAS 21, Lack of Exchangeability 1) January 1, FY 2025 2025 1) No material impact on the Company is expected from these standards and amendments issued but not effective.

Financial Instruments and Risk

Financial Instruments and Risk Management	12 Months Ended
	Dec. 31, 2023
Financial instruments and risk management [Abstract]
Financial instruments and risk management	5. Financial instruments and risk management The following table shows the carrying amounts of financial assets and financial liabilities: December 31, December 31, 2023 2022 Financial assets At amortized cost Cash and cash equivalents 617,409 15,395 Other non-current financial assets 80,001 194,263 Trade receivables - 6,525 Other receivables 18,905 - At fair value through profit and loss Derivative financial instruments 247,090 270,176 Total financial assets 963,405 486,359 Financial liabilities At amortized cost Trade and other payables 440,413 4,914,404 Accrued expenses 348,841 1,977,614 Loan - 5,869,797 Non-current lease liabilities - 343,629 Current lease liabilities 99,659 117,856 At fair value through profit and loss Derivative financial instruments - - Total financial liabilities 888,913 13,223,300 Fair values The carrying amount of cash and cash equivalents, financial assets, trade and other receivables, trade and other payables, accrued expenses, loan and lease liabilities is a reasonable approximation of their fair value due to the short-term nature of these instruments. Financial risk factors The Company’s activities expose it to a variety of financial risks: market risk, credit risk, interest rate and liquidity risk. The Company’s overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on the Company’s financial performance. Management identifies, evaluates and controls financial risks. No financial derivatives have been used in 2023 and 2022 to hedge risk exposures. The Company invests its available cash in instruments with the main objectives of preserving principal, meeting liquidity needs and minimizing foreign exchange risks. The Company allocates its liquid assets to first tier Swiss or international banks. Liquidity risk The Company’s principal source of liquidity is its cash reserves which are mainly obtained through the issuance of new shares. The Company has succeeded in raising capital to fund its development activities to date and has raised funds that will allow it to meet short-term development expenditures. The Company will require regular capital injections to continue its development work, which may be dependent on meeting development milestones, technical results and/or commercial success. Management monitors rolling forecasts of the Company’s liquidity requirements to ensure it has sufficient cash to meet operational needs. The ability of the Company to maintain adequate cash reserves to sustain its activities in the medium term is highly dependent on the Company’s ability to raise further funds. Consequently, the Company is exposed to continued liquidity risk. The table below analysis the remaining contractual maturities of financial liabilities, including estimated interest payments as of December 31, 2023 and 2022. The amounts disclosed in the table are the undiscounted cash flows: Between Carrying Less than 3 months and 2 years and amount 3 months 2 years later Total December 31, 2023 Trade and other payables 440,413 440,413 - - 440,413 Accrued expenses 348,841 348,841 - - 348,841 Loan and borrowings - - - - - Non-current lease liabilities - - - - - Current lease liabilities 99,659 33,677 67,354 - 101,031 Derivative financial instruments - - - Total 888,913 822,931 67,354 - 890,285 Between Carrying Less than 3 months and 2 years and amount 3 months 2 years later Total December 31, 2022 Trade and other payables 4,914,404 4,914,404 - - 4,914,404 Accrued expenses 1,977,614 1,977,614 - - 1,977,614 Loan and borrowings 5,869,797 5,759,877 357,192 - 6,117,069 Non-current lease liabilities 343,629 - 130,200 227,850 358,050 Current lease liabilities 117,856 32,550 97,650 - 130,200 Derivative financial instruments - - - Total 13,223,300 12,684,445 585,042 227,850 13,497,337 Fair values as at December 31, December 31, Fair value Financial assets / liabilities 2023 2022 hierarchy Valuation technique(s) and key input(s) Derivative financial Liability Liability Level 2 Black-Scholes option pricing model liabilities – Warrants from public offerings — — The share price is determined by Company’s NASDAQ quoted price. The strike price and maturity are defined by the contract. The volatility assumption is driven by Company’s historic quoted share price and the risk free rate is estimated based on observable yield curves at the end of each reporting period. Derivative financial liabilities – Embedded derivatives of 2023 FiveT Convertible (portion classified as liability) Liability Liability Level 3 Black-Scholes option pricing model The valuation is based on input parameters classified as level 3. Input parameters include the historical volatility of AMHL shares, risk-free rate, expected remaining life, expected exercise date and share prices of AMHL at valuation dates. Derivative financial liabilities – Embedded derivatives of 2022 FiveT Convertible Loan Liability Liability Level 3 Black-Scholes option pricing model The valuation is based on input parameters classified as level 3. Input parameters include the historical volatility of AMHL shares, risk-free rate, expected remaining life, expected exercise date and share prices of AMHL at valuation dates. Derivative financial asset - Option LPC purchase agreement Asset Asset Level 3 The fair value is equal to the price paid to the counterparty for obtaining the right under the purchase agreement. The price paid corresponds to the fair value of 2,500 commitment shares issued to LPC as consideration for its commitment to purchase our common shares under the purchase agreement. Subsequent, the fair value is adjusted proportionally for the part of the right consumed through equity. Non-cash changes Financing Fair Cash value Other 01.01.2023 Flows 1) revaluation changes 2) 31.12.2023 Loans 5,869,797 1,164,438 166,192 (7,200,427 ) - Lease liabilities 461,485 (134,707 ) - (227,119 ) 99,659 Total 6,331,282 1,029,731 166,192 (7,427,546 ) 99,659 Non-cash changes Financing Fair Cash value Other 01.01.2022 Flows 1) revaluation changes 2) 31.12.2022 Derivative financial instrument 1,233 - (1,233 ) - - Loans - 6,038,627 - (168,830 ) 5,869,797 Lease liabilities 575,736 (130,200 ) - 15,949 461,485 Total 576,969 5,908,427 (1,233 ) (152,881 ) 6,331,282 1) The financing cash flows are from loan borrowings or loan and lease repayments. 2) Other non-cash changes include conversion of convertible loan including de-recognition of embedded derivative and remeasurement of lease liability. Credit risk Credit risk is managed on a group basis. Credit risk arises from cash and cash equivalents and deposits with banks, as well as from trade and other receivables. The Company’s policy is to invest funds in low risk investments including interest bearing deposits. Trade and other receivables were current as of December 31, 2023 and December 31, 2022, not impaired and included only well-known counterparties. The Company has been holding cash and cash equivalents in the Company’s principal operating currencies (CHF, USD, EUR and AUD) with international banks of high credit rating. The Company’s maximum exposure to credit risk is represented by the carrying amount of each financial asset in the consolidated statement of financial position: December 31, December 31, 2023 2022 Financial assets Cash and cash equivalents 617,409 15,395 Other non-current financial assets 80,001 194,263 Trade receivables - 6,525 Other receivables 18,905 - Total 716,315 216,183 Market risk Currency risk The Company operates internationally and is exposed to foreign exchange risk arising from various exposures, primarily with respect to US Dollar, Euro and Australian Dollar. Foreign exchange risk arises from future commercial transactions, recognized assets and liabilities and net investments in foreign operations. The summary of quantitative data about the exposure of the Company’s financial assets and liabilities to currency risk was as follows: 2023 2022 in CHF USD EUR AUD USD EUR AUD Cash and cash equivalents 7,637 2,652 - 1,791 3,462 - Trade and other receivables 1,371,060 - - 1,523,292 91,864 879,531 Trade and other payables (129,943 ) (86,547 ) - (1,086,206 ) (1,452,883 ) - Accrued expenses (91,355 ) (26,737 ) - (220,616 ) (299,435 ) - Net statement of financial position exposure -asset/(liability) 1,157,400 (110,632 ) - 218,261 (1,656,992 ) 879,531 As of December 31, 2023, a 5% increase or decrease in the USD/CHF exchange rate with all other variables held constant would have resulted in a CHF 57,870 (2022: CHF 10,913) increase or decrease in the net result. A 5% increase or decrease in the EUR/CHF exchange rate with all other variables held constant would have resulted in a CHF 5,532 (2022: CHF 82,850) increase or decrease in the net result. Also, a 5% increase or decrease in the AUD/CHF exchange rate with all other variables held constant would have resulted in a CHF 0 (2022: CHF 43,977) increase or decrease in the net result. The Company has subsidiaries in the United States, and Ireland, whose net assets are exposed to foreign currency translation risk. Due to the small size of the subsidiaries the translation risk is not significant. Capital risk management The Company and its subsidiaries are subject to capital maintenance requirements under local law in the country in which it operates. To ensure that statutory capital requirements are met, the Company monitors capital, at the entity level, on an interim basis as well as annually. From time to time the Company may take appropriate measures or propose capital increases to ensure the necessary capital remains intact.

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2023
Segment information [Abstract]
Segment information	6. Segment information Geographical information The Company’s non-current assets by the Company’s country of domicile were as follows: December 31, December 31, 2023 2022 Switzerland 3,973,792 4,339,509 Australia - - Total 3,973,792 4,339,509 Non-current assets for geographical information exclude financial instruments and investments in associated companies.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2023
Property and Equipment [Abstract]
Property and equipment	7. Property and Equipment Office Production furniture equipment and EDP Total At cost As of January 1, 2022 353,488 233,706 587,194 Additions - - - Disposals - - - As of December 31, 2022 353,488 233,706 587,194 Additions - - - Disposals - - - As of December 31, 2023 353,488 233,706 587,194 Accumulated depreciation As of January 1, 2022 (353,488 ) (233,705 ) (587,193 ) Charge for the year - - - Disposals - - - As of December 31, 2022 (353,488 ) (233,705 ) (587,193 ) Charge for the year - - - Disposals - - - As of December 31, 2023 (353,488 ) (233,705 ) (587,193 ) Net book value As of December 31, 2022 - 1 1 As of December 31, 2023 - 1 1 As of December 31, 2023, and 2022 no items of property and equipment were pledged.

Right-of-Use Assets and Lease L

Right-of-Use Assets and Lease Liabilities	12 Months Ended
	Dec. 31, 2023
Right-of-use assets and lease liabilities [Abstract]
Right-of-use assets and lease liabilities	8. Right-of-use assets and lease liabilities Office Right-of-use assets building Total At cost As of January 1, 2022 594,436 594,436 Additions - - Disposals - - As of December 31, 2022 594,436 594,436 Additions - - Remeasurement (revised lease term) (246,413 ) (246,413 ) As of December 31, 2023 348,023 348,023 Accumulated depreciation As of January 1, 2022 (29,722 ) (29,722 ) Charge for the year (118,887 ) (118,887 ) Disposals - - As of December 31, 2022 (148,609 ) (148,609 ) Charge for the year (119,304 ) (119,304 ) Disposals - - As of December 31, 2023 (267,913 ) (267,913 ) Net book value As of December 31, 2022 445,827 445,827 As of December 31, 2023 80,110 80,110 December 31, December 31, Low value and short-term lease expenses 2023 2022 Expense related to short-term leases 6,600 6,001 Expense related to leases of low value assets - Total 6,600 6,001 December 31, December 31, Lease liabilities 2023 2022 As of January 1 461,485 575,736 Additions - - Interest expense 19,294 15,949 Repayment of lease liability (134,707 ) (130,200 ) Remeasurement (revised lease term) (246,413 ) - As of December 31 99,659 461,485 thereof non-current - 343,629 thereof current 99,659 117,856 December 31, December 31, Maturities of lease liabilities 2023 2022 Year 1 101,030 130,200 Year 2 - 130,200 Year 3 - 130,200 Year 4 - 97,650 Year 5 Undiscounted lease payments 101,030 488,250 Less: unearned interest (1,371 ) (26,765 ) Total 99,659 461,485 The total cash outflows for the principal element of lease payment amounted to CHF 0.1 million for the years ended December 31, 2023 and 2022.

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2023
Intangible Assets [Abstract]
Intangible assets	9. Intangible assets IP & Data Internally Licenses rights Patents generated Total At cost As of January 1, 2022 5,376,201 193,989 473,154 9,801,462 15,844,806 Exchange differences - - - - - Additions - - 275,281 1,700,503 1,975,784 As of December 31, 2022 5,376,201 193,989 748,435 11,501,965 17,820,590 Exchange differences - - - 168 168 Additions - - - - - As of December 31, 2023 5,376,201 193,989 748,435 11,502,133 17,820,758 Accumulated amortization and impairment losses As of January 1, 2022 (1,482,520 ) (47,409 ) - - (1,529,929 ) Impairment (146,580 ) (748,435 ) (11,502,133 ) (12,397,148 ) As of December 31, 2022 (1,482,520 ) (193,989 ) (748,435 ) (11,502,133 ) (13,927,077 ) Impairment - - - - - As of December 31, 2023 (1,482,520 ) (193,989 ) (748,435 ) (11,502,133 ) (13,927,077 ) Net book value As of December 31, 2022 3,893,681 - - - 3,893,681 As of December 31, 2023 3,893,681 - - - 3,893,681 Intangible assets comprise upfront and milestone payments related to licenses and capitalized development costs. Commencing with the business year 2018, the Company recorded intangibles related to direct development expenditure of its AM-125 program. In 2019, a US patent on AM-125 was issued and a related EU application was allowed. As a consequence, we started to capitalize patent prosecution and registration costs until and including the year 2022, where CHF 275,281 for patents and CHF 1,700,503 of internal development costs were capitalized. Based on the impairment testing performed under IFRS as of December 31, 2022, all intangible assets related to the AM-125 project were written off. Accordingly, in the year 2022 the Company recorded an impairment of CHF 12,397,148 to its recoverable amount for AM-125 taking in consideration uncertainties regarding the realization of the cash flows in connection with the planned sale or the out-licensing of the AM-125 assets. The recoverable amount was calculated based on an out-license model of AM-125 at current development stage. The recoverable amount of the relevant intangible asset has been determined to be nil on the basis of their value in use, with consideration of fair value less costs of disposal not supporting a higher recoverable amount. In the year 2023 no development costs were capitalized. As at December 31, 2023, intangible assets only include a license. The license is related to the acquisition of Trasir Therapeutics Inc. in 2021, which was treated as an asset acquisition because substantially all the fair value of Trasir was concentrated in a worldwide exclusive license agreement with Washington University (Note 3). Amortization will commence once the intangible assets are available for use, which will be the case after regulatory approvals are obtained and the related products are available for use.

Investment in an Associate

Investment in an Associate	12 Months Ended
	Dec. 31, 2023
Investment in an Associate [Abstract]
Investment in an associate	10. Investment in an associate On November 21, 2023 the Company closed the transaction for the partial divestiture of its Bentrio® business, by selling a 51% stake in its subsidiary Altamira Medica AG (“Medica”). The transaction also includes the sale of Auris Medical Pty Ltd, Melbourne (Australia), a wholly owned subsidiary of Altamira Medica AG. The two companies sold represent the entirety of the Bentrio® business and are presented as discontinued operations. Until the date of the transaction, Altamira Medica AG and Auris Medical Pty Ltd., Melbourne (Australia), were fully consolidated as the Company had control of these wholly owned subsidiaries. Following the sale, the new owner holds the majority of the voting rights and may appoint a majority of the Board of Directors of Medica. As a result of the transaction the Company has lost control but has the power to participate in the financial and operating policy decisions of its former subsidiary. Therefore, the retained share of 49% in Medica is accounted for as investment in an associate using the equity method. Further, the transaction included a cash contribution of CHF 1,000,000 in total to Altamira Medica’s capital by its two shareholders pro rata of their shareholdings following the closing. Accordingly, the Company has contributed CHF 490,000 in cash to its investment in Altamira Medica. The following table illustrates the summarized financial information of the Company’s investment in Altamira Medica: December 31, 2023 Current assets 1,793,690 Non-current assets - Current liabilities (897,665 ) Non-current liabilities (989,411 ) Equity (93,386) Company’s share in equity - 49% (45,759) Goodwill 2,463,071 Company’s carrying amount of the investment 2,417,312 The associate had no contingent liabilities or capital commitments as at December 31, 2023. Nov 22, 2023 Revenue from contracts with customers 379 Cost of sales (33,967 ) Operating expenses (29,321 ) Finance costs (15,732 ) Profit before tax (78,641 ) Income tax expense (2,087 ) Profit after tax (80,728 ) Other comprehensive income 14,018 Total comprehensive income (66,710 ) Company’s share of loss of associate for the period (39,557 )

Inventories

Inventories	12 Months Ended
	Dec. 31, 2023
Investment [Abstract]
Inventories	11. Inventories December 31, December 31, 2023 2022 Finished goods - 11,644 Total - 11,644 At December 31, 2022 the Company’s inventory of finished goods consisted of the product Bentrio®, a drug-free nasal spray for protection against airborne viruses and allergens. Bentrio® has a limited shelf life, which may affect the salability of the product, and is packaged in various configurations (stock keeping units, “SKUs”) for different markets and in different languages to address specific requirements under national rules and regulations or by trade channels. Based on a management review of the inventory as at December 31, 2022 for any obsolete or slow-moving items, the Company wrote down finished good inventories in the amount of CHF 0.9 million in 2022. After the Bentrio Business was sold in November 2023, the Company no longer had any inventory as at December 31, 2023.

Other Receivables

Other Receivables	12 Months Ended
	Dec. 31, 2023
Other Receivables [Abstract]
Other receivables	12. Other receivables December 31, December 31, 2023 2022 R&D tax credit receivable - 672,600 Value added tax receivable 22,036 78,650 Receivable from suppliers and other 52,787 4,737 Total other receivables 74,823 755,987 The R&D tax credit receivable as of December 31, 2022 relates to the reimbursement application for compensation of R&D expenditures incurred in 2022 under the Australian R&D Tax Incentive program. The subsidiary Auris Medical Pty Ltd, Melbourne, Australia, which is eligible for the tax credit, was sold in 2023. Other receivables were not considered impaired in the years presented herein. Receivable from suppliers include CHF 18,905 receivable from an associate.

Prepayments

Prepayments	12 Months Ended
	Dec. 31, 2023
Prepayments [Abstract]
Prepayments	13. Prepayments December 31, December 31, 2023 2022 Advance payments to suppliers 212,579 659,861 Insurance 71,253 49,405 Total prepayments 283,832 709,266

Cash and Cash Equivalents

Cash and Cash Equivalents	12 Months Ended
	Dec. 31, 2023
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	14. Cash and cash equivalents December 31, December 31, 2023 2022 Cash in bank accounts 617,409 15,395 Cash on hand - - Total cash and cash equivalents 617,409 15,395

Capital and Reserves

Capital and Reserves	12 Months Ended
	Dec. 31, 2023
Capital and Reserves [Abstract]
Capital and reserves	15. Capital and reserves Share capital The issued share capital of the Company at December 31 consisted of: December 31, December 31, 2023 2022 Number USD Number CHF Common shares with par value of USD 0.002 each* 1,477,785 2,956 59,003 236,011 Total 1,477,785 2,956 59,003 236,011 Common Shares (Number) 2023 2022 As of January 1 59,003 37,411 Exercise of warrants 81,274 - Public Offering 555,556 - LPC equity line 17,500 15,750 ATM program 104,147 5,842 Conversion convertible loans 660,345 - Fractional shares eliminated upon reverse split (40 ) - Total, as of December 31 1,477,785 59,003 * The par value of the common shares was reduced from CHF 4.00 and changed to USD 0.0001 following approval the Company’s special general meeting of October 31, 2023, and subsequently the board of directors in December 2023 consolidated the then common shares of par value $0.0001 each at a ratio of 20:1, into common shares of par value $0.002 each. In total the share capital was reduced by CHF 2,903,684 to CHF 2,646 (USD 2,956) and the amount of the reduction was credited to share premium. On July 10, 2023, the Company closed a public offering of 43,750 common shares and 511,806 pre-funded warrants and accompanying common warrants to purchase up to 555,556 common shares, at a combined public offering price of $9.00 per share, pre-funded warrant and accompanying common warrant. The common warrants have an exercise price of CHF 8.00 per share, are exercisable immediately and expire five years from the date of issuance. The Company additionally granted 36,113 warrants to the Placement Agent with a strike price of CHF 10.00 and an exercise period of 5 years. As of December 31, 2023, all pre-funded warrants were exercised for a total amount of $112,597 (CHF 102,361). The total gross proceeds from the offering amounted to $5,000,000 (CHF 4,444,445). Directly related transaction costs of $ 718,767 (CHF 639,873) were recorded as a deduction in equity. The fair value of each of the warrants issued was calculated using the Black-Scholes valuation model. The fair value calculation assumptions included volatility of 107.34% and an annual risk-free rate of 4.25%. The total fair value of the warrants issued amounted to CHF 3,921,647 and was recorded in equity as a cost of the offering. On May 1, 2023, we entered into a convertible loan agreement with FiveT IM, pursuant to which FiveT IM has agreed to loan to the Company CHF 2,500,000, which bears interest at the rate of 10% per annum and matures 22 months from May 4, 2023 (the “2023 FiveT Loan”). FiveT IM will have the right to convert all or part of the convertible loan, including accrued and unpaid interest, at its option, into common shares, subject to the limitation that FiveT IM own no more than 4.99% of the common shares at any time. The conversion price was fixed at CHF 28.40 per common share (subject to adjustment for share splits or other similar events). Commencing 60 days after May 4, 2023 we must repay at least 1/20th of the outstanding loan plus accrued interest pro rata in monthly tranches which, at our discretion, may be paid at any time during the month either in: (i) cash plus 3% of the principal amount of the tranche or (ii) common shares, or a combination of both. Such shares will be priced at the lower of (i) the mean daily trading volume weighted average price for the common shares on the 20 trading days preceding the repayment date or (ii) 90% of the daily trading volume weighted average price (“VWAP”) for common shares on the repayment date. We made the last amortization of the 2023 FiveT Loan on December 8, 2023. In total, we made aggregate cash payments of CHF 387,045 and issued an aggregate 443,294 common shares at an average price of CHF 5.07 to FiveT IM under the 2023 FiveT Loan. Share premium By decision of the Annual General Meeting of June 27, 2023, the share premium of the company was reduced by an amount of CHF 186,852,242 and credited to the contributed surplus account of the Company. Further, FiveT IM received warrants to purchase an aggregate of 81,274 common shares at an exercise price of CHF 30.76 per common share, which may be exercised up to five years. On December 7, 2023, we entered into a letter agreement (the “Warrant Inducement Agreement”) under which FiveT IM was granted the option to exercise the warrants by or before December 14, 2023 at a reduced exercise price which was defined as 90% of the daily trading volume weighted average price for our common shares on the NASDAQ stock exchange on the trading day following the date of each such exercise and receive additional warrants upon any such exercise. FiveT IM exercised all existing warrants at the weighted average exercise price of CHF 6.656 per common share, yielding proceeds of CHF 541,034 to the Company. The repricing in accordance with the warrant inducement agreement led to a reclassification of a portion of the existing warrants from equity to derivative financial liabilities. A revaluation gain from derivative financial instruments of CHF 15,066 was realized on the revaluation of the existing warrants between the date of the Warrant Inducement Agreement and the date of the exercise of the warrants. The fair value was determined using Black-Scholes valuation model. On December 15, 2023, we issued to FiveT IM new warrants to purchase 81,274 common shares at CHF 6.656 each for six months from their date of issuance and to purchase 81,274 common shares at CHF 6.656 each for two years from their date of issuance. The fair value of the new warrants issued was calculated using the Black-Scholes valuation model. Fair value assumptions included volatility of 113.4% and 115.0% and annual risk-free interest rates of 5.4% and 4.7% for the new warrants issued with 0.5 and 2 years maturity. The total fair value of the new warrants issued was CHF 165,041 and was recorded in equity. On February 4, 2022, the Company entered into a convertible loan agreement with FiveT IM. The convertible loan of CHF 5.0 million, as amended (the “2022 FiveT Loan”) carried interest at the rate of 10% per annum and was to mature on May 31, 2023. FiveT IM had the right to convert all or part of the 2022 FiveT Loan, including accrued and unpaid interest, at its option, into common shares, subject to the limitation that FiveT IM own no more than 4.9% of the common shares at any time. On April 13, 2023, the Company and FiveT IM entered into an amendment to the 2022 FiveT Loan (the “2022 FiveT Loan Amendment”), which amended the conversion price of the 2022 FiveT Loan to a fixed price equal to the lower of (a) the mean daily VWAP of the Company’s common shares on the Nasdaq Stock Market on the 20 trading days preceding the effective date of the 2022 FiveT Loan Amendment or (b) 90% of the VWAP on the effective date of the 2022 FiveT Loan Amendment. From April 13, 2023 to April 17, 2023, FiveT IM converted the entire 2022 FiveT Loan into an aggregate 217,051 common shares at a conversion price of $28.95 (CHF 25.73) per share. As a result, the 2022 FiveT Loan is no longer outstanding and has been terminated. On December 5, 2022, the Company entered into a purchase agreement and a Registration Rights Agreement with Lincoln Park Capital Fund, LLC (the “2022 Commitment Purchase Agreement”). Pursuant to the purchase agreement, LPC agreed to subscribe for up to $10,000,000 of our common shares over the 24-month term of the purchase agreement. As consideration for LPC’s irrevocable commitment to purchase common shares upon the terms of and subject to satisfaction of the conditions set forth in the 2022 Commitment Purchase Agreement, the Company agreed to issue 2,500 common shares immediately to LPC as commitment shares. In 2023, we issued an aggregate 17,500 common shares for aggregate proceeds of $854,475 (CHF 776,198) to LPC under the 2022 Commitment Purchase Agreement. The 2022 Commitment Purchase Agreement replaced the 2020 Commitment Purchase Agreement. Under the 2020 Commitment Purchase Agreement, LPC agreed to subscribe for up to $10,000,000 of our common shares over the 30-month term of the purchase agreement. Prior to its termination we had issued 16,250 common shares for aggregate proceeds of $4.0 million to LPC under the 2020 Commitment Purchase Agreement. On November 30, 2018, we entered into the A.G.P. Sales Agreement with A.G.P. Pursuant to the terms of the A.G.P. Sales Agreement, as amended on April 5, 2019, we may offer and sell our common shares, from time to time through A.G.P. by any method deemed to be an “at-the-market” offering as defined in Rule 415(a)(4) promulgated under the Securities Act. Pursuant to the A.G.P. Sales Agreement, we may sell common shares up to a maximum aggregate offering price of $25.0 million. In 2023, we sold 104,147 shares under the ATM for aggregate proceeds of $5.1 million (CHF 4.7 million). We terminated the A.G.P. Sales Agreement effective January 1, 2024. Prior to its termination, we sold an aggregate 123,512 of our common shares for an aggregate offering price of $13.1 million pursuant to the A.G.P. Sales Agreement. The related transaction costs were charged to equity. Authorized share capital Our authorized share capital as of December 31, 2023 consisted of 5,000,000 common shares, par value $0.002 per share, and 20,000,000 preference shares, par value $0.0001 per share.

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2023
Share Based Compensation [Abstract]
Share-based compensation	16. Share-based compensation Description In 2014, the Company introduced an equity incentive plan (the (“EIP”), which was amended in 2017 and 2019. In 2023, the Company granted 138,907 options (2022: 4,885 options) under the EIP. Holders of vested options are entitled to purchase common shares of the Company. Under the Equity Incentive Plan, the Board of Directors defined the exercise price as the average daily closing price of the Company’s shares during the 30 days preceding the date of grant. All options are to be settled by the physical delivery of shares. The key terms and conditions related to the grants under these programs at December 31, 2023 are as follows: Number of Contractual options life of Plan outstanding Vesting conditions options Equity Incentive Plan Board 7,898 1 year service from grant date 6 years Equity Incentive Plan Management & Staff 68,713 2 years’ service from grant date (50%) 8 years Equity Incentive Plan Management & Staff 68,713 3 years’ service from grant date (50%) 8 years Measurement of fair values The fair value of the options was measured based on the Black-Scholes formula. Stock Option Plan Equity Incentive Equity Incentive Equity Incentive Equity Incentive Plan 2023 Plan 2023 Plan 2022 Plan 2022 Fair value at grant date USD 1.72 (2 year vesting) 1) 1) USD 6.674 (1 year vesting) 2) USD 10.918 (2 year vesting) 2) 2) USD 86.94 (2 year vesting) 1) 1) USD 132.88 (1 year vesting) 2) 2) 2) Share price at grant date USD 2.92 USD 19.2 USD 149.6 USD 356 Exercise price USD 2.92 USD 19.2 USD 127.06 USD 415.60 Expected volatility 108.87% 111.23% 100.2% 99.1% Expected life 2 and 3 years 1, 2 and 3 years 2 and 3 years 1, 2 and 3 years Expected dividends — — — — Risk-free interest rate 4.90% 4.37% 4.45% 2.87% 1) October grants for the respective year 2) April grants for the respective year The Company uses its own historic volatility to calculate expected volatility. The expected life of all options is assumed to correspond to the vesting period. The total expense recognized for equity-settled share-based payment transactions were CHF 379,414 in 2023 (2022: CHF 342,799, 2021: CHF 1,206,303). The number and weighted average exercise prices (in CHF) of options under the share option programs are as follows: The range of exercise prices for outstanding options was CHF 2.46 to CHF 10,637 as of December 31, 2023 and CHF 117.6 to CHF 11,693.20 as of December 31, 2022. 2023 2022 Weighted Weighted Weighted Weighted average average average average Number of exercise remaining Number of exercise remaining options price term options price term Outstanding at January 1 7,884 385.60 6.22 3,324 660.00 6.56 Expired during the year - - - - - - Forfeited during the year (1,467 ) - - (325 ) - - Exercised during the year - - - - - Granted during the year 138,907 4.76 - 4,885 188.00 - Outstanding at December 31 145,324 22.17 5.62 7,884 385.60 6.22 Exercisable at December 31 2,630 - - 1,440 - -

Trade and Other Payables

Trade and Other Payables	12 Months Ended
	Dec. 31, 2023
Trade and Other Payables [Abstract]
Trade and other payables	17. Trade and other payables December 31, December 31, 2023 2022 Trade accounts payable - third parties 413,111 4,767,940 Other 27,303 146,464 Total trade and other payables 440,414 4,914,404

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2023
Accrued Expenses [Abstract]
Accrued expenses	18. Accrued expenses December 31, December 31, 2023 2022 Accrued research and development costs including milestone payments 87,522 741,291 Professional fees 17,412 326,365 Accrued vacation & overtime 52,368 46,868 Employee benefits incl. share based payments 190,610 362,497 Accrued interest - 457,812 Other 929 42,781 Total accrued expenses 348,841 1,977,614

Deferred Income

Deferred Income	12 Months Ended
	Dec. 31, 2023
Deferred Income [Abstract]
Deferred income	19. Deferred income December 31, December 31, 2023 2022 Upfront payment - 932,200 Total deferred income - 932,200 As of December 31, 2022, deferred income included an upfront payment of $1 million (CHF 0.9 million) related to the exclusive licensing and distribution agreement with Nuance for Bentrio® in the defined territory. Revenue recognition for the upfront payment is deferred until transfer of production to Nuance, which will occur 4 years after Nuance obtaining the first national registration of Bentrio® in the territory or upon Nuance’s cumulative orders for Bentrio® reaching a contractually defined minimum quantity of Bentrio® from the Company, whichever comes later. Deferred income at December 31, 2023 is zero, as this item is part of the net assets disposed in the sale of Altamira Medica.

Other Operating Income

Other Operating Income	12 Months Ended
	Dec. 31, 2023
Other Operating Income [Abstract]
Other operating income	20. Other operating income 2023 2022 2021 Income from Government grants 228,302 - - Other income 27,287 9,327 - Total other operating income 255,589 9,327 - Revised for the reclassification of certain activities as discontinued operations in 2022 and 2021 – refer to Notes 1, 10 and 27.

Research and Development Expens

Research and Development Expense	12 Months Ended
	Dec. 31, 2023
Research and Development Expense [Abstract]
Research and development expense	21. Research and development expense 2023 2022 2021 Pre-clinical projects 505,031 389,673 96,840 Clinical projects 128,717 67,096 63,757 Product and process development 364,392 199,225 164,684 Employee benefits and expenses 1,429,564 1,426,299 934,577 Patents and trademarks 414,718 155,589 333,519 Regulatory projects 59,531 34,098 32,564 Impairment intangible assets - 12,338,837 1,529,929 Depreciation tangible assets - - 46,635 Other research and development expense 133,459 10,753 - Total research and development expense 3,035,413 14,621,570 3,202,505 Revised for the reclassification of certain activities as discontinued operations in 2022 and 2021 – refer to Notes 1, 10 and 27.

General and Administrative Expe

General and Administrative Expenses	12 Months Ended
	Dec. 31, 2023
General and Administrative Expenses [Abstract]
General and administrative expenses	22. General and administrative expenses 2023 2022 2021 Employee benefits and expenses 655,967 645,138 1,371,526 Business development 15,348 15,727 39,916 Travel expenses 43,055 95,503 75,829 Administration expenses 2,274,159 2,517,309 2,098,866 Lease expenses from short-term lease 15,705 6,001 52,280 Depreciation of Right-of-use assets 119,304 118,887 29,722 Depreciation of tangible assets - - - Capital tax expenses 12,738 3,110 706 Total general and administrative expenses 3,136,275 3,401,676 3,668,845 Revised for the reclassification of certain activities as discontinued operations in 2022 and 2021 – refer to Notes 1, 10 and 27.

Employee Benefits

Employee Benefits	12 Months Ended
	Dec. 31, 2023
Employee Benefits [Abstract]
Employee benefits	23. Employee benefits 2023 2022 2021 Salaries 2,145,943 2,815,411 1,865,633 Pension costs 172,460 266,256 165,801 Other social benefits 293,753 294,017 275,258 Share based payments costs 379,414 342,799 1,223,696 Other personnel expenditures 9,999 2,024 214,940 Total employee benefits 3,001,569 3,720,507 3,745,328 Employee benefits attributable to continuing operations 2,243,955 2,071,436 2,375,668 Employee benefits attributable to discontinued operations 757,614 1,649,071 1,369,660 Benefit plans The Company participates in a retirement plan (the “Plan”) organized as an independent collective foundation, that covers all of its employees in Switzerland, including management. The collective foundation is governed by a foundation board. The board is made up of an equal number of employee and employer representatives of the affiliated companies. The Company has no direct influence on the investment strategy of the collective foundation. Moreover, certain elements of the employee benefits are defined in the same way for all affiliated companies. This is mainly related to the annuity factors at retirement and to interest allocated on retirement savings. The employer itself cannot determine the benefits or how they are financed directly. The foundation board of the collective foundation is responsible for the determination of the investment strategy, for making changes to the pension fund regulations and in particular also for defining the financing of the pension benefits. The old age benefits are based on retirement savings for each employee, coupled with annual retirement credits and interest (there is no possibility to credit negative interest). At retirement age, the insured members can choose whether to take a pension for life, which includes a spouse’s pension, or a lump sum. In addition to retirement benefits, the plan benefits also include disability and death benefits. Insured members may also buy into the scheme to improve their pension provision up to the maximum amount permitted under the rules of the plan and may withdraw funds early for the purchase of a residential property for their own use subject to limitations under Swiss law. On leaving the Company, retirement savings are transferred to the pension institution of the new employer or to a vested benefits institution. This type of benefit may result in pension payments varying considerably between individual years. In defining the benefits, the minimum requirements of the Swiss Law on Occupational Retirement, Survivors and Disability Pension Plans (BVG) and its implementing provisions must be observed. The BVG defines the minimum pensionable salary and the minimum retirement credits. In Switzerland, the minimum interest rate applicable to these minimum retirement savings is set by the Swiss Federal Council at least once every two years. The rate was 1.00% in 2021, 1.00% in 2022 and 1.00% in 2023. The assets are invested by the collective foundation to which many companies contribute, in a diversified portfolio that respects the requirements of the Swiss BVG. Therefore, disaggregation of the pension assets and presentation of plan assets in classes that distinguish the nature and risks of those assets is not possible. Under the Plan, both the Company and the employee share the costs equally. The structure of the plan and the legal provisions of the BVG mean that the employer is exposed to actuarial risks. The main risks are investment risk, interest risk, disability risk and the risk of longevity. Through the affiliation to a collective foundation, the Company has minimized these risks, since they are shared between a much greater number of participants. For accounting purposes under IFRS, the plan is treated as a defined benefit plan. The following tables present information about the net defined benefit liability and its components: Change in defined benefit obligation 2023 2022 Defined benefit obligation at January 1 3,544,161 4,677,632 Service costs 163,101 256,336 Plan participants’ contribution 130,875 154,116 Interest cost 76,139 13,762 Actuarial losses 104,860 (931,636 ) Plan amendments - - Benefits paid through pension assets (78,957 ) (626,049 ) Defined benefit obligation at December 31 3,940,179 3,544,161 The defined benefit obligation includes only liabilities for active employees. The weighted average modified duration of the defined benefit obligation at December 31, 2023 is 17.7 years (2022: 17.1 years). Change in fair value of plan assets 2023 2022 Fair value of plan assets at January 1 3,207,955 4,009,313 Interest income 71,813 12,187 Return on plan assets excluding interest income 136,023 (490,359 ) Employer contributions 130,875 154,116 Plan participants’ contributions 130,875 154,116 Benefits paid through pension assets (78,957 ) (626,049 ) Administration expense (5,033 ) (5,369 ) Fair value of plan assets at December 31 3,593,551 3,207,955 Expected employer and plan participants’ contributions to the plan for the annual reporting period 2024 are CHF 128,608 each. December 31, December 31, 2023 2022 Present value of funded defined benefit obligation 3,940,179 3,544,161 Fair value of plan assets (3,593,551 ) (3,207,955 ) Net defined benefit liability 346,628 336,206 Defined Benefit Cost 2023 2022 2021 Service cost 163,101 256,336 159,085 Net interest expense 3,270 1,575 1,878 Administration expense 4,259 5,369 6,030 Total defined costs for the year recognized in profit or loss 170,630 263,280 166,993 Remeasurement of the Defined Benefit Liability 2023 2022 2021 Actuarial loss (gain) arising from changes in financial assumptions 247,262 (876,841 ) (74,284 ) Actuarial loss (gain) arising from experience adjustments (138,497 ) (54,795 ) 463,238 Actuarial gain arising from demographic assumptions (3,905 ) - (229,109 ) Return on plan assets excluding interest income (136,023 ) 490,359 (424,829 ) Total defined benefit cost for the year recognized in other comprehensive income (31,163 ) (441,277 ) (264,984 ) Assumptions 2023 2022 2021 Discount rate 1.50 % 2.20 % 0.30 % Future salary increases 1.35 % 1.60 % 0.85 % Pension indexation 0.00 % 0.00 % 0.00 % BVG2020 BVG2020 BVG2020 Sensitivity analysis Reasonably possible changes at the reporting date to one of the relevant actuarial assumptions, holding other assumptions constant, would have affected the defined benefit obligation by the amounts shown below. 2023 2022 Change in assumption 0.25% increase 0.25% increase Discount rate (141,340 ) (177,546 ) Salary increase (22,950 ) 23,058 Pension indexation 78,491 63,916 Change in assumption +1 year +1 year Life expectancy 63,383 48,531 The above sensitivity analyses are based on a change in an assumption while holding all other assumptions constant. In practice, this is unlikely to occur, and changes in some of the assumptions may be correlated. When calculating the sensitivity of the defined benefit obligations to significant actuarial assumptions the same method (present value of the defined benefit obligation calculated with the projected unit credit method at the end of the reporting period) has been applied as that used in calculating the pension liability recorded on consolidated balance sheets. The methods and types of assumptions used in preparing the sensitivity analysis did not change compared to the prior period.

Finance Income and Finance Expe

Finance Income and Finance Expense	12 Months Ended
	Dec. 31, 2023
Finance Income and Finance Expense [Abstract]
Finance income and finance expense	24. Finance income and finance expense 2023 2022 2021 Interest income 302,249 114,268 26,990 Net foreign currency exchange gain - - 47,161 Revaluation gain from derivative financial instruments 15,066 451,131 5,085 Gain on modification of financial instruments 36,778 - - Total finance income 354,093 565,399 79,236 Interest expense (incl. bank charges) 1,032,444 904,345 14,112 Net foreign currency exchange loss 447,456 305,560 - Revaluation loss from derivative financial instruments 181,258 - - Loss on modification of financial instruments 7,317 - - Transaction costs - 1,137 - Total finance expense 1,668,475 1,211,042 14,112 Finance expense, net (1,314,382 ) (645,643 ) 65,124 Revised for the reclassification of certain activities as discontinued operations in 2022 and 2021 – refer to Notes 1, 10 and 27. In 2023, the revaluation gain from derivative financial instruments of CHF 15,066 relates to the fair value change of warrants attached to the 2023 FiveT convertible loan. The revaluation loss from derivative financial instruments of CHF 181,258 is related to the revaluation of the financial derivatives embedded in the 2022 FiveT convertible loan at conversion. The gain and loss on modification of financial instruments of CHF 36,778 and CHF 7,317 respectively, were realized on the modification of loans with warrants. In 2022, the revaluation gain from derivative financial instruments of CHF 451,131 includes CHF 449,898 related to the revaluation of the financial derivatives embedded in the 2022 FiveT convertible loan and CHF 1,233 related to the revaluation of outstanding warrants from public offerings. Total interest expense recognized using the effective interest rate method amounted to CHF 1,007,437 in 2023, CHF 892,005 in 2022 and CHF 4,991 in 2021.

Taxation

Taxation	12 Months Ended
	Dec. 31, 2023
Taxation [Abstract]
Taxation	25. Taxation The Group’s income tax expense recognized in the consolidated statement of profit or loss and other comprehensive loss was as follows: 2023 2022 2021 Deferred income tax expense from continuing operations - (11,604 ) (431,164 ) Deferred income tax gain from continuing operations - 19,524 549,109 Deferred income tax expense from discontinued operations - (52,004 ) (139,565 ) Deferred income tax gain from discontinued operations 99,847 54,413 - Income tax gain/(loss) 99,847 10,329 (21,620 ) The Company’s effective income tax expense differed from the expected theoretical amount computed by applying the Company’s applicable weighted average tax rate of 15.8% in 2023 (2022: 13.7%, 2021: 13.5%) as summarized in the following table: Reconciliation 2023 2022 2021 Loss before income tax from continuing operations (7,270,038 ) (18,659,562 ) (6,806,226 ) Profit before income tax from discontinued operations 3,301,018 (7,879,178 ) (10,230,597 ) Accounting Profit before income tax (3,969,020 ) (26,538,740 ) (17,036,823 ) Income tax at statutory tax rates applicable to results in the respective countries 626,286 3,641,775 2,348,057 Effect of unrecognized temporary differences (5,423 ) (125,260 ) (632,031 ) Effect of unrecognized taxable losses (543,086 ) (3,015,088 ) (1,885,486 ) Effect of impact from application of different tax rates (43,534 ) (491,098 ) 223,215 Other effects 65,604 - (75,375 ) Income tax gain 99,847 10,329 (21,620 ) Income tax gain reported in the statement of profit or loss - 7,919 117,945 Income tax gain/(loss) attributable to discontinued operations 99,847 2,410 (139,565 ) As of December 31, 2023, the Company had unrecognized tax loss carryforwards amounting to CHF 60.6 million (2022: CHF 103.1 million), of which CHF 59.0 million related to Auris Medical AG, Otolanum AG and Altamira Therapeutics AG in Switzerland and CHF 1.6 million to Altamira Therapeutics Inc. in the United States (2022: CHF 101.4 million for Auris Medical AG, Otolanum AG, Zilentin AG and Altamira Medica AG and CHF 1.7 million for Auris Medical Inc.). The Company’s unrecognized tax loss carryforwards with their expiry dates are as follows: December 31, December 31, 2023 2022 Within 1 year 22,717,044 27,956,899 Between 1 and 3 years 13,625,930 31,668,498 Between 3 and 7 years 22,681,981 41,797,708 More than 7 years 1,581,616 1,691,572 Total 60,606,571 103,114,677 Due to the uncertainty surrounding the future results of operations and the uncertainty as to whether the Company can use the loss carryforwards for tax purposes, deferred tax assets on tax loss carryforwards were only considered to the extent that they offset taxable temporary differences within the same taxable entity. No deferred tax assets are calculated on temporary differences related to pension obligations from IAS 19. The tax effect of the major unrecognized temporary differences and loss carryforwards is presented in the table below: December 31, December 31, 2023 2022 Deductible temporary differences Deferred income - 111,025 Employee benefit plan 45,200 43,841 Total potential tax assets 45,200 154,866 Potential tax assets from loss carry-forwards not recognized 7,936,946 13,297,723 Total potential tax assets from loss carry-forwards and temporary differences not recognized 7,982,146 13,452,589

Loss Per Share

Loss Per Share	12 Months Ended
	Dec. 31, 2023
Loss Per Share [Abstract]
Loss per share	26. Loss per share Loss per share 2023 2022 2021 Loss attributable to owners of the Company (3,869,173 ) (26,528,411 ) (17,058,443 ) Weighted average number of shares outstanding 491,258 45,536 33,116 Basic and diluted loss per share (7.88 ) (582.58 ) (515.11 ) Loss per share for continuing operations 2023 2022 2021 Loss attributable to owners of the Company (7,270,038 ) (18,651,643 ) (6,688,281 ) Weighted average number of shares outstanding 491,258 45,536 33,116 Basic and diluted loss per share (14.80 ) (409.60 ) (201.97 ) For the years ended December 31, 2023 and 2022 basic and diluted loss per share is based on the weighted average number of shares issued and outstanding and excludes shares to be issued under the Stock Option Plans (Note 16) as they would be anti-dilutive. As of December 31, 2023, the Company had 145,324 options outstanding under its stock option plans. The average number of options outstanding between January 1, 2023 and December 31, 2023 was 41,803 (45,536 for the period between January 1, 2022 and December 31, 2022). As of December 31, 2023, the Company had warrants to purchase up to 759,167 of its common shares issued and outstanding (as of December 31, 2022, the Company had warrants to purchase up to 4,958 common shares).

Discontinued Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2023
Discontinued Operations [Abstract]
Discontinued operations	27. Discontinued operations On November 21, 2023 the Company closed the transaction for the partial divestiture of its Bentrio® business, by selling a 51% stake in its subsidiary Altamira Medica AG. The transaction also includes the sale of Auris Medical Pty Ltd, Melbourne (Australia), a wholly owned subsidiary of Altamira Medica AG. The two companies sold represent the entirety of the Bentrio® business and are presented as one discontinued operation. The retained share of 49% in Altamira Medica is accounted for as investment in an associate using the equity method. The gain on disposal of discontinued operations was determined as follows: November 21, Cash consideration received 2,040,000 Other consideration received 32,685 Total consideration received 2,072,685 Net assets disposed: Inventories (331,466 ) Prepaid expenses (218,395 ) Receivables and other assets (677,544 ) Cash and cash equivalents (115,676 ) Trade and other payables 1,104,399 Accrued liabilities 318,083 Deferred income 932,200 Foreign currency translation reserve, transfer to profit or loss 161,249 Total net assets disposed incl. currency translation reserve 1,172,850 Remeasurement of retained interest at fair value 1,960,000 Pre-tax gain on disposal of discontinued operation 5,205,535 Related tax expense - Gain on disposal of discontinued operation 5,205,535 Net cash inflow on disposal of discontinued operations Cash consideration received 2,040,000 Cash disposed of (115,676 ) Net cash inflow on disposal 1,924,324 Result of discontinued operations: 2023 2022 2021 Revenue 157,834 305,616 63,882 Cost of Sales (191,922 ) (1,443,855 ) (2,240,554 ) Other income 131,702 700,122 214,217 Operating expenses (1,870,939 ) (7,680,444 ) (7,934,264 ) Financial income/(expense), net (131,192 ) 239,383 (333,878 ) Tax (expense) / credit 99,847 2,410 (139,565 ) Gain on disposal of discontinued operation 5,205,535 - - Profit after tax from discontinued operations 3,400,865 (7,876,768 ) (10,370,162 ) Earnings per share from discontinued operations: 2023 2022 2021 Basic and diluted earnings / (loss) per share from discontinued operations 6.92 (172.98 ) (313.15 ) Statement of cash flows: 2023 2022 2021 Operating activities (1,092,385 ) (1,104,053 ) (2,612,264 ) Investing activities 67 67,406 (116,330 ) Financing activities 1,056,532 859,610 2,000,000 Net cash from discontinued operations (35,786 ) (177,037 ) (728,594 )

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies [Abstract]
Commitments and contingencies	28. Commitments and contingencies Lease commitments The future minimum lease payments under non-cancellable lease term that are not accounted for in the statement of financial position were as follows: December 31, December 31, 2023 2022 Within one year 3,946 3,450 Between one and five years - - Total 3,946 3,450 Office lease expenses of CHF 6,600 and CHF 6,001 were recorded in 2023 and 2022, respectively, in the consolidated statement of profit or loss and other comprehensive loss.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2023
Related Party Transactions [Abstract]
Related party transactions	29. Related party transactions For purposes of these consolidated financial statements, parties are considered to be related if one party has the ability to control the other party or exercise significant influence over the other party in making financial or operational decisions. Also, parties under common control of the Company are considered to be related. Key management personnel are also related parties. In considering each possible related party relationship, attention is directed to the substance of the relationship, and not merely the legal form. As of December 31, 2023, the Company held a receivable of CHF 18,905 against Auris Medical Pty Ltd, Melbourne (Australia), a wholly owned subsidiary of the associated company Altamira Medica AG. Gremaud GmbH provides the Chief Financial Officer to the Company since November 19, 2021. The Chief Financial Officer is an employee of Gremaud GmbH and is not paid directly by the Company. Fees paid to Gremaud GmbH for CFO services in 2023 were CHF 251,110 (2022: CHF 195,988). Fees paid to Gremaud GmbH for other services provided during the year ended December 31, 2023 were CHF 0 (2022: CHF 0). Samuel Wickline, Ph.D., the founder of Trasir, has been providing consulting services as Chief Scientific Adviser to the Company since January 2023. He was employed as Chief Scientific Officer from June 2021 to December 2022. Fees paid to Dr Wickline in 2023 amounted to CHF 172,512. Thomas Meyer, the Company’s CEO lent CHF 200,000 to the Company under the “September 9, 2022 Loan Agreement” with FiveT Investment Management Ltd., Dominik Lysek and Thomas Meyer for a total amount of CHF 600,000. The Loan was repaid in July 2023 including accrued interest. From December 8, 2022 to March 8, 2023, Mr. Meyer’s spouse provided one of the Company’s subsidiaries with a short-term loan of CHF 100,000.00, bearing interest at the rate of 5% per annum. Compensation of the members of the Board of Directors and Management In 2023, the compensation paid to management, excluding share bonuses and share-based payment charge, amounted to CHF 681,353 (2022: CHF 1,038,810; 2021: CHF 810,671). The fees paid to members of the Board of Directors in 2023 for their activities as board members totaled CHF 138,507 (2022: CHF 183,058; 2021: CHF 165,245). Executive Management Board of Directors Total 2023 2022 2021 2023 2022 2021 2023 2022 2021 Short term benefits 636,884 989,760 781,204 138,507 183,058 165,245 775,391 1,172,818 946,449 Post-employee benefits years 44,469 49,050 29,467 - - 44,469 49,050 29,467 Share bonuses - - 902,817 - - - - 902,817 Share-based payment 242,269 172,115 192,362 41,319 51,171 48,046 283,588 223,286 240,408 Total 923,622 1,210,925 1,905,850 179,826 234,229 213,291 1,103,448 1,445,154 2,119,141 In 2023, CHF 283,588 (2022: CHF 223,286; 2021: CHF 240,408) was expensed for grants of stock options to members of the Board of Directors and management. Contributions to pension schemes amounted to CHF 44,469, CHF 49,050 and CHF 29,467 during the years 2022, 2021 and 2020, respectively. No termination benefits or other long-term benefits were paid. Members of the Board of Directors and management held 99,318, 5,355 and 2,474 stock options as of December 31, 2023, 2022, and 2021, respectively.

Loans

Loans	12 Months Ended
	Dec. 31, 2023
Loans [Abstract]
Loans	30. Loans December 31, December 31, 2023 2022 Convertible loan February 2022 - 4,898,377 Loans with warrants - 871,420 Short-term loan from related party - 100,000 - 5,869,797 Convertible loan agreements December 31, December 31, 2023 2022 As of January 1 4,898,377 - Gross proceeds at disbursement date 2,500,000 5,000,000 Embedded derivative, separated (435,023 ) (449,898 ) Transaction costs allocated to host - (10,236 ) Carrying amount at initial recognition 6,963,354 4,539,866 Repayment in cash (285,562 ) - Converted principal amount (7,214,438 ) - Accrued interest - 447,945 Amortization 536,646 358,511 Total - 5,346,322 Accrued interest balance of December 31 - 447,945 Convertible loan balance of December 31 - 4,898,377 On April 13, 2023, the Company and FiveT IM entered into an amendment to the 2022 FiveT Loan (see below), which amended the conversion price of the 2022 FiveT Loan to a fixed price equal to the lower of (a) the mean daily trading volume weighted average price (“VWAP”) of the Company’s common shares on the Nasdaq Stock Market on the 20 trading days preceding the effective date of the FiveT Loan Amendment or (b) 90% of the VWAP on the effective date of the FiveT Loan Amendment. From April 13, 2023 to April 17, 2023, FiveT IM converted the entire 2022 FiveT Loan into an aggregate of 217,050 common shares at an average conversion price of $28.95 per share (CHF 25.69 per share). As a result, the 2022 FiveT Loan is no longer outstanding and has been terminated. The fair value of the embedded derivative in the 2022 FiveT Loan as of December 31, 2022, was zero. The amendment of the conversion price and the revaluation before conversion resulted in a revaluation loss from derivative financial instruments of CHF 181,258 recognized in profit and loss. On May 1, 2023, the Company entered into a convertible loan agreement with FiveT IM, pursuant to which FiveT IM has agreed to loan to the Company CHF 2,500,000, which bears interest at the rate of 10% per annum and matures 22 months from May 4, 2023 (the “2023 FiveT Loan”). FiveT IM had the right to convert all or part of the convertible loan, including accrued and unpaid interest, at its option, into common shares, subject to the limitation that FiveT IM own no more than 4.99% of the common shares at any time. The conversion price was fixed at CHF 28.40 per common share. Further, FiveT IM received warrants to purchase an aggregate of 81,274 common shares at an exercise price of CHF 30.76 per common share, which could be exercised for up to five years. Commencing 60 days after May 4, 2023 the Company had to repay at least 1/20th of the outstanding loan plus accrued interest pro rata in monthly tranches which, at the Company’s discretion, may be paid at any time during the month either in: (i) cash plus 3% or (ii) common shares, or a combination of both. Such shares are priced at the lower of (i) the mean daily trading volume weighted average price for the common shares on the 20 trading days preceding the repayment date or (ii) 90% of the daily trading volume weighted average price for common shares on the repayment date. On December 28, 2022, we entered into two separate loan agreements with two private investors (“Private Lenders”), as amended, pursuant to which Private Lenders have agreed to loan to the Company an aggregate of CHF 350,000, which loans bear interest at the rate of 5% per annum and was to mature as of May 30, 2023. The Company agreed to grant to the Private Lenders warrants to purchase an aggregate 2,359 common shares. The warrants are exercisable at an exercise price of CHF 89.02 per share for up to five years from the date of issuance. On May 12, 2023, the Company and the Private Lenders entered into an amendment to the loan agreement, which extended the maturity date of the loan from May 31, 2023 to July 31, 2023 and lowered the strike price for the Warrants attached to the loan to CHF 17.62 per common share, which is the Swiss Franc equivalent of the trading volume weighted average price for common shares on the NASDAQ stock exchange on the trading day preceding the date of the amendment. The loan was repaid on July 14, 2023. The loans with warrants are classified as a hybrid contract containing a host that is a financial liability and embedded derivatives (warrants) separated from the host. The embedded derivatives are classified as an equity component as they may be settled by the company exchanging a fixed amount of cash for a fixed number of its own equity instruments. The embedded derivatives are valued at initial recognition applying a Black-Scholes option pricing model. The valuation is based on input parameters, classified as Level 3. The fair value of the embedded derivative at initial recognition amounted to CHF 48,185 and was directly recognized in equity. The initial fair value of the liability component was derived by subtracting the fair value of the equity component from the nominal value of the loan. The host is subsequently carried at amortized cost, as of December 31, 2022, the carrying amount of the host amounted to CHF 305,873 and is included in the balance sheet under current liabilities. On September 9, 2022, the Company entered into a loan agreement with FiveT Investment Management Ltd. (“FiveT IM”), Dominik Lysek and Thomas Meyer, the Company’s CEO (the “Lenders”), pursuant to which the Lenders have agreed to loan to the Company an aggregate of CHF 600,000.00 (the “September 2022 Loan Agreement”), which loan bears interest at the rate of 5% per annum and matures as of March 31, 2023. The Company agreed to issue to the Lenders warrants to purchase an aggregate 2,085 common shares. Such warrants became exercisable immediately at an exercise price of CHF 144.00 per share, may be exercised up to five years from the date of issuance and may be exercised on a cashless basis in certain circumstances specified therein. Mr. Meyer lent CHF 200,000 of the total principal amount. On May 12, 2023, the Company and the Lenders entered into an amendment to the loan agreement, which extended the maturity date of the loan from May 31, 2023 to July 31, 2023, introduced a right for Lenders to convert the loan into common shares of the Company at CHF 22.40 per common share, which is the Swiss Franc equivalent of 120% of the mean daily trading volume weighted average price for common shares on the NASDAQ stock exchange on the 20 trading days preceding the date of the amendment, and a right for the Company to repay the loan in common shares of the Company priced at the lower of (i) the mean daily trading volume weighted average price for the common shares on the 20 trading days preceding the repayment date or (ii) 90% of the daily trading volume weighted average price for common shares on the repayment date, and lowered the strike price for the Warrants attached to the loan to CHF 17.62 per common share, which is the Swiss Franc equivalent of the trading volume weighted average price for common shares on the NASDAQ stock exchange on trading day preceding the date of the amendment. The loan was repaid on July 14, 2023. The loan with warrants is classified as a hybrid contract containing a host that is a financial liability and embedded derivatives (warrants) separated from the host. The embedded derivatives are classified as an equity component as they may be settled by the company exchanging a fixed amount of cash for a fixed number of its own equity instruments. The embedded derivatives are valued at initial recognition applying a Black-Scholes option pricing model. The valuation is based on input parameters, classified as Level 3. The fair value of the embedded derivative at initial recognition amounted to CHF 86,744 and was directly recognized in equity. The initial fair value of the liability component was derived by subtracting the fair value of the equity component from the nominal value of the loan. The host is subsequently carried at amortized cost, as of December 31, 2022, the carrying amount of the host amounted to CHF 561,062 and is included in the balance sheet under current liabilities. On February 4, 2022, the Company entered into a convertible loan agreement with FiveT IM. The convertible loan of CHF 5.0 million, as amended (the “2022 FiveT Loan”) carried interest at the rate of 10% per annum and was to mature on May 31, 2023. FiveT IM had the right to convert all or part of the 2022 FiveT Loan, including accrued and unpaid interest, at its option, into common shares, subject to the limitation that FiveT IM own no more than 4.9% of the common shares at any time. On April 13, 2023, the Company and FiveT IM entered into an amendment to the 2022 FiveT Loan (the “2022 FiveT Loan Amendment”), which amended the conversion price of the 2022 FiveT Loan to a fixed price equal to the lower of (a) the mean daily trading volume weighted average price (“VWAP”) of the Company’s common shares on the Nasdaq Stock Market on the 20 trading days preceding the effective date of the FiveT Loan Amendment or (b) 90% of the VWAP on the effective date of the FiveT Loan Amendment. From April 13, 2023 to April 17, 2023, FiveT IM converted the entire FiveT Loan into an aggregate of 217,051 common shares at an average conversion price of $28.95 per share. As a result, the FiveT Loan is no longer outstanding and has been terminated. The FiveT Loan was classified as a hybrid contract containing a host that is a financial liability and embedded derivatives separated from the host and measured at fair value with all changes in fair value recognized in profit or loss. The embedded financial derivatives are initially valued by an independent consultant, applying a simulation-based valuation approach. The valuation of the embedded financial derivatives is based on input parameters, classified as Level 3. One of the significant inputs is the historical volatility of the Company’s common shares. The underlying share price development has been simulated based on a Geometric Brownian Motion (GBM). In accordance with the GBM definition, a normalized, sustainable level of volatility was applied. The normalized volatility used at initial recognition was 90.7%, over a lookback period of 12 months. Other significant assumptions relate to the expected exercise date, the expected execution date, the calculation of the repayment amount, as well as assumptions with regards to the early repayment trigger and to the conversion option in Altamira shares. The embedded derivatives of the convertible loan are closely related to each other and are therefore accounted for as a single instrument (i.e., a compound derivative). Due to the conversion based on market share price, the conversion right may result in a variable number of conversion shares and the embedded derivatives are therefore classified as a financial liability. As of December 31, 2022, the carrying amount of the host for the unconverted outstanding loan amounted to CHF 4,898,377 and is included in the balance sheet under current liabilities. The fair value of the embedded derivatives amounted to CHF 0 (at initial recognition February 8, 2022: CHF 449,898). A revaluation gain related to fair value measurement of embedded derivatives of CHF 449,898 as well as effective interest expenses and transaction costs of CHF 807,593 in total were recorded in profit or loss.

Warrants from Public Offering

Warrants from Public Offering	12 Months Ended
	Dec. 31, 2023
Warrants from Public Offering [Abstract]
Warrants from Public Offering	31. Warrants from Public Offering On July 10, 2023, the Company closed a public offering of 43,750 common shares and 511,806 pre-funded warrants and accompanying common warrants to purchase up to 555,556 common shares, at a combined public offering price of $9.00 per share, pre-funded warrant and accompanying common warrant. The common warrants have an exercise price of CHF 8.00 per share, are exercisable immediately and expire five years from the date of issuance. The Company additionally granted 36,113 warrants to the Placement Agent with a strike price of CHF 10.0 and an exercise period of 5 years. As of December 31, 2023, all pre-funded warrants have been exercised for a total amount of $112,597 (CHF 102,361). The total gross proceeds from the offering amounted to $5,000,000 (CHF 4,444,445). Directly related transaction costs of $ 728,728 (CHF 639,873) were recorded as a deduction in equity. The fair value of each of the warrants issued was calculated using the Black-Scholes valuation model. The fair value calculation assumptions included volatility of 107.34 % and an annual risk-free rate of 4.25%. The total fair value of the warrants issued amounted to CHF 3,921,647 and has been recorded in equity as a cost of the offering.

Events After the Balance Sheet

Events After the Balance Sheet Date	12 Months Ended
	Dec. 31, 2023
Events after the balance sheet date [Abstract]
Events after the balance sheet date	32. Events after the balance sheet date On January 19, 2024, we entered into a sales agreement with H.C. Wainwright & Co., LLC (“HCW” and the “HCW Sales Agreement”). Pursuant to the terms of the HCW Sales Agreement we may offer and sell our common shares, from time to time through HCW by any method deemed to be an “at-the-market” offering as defined in Rule 415(a)(4) promulgated under the Securities Act. Pursuant to the HCW Sales Agreement. As of the date of this Annual Report, we have sold 637,460 shares under the HCW Sales Agreement for aggregate gross proceeds of $1.66 million.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Basis of consolidation	Basis of consolidation Subsidiaries Subsidiaries are entities controlled by the Company. The Company controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases. Transactions eliminated on consolidation All inter-company balances, transactions and unrealized gains on transactions have been eliminated in consolidation. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred.
Segment reporting	Segment reporting A segment is a distinguishable component of the Company that engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses that relate to transactions with any of the Company’s other components. The Chief Executive Officer is determined to be the Company’s Chief Operating Decision Maker (“CODM”). The CODM assesses the performance and allocates the resources of the Company as a whole, as all of the Company’s activities are focusing on the development of therapeutics for important unmet medical needs. Financial information is only available for the Company as a whole. Therefore, management considers there is only one operating segment under the requirements of IFRS 8, Operating Segments.
Foreign currency	Foreign currency Foreign currency transactions Items included in the financial statements of Company entities are measured using the currency of the primary economic environment in which the entity operates. Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in profit or loss. Non-monetary items that are measured based on historical cost in a foreign currency are not re-translated. Foreign operations Assets and liabilities of Company entities whose functional currency is other than CHF are included in the consolidation by translating the assets and liabilities into the reporting currency at the exchange rates applicable at the end of the reporting period. Income and expenses are translated at average exchange rates (unless this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transaction). These foreign currency translation differences are recognized in Other Comprehensive income/(loss) and presented in the foreign currency translation reserve in equity. When a foreign operation is disposed of such that control is lost, the cumulative amount in the translation reserve related to that foreign operation is reclassified to profit or loss as part of the gain or loss on disposal. Closing rates for the most significant foreign currencies relative to CHF: Geographical Reporting December 31, December 31, Currency area entities 2023 2022 CHF Swiss Franc Switzerland 5 1.0000 1.0000 USD Dollar United States 1 0.8451 0.9251 EUR Euro Europe 1 0.9287 0.9901 AUD Dollar Australia 1 0.5735 0.6305 Average exchange rates for the year for the most significant foreign currencies relative to CHF: Geographical Reporting Currency area entities 2023 2022 CHF Swiss Franc Switzerland 5 1.0000 1.0000 USD Dollar United States 1 0.8985 0.9550 EUR Euro Europe 1 0.9721 1.0050 AUD Dollar Australia 1 0.5971 0.6629
Property and equipment	Property and equipment Property and equipment is measured at historical costs less accumulated depreciation and any accumulated impairment losses. Historical costs include expenditures that are directly attributable to the acquisition of the items. When parts of an item of tangible assets have different useful lives, they are accounted for as separate tangible asset items (major components). Depreciation is calculated on a straight-line basis over the expected useful life of the individual asset. The applicable estimated useful lives are as follows: Production equipment 5 years Office furniture and electronic data processing equipment (“EDP”) 3 years Subsequent costs are included in the asset’s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. The carrying amount of the replaced part is derecognized. All other repairs and maintenance are charged to profit or loss during the financial period in which they are incurred. Depreciation methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate. When an asset is reviewed for impairment, the asset’s carrying amount may be written down immediately to its recoverable amount, provided the asset’s carrying amount is greater than its estimated recoverable amount. Management assesses the recoverable amount by assessing the higher of its fair value less costs to sell or its value in use. Cost and accumulated depreciation related to assets retired or otherwise disposed are removed from the accounts at the time of retirement or disposal and any resulting gain or loss is included in profit or loss in the period of disposition.
Intangible assets	Intangible assets Research and development Expenditures on the Company’s research programs are not capitalized, they are expensed when incurred. Expenditures on the Company’s development programs are generally not capitalized except if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development and to use or sell the asset. For the development projects of the Company, these criteria are generally only met when regulatory approval for commercialization is obtained. For the AM-125 program for the treatment of vertigo it was the Company’s assessment up to 2022 that the criteria mentioned above were met and therefore direct development expenditures were capitalized for AM-125 in 2021 and 2022, including intellectual property-related costs for the prosecution and registration of patents. As of December 31, 2022, all capitalized direct development costs related to AM-125 were impaired based on the impairment test performed under IFRS. The impairment was recognized as an R&D expense in 2022. Licenses, intellectual property and data rights Intellectual property rights that are acquired by the Company are capitalized as intangible assets if they are controlled by the Company, are separately identifiable and are expected to generate future economic benefits, even if uncertainty exists as to whether the research and development will ultimately result in a marketable product. Consequently, upfront and milestone payments to third parties for the exclusive use of pharmaceutical compounds in specified areas of treatment are recognized as intangible assets. Measurement Intangible assets acquired that have finite useful lives are measured at cost less accumulated amortization and any accumulated impairment losses. Subsequent expenditure Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditure, including expenditure on internally generated goodwill and brands, is recognized in profit or loss as incurred. Amortization All licenses of the Company have finite lives. Amortization will commence once the Company’s intangible assets are available for use which will be the case after regulatory approvals are obtained and the related products are available for use. Amortization of licenses is calculated on a straight-line basis over the period of the expected benefit or until the license expires, whichever is shorter. The estimated useful life is 10 years or the remaining term of patent protection. The Company assesses at each statement of financial position date whether intangible assets which are not yet ready for use are impaired.
Impairment of non-financial assets	Impairment of non-financial assets Property and equipment and intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. For the purpose of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (cash-generating units). An impairment loss is recognized as the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs to sell or value in use. Impairment losses are recognized in profit or loss. Assets that were previously impaired are reviewed for possible reversal of the impairment at each reporting date. Any increase in the carrying amount of an asset will be based on the depreciated historical costs had the initial impairment not been recognized.
Asset purchase	Asset purchase On June 1, 2021, we acquired 100% of the share capital of privately held Trasir Therapeutics Inc. (“Trasir”) through the merger of our subsidiary Auris Medical Inc. with and into Trasir (the “Merger”), with Trasir surviving the merger as the surviving entity. Trasir was subsequently renamed Altamira Therapeutics, Inc. and redomiciled in Dover, Delaware. Founded in 2014, Trasir has been a pioneer in the development of nanoparticles for extrahepatic oligonucleotide delivery. The purchase price for Trasir comprised: (i) 1,911 non-registered common shares of the Company, par value CHF 4.00 per share, calculated based on a value of $2,500,000 divided by the average closing price of the Common Shares on the 15 trading days preceding the closing date (the “Reference Price”, which amounted to $1,308 per Common Share); (ii) contingent on the occurrence of positive results from a subsequent post-closing scientific study led by Trasir (“Positive Results”), $1,500,000 of common shares of the Company to be calculated based on the average closing price of the common shares on the 15 trading days preceding the occurrence of Positive Results; and (iii) $210,000 for expenses incurred by certain selling Trasir shareholders paid in $180,000 in cash and 23 non-registered common shares based on the Reference Price. Trasir’s main asset is an exclusive license agreement (the “License Agreement”) with Washington University located in St. Louis, Missouri (“WU”). Pursuant to the License Agreement, WU granted Trasir an exclusive, worldwide, royalty-bearing license (with the right to sublicense) during the term of the License Agreement under certain patent rights owned or controlled by WU to research, develop, make, have made, sell, offer for sale, use and import pharmaceutical products covered under such patent rights for all fields of use. Such licensed products may include “silencing RNA” (siRNAs) pharmaceutical preparations formulated in combination with Trasir’s proprietary delivery technologies. In consideration for such worldwide, exclusive license, the Company (through its acquisition of Trasir, described above) will be obligated to pay WU: annual license maintenance fees in the low five figures through first commercial sale; pre-clinical and clinical regulatory milestones; sales milestones; and a low single digit royalty based on annual net sales of licensed products worldwide for at least the applicable patent term or period of marketing exclusivity, whichever is longer, but in no case less than a minimum royalty term of 12 years; and a percentage share (in the double digits) of sublicensing revenues received by the Company in connection with licensed products. Such regulatory and sales milestones may total up to an aggregate of $4,375,000. In the event the Company fails to meet certain regulatory diligence milestones, WU will have the right to terminate the license. The acquisition of Trasir was treated as an asset acquisition because substantially all the fair value is concentrated in a single identifiable asset, the License Agreement with WU. The acquisition of the license is settled to a large extent in exchange for a variable number of the Company’s publicly listed shares. IFRS 2 “Share-based payments” was applied. With regards to the contingent part of the purchase price as mentioned under (ii) above, a downward adjustment of CHF 269,700 to the estimated fair value was made to reflect the possibility of not meeting the condition of Positive Results. As of December 31, 2022 and December 31, 2023, the total carrying amount of the license acquired amounted to CHF 3,893,681, including directly attributable transaction costs of CHF 198,246.
Leases	Leases The Company assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Company recognizes lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets. Right-of-use assets The Company recognizes right-of-use assets at the commencement date of the lease. Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurements of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date. Unless the Company is reasonably certain to obtain ownership of the leased asset at the end of the lease term, the recognized right-of-use assets are depreciated on a straight-line basis over the shorter of its estimated useful life and the lease term. Right-of-use assets are subject to impairment. Lease liabilities At the commencement date of the lease, the Company recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Company and payments of penalties for terminating a lease, if the lease term reflects the Company exercising the option to terminate. The variable lease payments that do not depend on an index or a rate are recognized as expense in the period during which the event or condition that triggers the payment occurs. In calculating the present value of lease payments, the Company uses the incremental borrowing rate at the lease commencement date if the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accumulation of interest and reduced by the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change in the assessment to purchase the underlying asset. Short-term leases and leases of low-value assets The Company applies the short-term lease recognition exemption to its short-term leases. It also applies the lease of low-value assets recognition exemption to leases that are considered of low value (i.e. below CHF 5,000). Lease payments on short-term leases and leases of low-value assets are recognized as expense over the lease term.
Associates	Associates Where the Company has the power to participate in (but not control) the financial and operating policy decisions of another entity, it is classified as an associate. Associates are initially recognized in the consolidated statement of financial position at cost. An investment in an associate that represents the retained interest in a former subsidiary is recognized at its fair value at the date when control is lost. Subsequently associates are accounted for using the equity method, where the Company’s share of post-acquisition profits and losses and other comprehensive income is recognized in the consolidated statement of profit and loss and other comprehensive income (except for losses in excess of the Company’s investment in the associate unless there is an obligation to make good on those losses). Profits and losses arising on transactions between the Company and its associates are recognized only to the extent of unrelated investors’ interests in the associate. The investor’s share in the associate’s profits and losses resulting from these transactions is eliminated against the carrying value of the associate. Any premium paid for an associate above the fair value of the Company’s share of the identifiable assets, liabilities and contingent liabilities acquired is capitalized and included in the carrying amount of the associate. Where there is objective evidence that the investment in an associate has been impaired the carrying amount of the investment is tested for impairment in the same way as other non-financial assets.
Inventories	Inventories Inventories are stated at the lower of cost and net realizable value. Cost comprises direct materials and, where applicable, direct labor costs and those overheads that have been incurred in bringing the inventories to their present location and condition. Cost is calculated using the first-in, first-out method. Net realizable value represents the estimated selling price less all estimated costs of completion and costs to be incurred in marketing, selling and distribution.
Discontinued operations	Discontinued operations A discontinued operation is a component of the Company’s business that represents a separate major line of business or geographical area of operations or is a subsidiary acquired exclusively with a view to resale, that has been disposed of, has been abandoned or that meets the criteria to be classified as held for sale. Discontinued operations are presented in the consolidated statement of comprehensive income/(loss) as a single line which comprises the post-tax profit or loss of the discontinued operation along with the post-tax gain or loss recognized on the re-measurement to fair value less costs to sell or on disposal of the assets or disposal Companies constituting discontinued operations. When an operation is classified as a discontinued operation, the comparative statement of profit or loss is re-presented as if the operation had been discontinued from the start of the comparative year. The objective is to provide the users of the financial statements with the most useful information to evaluate the financial effects of discontinued operations. Transactions between continuing and discontinued operations are presented as part of the respective continuing or discontinued operations. For the divested Bentrio business, this approach best reflects the continuance of the relationship. However, intragroup transactions between continuing and discontinued operations are eliminated in the financial statements as a whole.
Financial instruments	Financial instruments The Company classifies its financial assets in the following categories: loans and receivables based on the expected loss model. The classification depends on the nature and purpose of the financial assets and is determined at the time of initial recognition. Recognition and derecognition of non-derivative financial assets and liabilities The Company initially recognizes loans and receivables and debt securities issued on the date when they are originated. All other financial assets and financial liabilities are initially recognized on the trade date. The Company derecognizes a financial asset when the contractual rights to the cash flows from the asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred, or it neither transfers nor retains substantially all of the risks and rewards of ownership and does not retain control over the transferred asset. Any interest in such derecognized financial assets that is created or retained by the Company is recognized as a separate asset or liability. The Company derecognizes a financial liability when its contractual obligations are discharged, cancelled, or expired. Financial assets and financial liabilities are offset and the net amount presented in the statement of financial position when, and only when, the Company has a legal right to offset the amounts and intends either to settle them on a net basis or to realize the asset and settle the liability simultaneously. Non-derivative financial assets and liabilities—measurement Loans and receivable These are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. Loans and receivables are initially recognized at fair value plus any directly attributable transaction costs. Subsequent to initial recognition, they are measured at amortized cost using the effective interest method, less expected losses. Cash and cash equivalents The Company considers all short-term, highly liquid investments that are readily convertible into known amounts of cash and which are subject to an insignificant risk of changes in value with original maturities of three months or less at the date of the purchase to be cash equivalents. Non-derivative financial liabilities—measurement Non-derivative financial liabilities are initially recognized at fair value less any directly attributable transaction costs. Subsequent to initial recognition, these liabilities are measured at amortized cost using the effective interest method. Convertible loans In a convertible loan classified as a hybrid contract containing a host and a separated embedded derivative, both classified as liability, the carrying amount of the host contract at initial recognition is the difference between the carrying amount of the hybrid contract and the fair value of the embedded derivative. Transaction costs that relate to the issue of the convertible loan are allocated to the host and embedded derivative in proportion to the allocation of the gross proceeds. Transaction costs relating to the embedded derivative are immediately recognized in profit and loss. Transaction costs relating to the host contract are included in the carrying amount of the liability. The host contract is then subsequently measured at amortized cost, using the effective interest method. Share capital All shares of the Company are registered shares and classified as part of shareholders’ equity. Incremental costs directly attributable to the issue of the Company’s shares, net of any tax effects, are recognized as a deduction from equity. The warrants are classified as a financial liability at fair value through profit or loss and the cost allocated to the liability component will be immediately expensed to the income statement. The Company has not paid any dividends since its inception and does not anticipate paying dividends in the foreseeable future.
Impairment of non-derivative financial assets	Impairment of non-derivative financial assets Financial assets are assessed at each reporting date to determine whether there is objective evidence of impairment. Objective evidence that financial assets are impaired includes: ● default or delinquency by a debtor; ● indications that a debtor or issuer will enter bankruptcy; ● adverse changes in the payment status of borrowers or issuers; ● the disappearance of an active market for a security; or ● observable data indicating that there is measurable decrease in expected cash flows from a Company of financial assets. Financial assets measured at amortized cost The Company considers evidence of impairment for these assets at an individual asset level. An impairment loss is calculated as the difference between an asset’s carrying amount and the present value of the estimated future cash flows discounted at the asset’s original effective interest rate. Losses are recognized in profit or loss and reflected in an allowance account. When the Company considers that there are no realistic prospects of recovery of the asset, the relevant amounts are written off. If the amount of impairment loss subsequently decreases and the decrease can be related objectively to an event occurring after the impairment was recognized, then the previously recognized impairment loss is reversed through profit or loss.
Derivative Financial Instruments	Derivative Financial Instruments Derivative financial instruments (assets) are accounted as the cost to obtain the rights from a third party to issue shares under the purchase agreement. The fair value calculation of the derivative financial instrument (asset) is adjusted on the utilization of the asset based on total dollar amount of the purchase agreement. At each period-end, relative to the portion of shares sold under the contract, a portion of the option value is derecognized to equity. Derivative financial instruments (liabilities) are accounted at fair value and changes in fair value are shown as profit or loss. The fair value calculation of the derivative financial instruments is based on the Black-Scholes option pricing model. Assumptions are made for volatility and the risk-free rate in order to estimate the fair value of the instrument. Transaction cost related to derivative financial instruments are recorded through profit and loss. Embedded Derivatives Derivatives may be embedded in another contractual arrangement. The Company accounts for an embedded derivative separately from the host contract when: - The host contract is not an asset in the scope of IFRS 9 - The host contract is not itself carried at fair value through profit and loss (FVPL) - The terms of the Embedded Derivative would meet the definition of a derivative if they were contained in a separate contract - The economic characteristics and risks of the embedded derivative are not closely related to the economic characteristics and risks of the host The separated embedded derivative in the 2022 FiveT convertible loan was initially measured at fair value by an independent consultant applying a simulation-based valuation approach. On December 31, 2022, the embedded derivative was measured based on the Black-Scholes option pricing model, resulting in a fair value of zero. Assumptions are made for volatility, risk free rate and other features of the instrument. All changes in the fair value of embedded derivatives were recognized in profit and loss. The 2023 FiveT convertible loan was classified as a compound financial instrument containing a host liability and two equity components (conversion right and warrants). The fair value of the liability component was determined first by discounting the future cash flows at the rate of interest that would apply to an identical financial instrument without these features. The equity components were measured at the residual amount, by deducting the amount calculated for the liability component from the fair value of the instrument as a whole. The residual amount was allocated to the two equity components based on their relative fair values. The host liability was subsequently measured at amortized cost, using the effective interest rate method.
Income tax	Income tax Income tax expense comprises current and deferred tax. It is recognized in profit or loss except to the extent that it relates to a business combination, or items recognized directly in equity or in Other Comprehensive Income. Current tax Current tax comprises the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to tax payable or receivable in respect of previous years. It is measured using tax rates enacted or substantively enacted at the reporting date. Deferred tax Deferred income tax is recognized, using the balance sheet liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred tax is not recognized for: ● temporary differences on the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit or loss; ● temporary differences related to investments in subsidiaries to the extent that the Company is able to control the timing of the reversal of the temporary differences and it is probable that they will not reverse in the foreseeable future; and ● taxable temporary differences arising on the initial recognition of goodwill. Deferred income tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled. Deferred income tax assets are recognized to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized. Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off tax assets against tax liabilities and when they relate to income taxes levied by the same taxation authority and the Company intends to settle its tax assets and liabilities on a net basis.
Employee benefits	Employee benefits The Company maintains a pension plan for all employees in Switzerland through payments to a legally independent collective foundation. This pension plan qualifies under IFRS as defined benefit pension plan. There are no pension plans for the subsidiaries in Ireland, Australia and the United States. The Company’s net obligation in respect of defined benefit plans is calculated by estimating the amount of future benefit that employees have earned in return for their service in the current and prior periods, discounting that amount and deducting the fair value of any plan assets. The recognized asset is limited to the present value of economic benefits available in the form of any future refunds from the plan or reductions in future contributions to the plan. In order to calculate the present value of economic benefits, consideration is given to any minimum funding requirements. Remeasurements of the net defined benefit liability, which comprise actuarial gains and losses, the return on plan assets (excluding interest) and the effect of the asset ceiling (if any, excluding interest), are recognized immediately in Other Comprehensive Income. Past service costs, including curtailment gains or losses, are recognized immediately in general and administrative expenses within the operating results. Settlement gains or losses are recognized in general and administrative expenses within the operating results. The Company determines the net interest expense (income) on the net defined benefit liability (asset) for the period by applying the discount rate used to measure the defined benefit obligation at the beginning of the annual period or in case of any significant events between measurement dates to the then-net defined benefit liability (asset), taking into account any changes in the net defined benefit liability (asset) during the period as a result of contributions and benefit payments. Net interest expense and other expenses related to defined benefit plans are recognized in profit or loss.
Share-based compensation	Share-based compensation The Company maintains a share-based payment plan in the form of a stock option plan for its employees, members of the Board of Directors as well as key service providers. Stock options are granted at the Board’s discretion without any contractual or recurring obligations. The share-based compensation plans qualify as equity settled plans. The grant-date fair value of share-based payment awards granted to employees is recognized as an expense, with a corresponding increase in equity, over the period that the employees become unconditionally entitled to the awards. Under the Company’s Long Term Equity Incentive Plan (the “Equity Incentive Plan” or “EIP”), 50% of granted share options granted to employees vest after a period of service of two years from the grant date and the remaining 50% vest after a period of service of three years from the grant date. Share options granted to members of the Board of Directors granted from 2016 onwards vest after a period of one year after the grant date. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market performance conditions are expected to be met, such that the amount ultimately recognized as an expense is based on the number of awards that meet the related service and non-market performance conditions at the vesting date. Share-based payments that are not subject to any further conditions are expensed immediately at grant date. In the year the options are exercised the proceeds received net of any directly attributable transaction costs are credited to share capital (par value) and share premium. Valuation of share options Option pricing and values are determined based on the Black Scholes option pricing model and assumptions are made for inputs such as volatility of the Company’s stock and the risk-free rate.
Provisions	Provisions Provisions are recognized when the Company has a present obligation (legal or constructive) as a result of a past event, where it is more likely than not that an outflow of resources will be required to settle the obligation, and where a reliable estimate can be made of the amount of the obligation. Provisions are not recognized for future operating losses. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability.
Revenue recognition	Revenue recognition The Company recognizes revenue from the license of intellectual property and from the sale of products. To assess revenue recognition for arrangements that the Company determines are within the scope of IFRS 15, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of IFRS 15, the Company assesses the services promised within each contract and determine those that are performance obligations and assess whether each promised service is distinct. License of intellectual property The Company recognizes as revenue its non-refundable license fees, milestone payments and royalties when its customer obtains control of promised services, in an amount that reflects the consideration which the Company expects to receive in exchange for those rendered services. If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues when the license conveys a right of use, or there is a right of access to the underlying intellectual property. However, revenue for a license that provides a right to use the Company’s intellectual property before the beginning of the period during which the customer is able to use and benefit from the license is deferred. Revenue from sales-based royalty, in exchange for a license of intellectual property is recognized only when the subsequent sale occurs and the performance obligation to which the sales-based royalty has been allocated has been satisfied (in whole or in part). Sale of products Up to the partial divestiture of the Bentrio Business on November 21, 2023, the Company sold a single product, Bentrio®, a drug-free nasal spray for protection against airborne viruses and allergens. Due to the partial divestiture of the Bentrio® business, revenue from Bentrio® sales in 2023 and 2022 is presented as part of the result from discontinued operations. Revenue from sale of products is recognized at the point in time when control of the asset is transferred to the customer, generally on delivery of the product if no other agreement has been made. Revenue is net of value-added tax, rebates, discounts and returns.
Government grants	Government grants Government grants are not recognized until there is reasonable assurance that the Company will comply with the conditions attaching to them and that the grants will be received. Government grants are recognized in profit or loss on a systematic basis over the periods in which the Company recognizes as expenses the related research and development costs for which the grants are intended to compensate. Government grants that are receivable as compensation for expenses already incurred are recognized in profit or loss in the period in which they become receivable. The income from grants related to R&D expenditures are presented separately under the heading of ‘other operating income’. Grants that relate to the acquisition of an asset are recognized in profit or loss as the asset is depreciated or amortized. These grants are recognized as a reduction in the cost of the asset. Auris Medical Pty Ltd obtains credits under the Australian R&D Tax Incentive program (R&DITC) which are reported under discontinued operations. The program provides a tax offset of 43.5% of eligible R&D expenditures if the company qualifies as a Base Rate Entity (“BRE”), or a tax offset of 48.5% if the company is not a BRE. The assessment is carried out annually and the calculation of tax credits available are adjusted accordingly. If the tax offset exceeds the Company’s tax liability, the balance is paid in cash after submission of a valid claim. Based on the specific features of the program, IAS 20 Government Grants is applied for the accounting treatment of the Australian R&DITC. The reimbursement application is made by the Company annually, once the fiscal year is closed, based on the financial statements. Altamira Therapeutics Inc (former Trasir Therapeutics Inc) has obtained a grant from the NIH National Institutes of Health, to compensate for R&D expenses related to the development of “a Peptide-Based Polyplex Platform for Nucleotides Delivery to the Sites of Inflammation”. The income from the NIH grant which is related to R&D expenditures is recognized in profit or loss as other operating income (refer to Note 20).
Earnings/(loss) per share	Earnings/(loss) per share Basic earnings/(loss) per share are calculated by dividing the net profit/(loss) attributable to owners of the Company by the weighted average number of shares outstanding during the period. Diluted earnings/(loss) per share are calculated by dividing the net profit/(loss) attributable to the owners of the Company by the weighted average number of shares outstanding during the period adjusted for the conversion of all dilutive potential ordinary shares. Earnings/(loss) per share is calculated on the net profit/(loss) attributable to owners of the company as a whole and to continuing and discontinued operations (refer to notes 26 and 27).

Material Accounting Policies (T

Material Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2023
Significant Accounting Policies [Abstract]
Schedule of Closing Rates for the Most Significant Foreign Currencies	Closing rates for the most significant foreign currencies relative to CHF: Geographical Reporting December 31, December 31, Currency area entities 2023 2022 CHF Swiss Franc Switzerland 5 1.0000 1.0000 USD Dollar United States 1 0.8451 0.9251 EUR Euro Europe 1 0.9287 0.9901 AUD Dollar Australia 1 0.5735 0.6305 Geographical Reporting Currency area entities 2023 2022 CHF Swiss Franc Switzerland 5 1.0000 1.0000 USD Dollar United States 1 0.8985 0.9550 EUR Euro Europe 1 0.9721 1.0050 AUD Dollar Australia 1 0.5971 0.6629
Schedule of Estimated Useful Lives	The applicable estimated useful lives are as follows: Production equipment 5 years Office furniture and electronic data processing equipment (“EDP”) 3 years

Financial Instruments and Ris_2

Financial Instruments and Risk Management (Tables)	12 Months Ended
	Dec. 31, 2023
Financial instruments and risk management [Abstract]
Schedule of Carrying Amounts of Financial Assets and Financial Liabilities	The following table shows the carrying amounts of financial assets and financial liabilities: December 31, December 31, 2023 2022 Financial assets At amortized cost Cash and cash equivalents 617,409 15,395 Other non-current financial assets 80,001 194,263 Trade receivables - 6,525 Other receivables 18,905 - At fair value through profit and loss Derivative financial instruments 247,090 270,176 Total financial assets 963,405 486,359 Financial liabilities At amortized cost Trade and other payables 440,413 4,914,404 Accrued expenses 348,841 1,977,614 Loan - 5,869,797 Non-current lease liabilities - 343,629 Current lease liabilities 99,659 117,856 At fair value through profit and loss Derivative financial instruments - - Total financial liabilities 888,913 13,223,300
Schedule of Analysis the Remaining Contractual Maturities of Financial Liabilities	The table below analysis the remaining contractual maturities of financial liabilities, including estimated interest payments as of December 31, 2023 and 2022. The amounts disclosed in the table are the undiscounted cash flows: Between Carrying Less than 3 months and 2 years and amount 3 months 2 years later Total December 31, 2023 Trade and other payables 440,413 440,413 - - 440,413 Accrued expenses 348,841 348,841 - - 348,841 Loan and borrowings - - - - - Non-current lease liabilities - - - - - Current lease liabilities 99,659 33,677 67,354 - 101,031 Derivative financial instruments - - - Total 888,913 822,931 67,354 - 890,285 Between Carrying Less than 3 months and 2 years and amount 3 months 2 years later Total December 31, 2022 Trade and other payables 4,914,404 4,914,404 - - 4,914,404 Accrued expenses 1,977,614 1,977,614 - - 1,977,614 Loan and borrowings 5,869,797 5,759,877 357,192 - 6,117,069 Non-current lease liabilities 343,629 - 130,200 227,850 358,050 Current lease liabilities 117,856 32,550 97,650 - 130,200 Derivative financial instruments - - - Total 13,223,300 12,684,445 585,042 227,850 13,497,337
Schedule of Fair Value Measurement of Assets and Liabilities and Valuation Techniques	Fair values as at December 31, December 31, Fair value Financial assets / liabilities 2023 2022 hierarchy Valuation technique(s) and key input(s) Derivative financial Liability Liability Level 2 Black-Scholes option pricing model liabilities – Warrants from public offerings — — The share price is determined by Company’s NASDAQ quoted price. The strike price and maturity are defined by the contract. The volatility assumption is driven by Company’s historic quoted share price and the risk free rate is estimated based on observable yield curves at the end of each reporting period. Derivative financial liabilities – Embedded derivatives of 2023 FiveT Convertible (portion classified as liability) Liability Liability Level 3 Black-Scholes option pricing model The valuation is based on input parameters classified as level 3. Input parameters include the historical volatility of AMHL shares, risk-free rate, expected remaining life, expected exercise date and share prices of AMHL at valuation dates. Derivative financial liabilities – Embedded derivatives of 2022 FiveT Convertible Loan Liability Liability Level 3 Black-Scholes option pricing model The valuation is based on input parameters classified as level 3. Input parameters include the historical volatility of AMHL shares, risk-free rate, expected remaining life, expected exercise date and share prices of AMHL at valuation dates. Derivative financial asset - Option LPC purchase agreement Asset Asset Level 3 The fair value is equal to the price paid to the counterparty for obtaining the right under the purchase agreement. The price paid corresponds to the fair value of 2,500 commitment shares issued to LPC as consideration for its commitment to purchase our common shares under the purchase agreement. Subsequent, the fair value is adjusted proportionally for the part of the right consumed through equity.
Schedule of Fair Value Measurement of Derivative Financial Instrument	Non-cash changes Financing Fair Cash value Other 01.01.2023 Flows 1) revaluation changes 2) 31.12.2023 Loans 5,869,797 1,164,438 166,192 (7,200,427 ) - Lease liabilities 461,485 (134,707 ) - (227,119 ) 99,659 Total 6,331,282 1,029,731 166,192 (7,427,546 ) 99,659 Non-cash changes Financing Fair Cash value Other 01.01.2022 Flows 1) revaluation changes 2) 31.12.2022 Derivative financial instrument 1,233 - (1,233 ) - - Loans - 6,038,627 - (168,830 ) 5,869,797 Lease liabilities 575,736 (130,200 ) - 15,949 461,485 Total 576,969 5,908,427 (1,233 ) (152,881 ) 6,331,282 1) The financing cash flows are from loan borrowings or loan and lease repayments. 2) Other non-cash changes include conversion of convertible loan including de-recognition of embedded derivative and remeasurement of lease liability.
Schedule of Carrying Amount of Each Financial Asset in the Consolidated Statement of Financial Position	The Company’s maximum exposure to credit risk is represented by the carrying amount of each financial asset in the consolidated statement of financial position: December 31, December 31, 2023 2022 Financial assets Cash and cash equivalents 617,409 15,395 Other non-current financial assets 80,001 194,263 Trade receivables - 6,525 Other receivables 18,905 - Total 716,315 216,183
Schedule of Quantitative Data about the Exposure of Financial Assets and Liabilities to Currency Risk	The summary of quantitative data about the exposure of the Company’s financial assets and liabilities to currency risk was as follows: 2023 2022 in CHF USD EUR AUD USD EUR AUD Cash and cash equivalents 7,637 2,652 - 1,791 3,462 - Trade and other receivables 1,371,060 - - 1,523,292 91,864 879,531 Trade and other payables (129,943 ) (86,547 ) - (1,086,206 ) (1,452,883 ) - Accrued expenses (91,355 ) (26,737 ) - (220,616 ) (299,435 ) - Net statement of financial position exposure -asset/(liability) 1,157,400 (110,632 ) - 218,261 (1,656,992 ) 879,531

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2023
Segment information [Abstract]
Schedule of Non-Current Assets	The Company’s non-current assets by the Company’s country of domicile were as follows: December 31, December 31, 2023 2022 Switzerland 3,973,792 4,339,509 Australia - - Total 3,973,792 4,339,509

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2023
Property and Equipment [Abstract]
Schedule of Property and Equipment	Office Production furniture equipment and EDP Total At cost As of January 1, 2022 353,488 233,706 587,194 Additions - - - Disposals - - - As of December 31, 2022 353,488 233,706 587,194 Additions - - - Disposals - - - As of December 31, 2023 353,488 233,706 587,194 Accumulated depreciation As of January 1, 2022 (353,488 ) (233,705 ) (587,193 ) Charge for the year - - - Disposals - - - As of December 31, 2022 (353,488 ) (233,705 ) (587,193 ) Charge for the year - - - Disposals - - - As of December 31, 2023 (353,488 ) (233,705 ) (587,193 ) Net book value As of December 31, 2022 - 1 1 As of December 31, 2023 - 1 1

Right-of-Use Assets and Lease_2

Right-of-Use Assets and Lease Liabilities (Tables)	12 Months Ended
	Dec. 31, 2023
Right-of-use assets and lease liabilities [Abstract]
Schedule of Right-of-Use Assets and Lease Liabilities	Office Right-of-use assets building Total At cost As of January 1, 2022 594,436 594,436 Additions - - Disposals - - As of December 31, 2022 594,436 594,436 Additions - - Remeasurement (revised lease term) (246,413 ) (246,413 ) As of December 31, 2023 348,023 348,023 Accumulated depreciation As of January 1, 2022 (29,722 ) (29,722 ) Charge for the year (118,887 ) (118,887 ) Disposals - - As of December 31, 2022 (148,609 ) (148,609 ) Charge for the year (119,304 ) (119,304 ) Disposals - - As of December 31, 2023 (267,913 ) (267,913 ) Net book value As of December 31, 2022 445,827 445,827 As of December 31, 2023 80,110 80,110
Schedule of Low Value and Short-Term Lease Expenses	December 31, December 31, Low value and short-term lease expenses 2023 2022 Expense related to short-term leases 6,600 6,001 Expense related to leases of low value assets - Total 6,600 6,001
Schedule of Lease Liabilities	December 31, December 31, Lease liabilities 2023 2022 As of January 1 461,485 575,736 Additions - - Interest expense 19,294 15,949 Repayment of lease liability (134,707 ) (130,200 ) Remeasurement (revised lease term) (246,413 ) - As of December 31 99,659 461,485 thereof non-current - 343,629 thereof current 99,659 117,856
Schedule of Maturities of Lease Liabilities	December 31, December 31, Maturities of lease liabilities 2023 2022 Year 1 101,030 130,200 Year 2 - 130,200 Year 3 - 130,200 Year 4 - 97,650 Year 5 Undiscounted lease payments 101,030 488,250 Less: unearned interest (1,371 ) (26,765 ) Total 99,659 461,485

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2023
Intangible Assets [Abstract]
Schedule of Intangible Assets	IP & Data Internally Licenses rights Patents generated Total At cost As of January 1, 2022 5,376,201 193,989 473,154 9,801,462 15,844,806 Exchange differences - - - - - Additions - - 275,281 1,700,503 1,975,784 As of December 31, 2022 5,376,201 193,989 748,435 11,501,965 17,820,590 Exchange differences - - - 168 168 Additions - - - - - As of December 31, 2023 5,376,201 193,989 748,435 11,502,133 17,820,758 Accumulated amortization and impairment losses As of January 1, 2022 (1,482,520 ) (47,409 ) - - (1,529,929 ) Impairment (146,580 ) (748,435 ) (11,502,133 ) (12,397,148 ) As of December 31, 2022 (1,482,520 ) (193,989 ) (748,435 ) (11,502,133 ) (13,927,077 ) Impairment - - - - - As of December 31, 2023 (1,482,520 ) (193,989 ) (748,435 ) (11,502,133 ) (13,927,077 ) Net book value As of December 31, 2022 3,893,681 - - - 3,893,681 As of December 31, 2023 3,893,681 - - - 3,893,681

Investment in an Associate (Tab

Investment in an Associate (Tables)	12 Months Ended
	Dec. 31, 2023
Investment in an Associate [Abstract]
Schedule of Financial Information of the Company’s Investment	The following table illustrates the summarized financial information of the Company’s investment in Altamira Medica: December 31, 2023 Current assets 1,793,690 Non-current assets - Current liabilities (897,665 ) Non-current liabilities (989,411 ) Equity (93,386) Company’s share in equity - 49% (45,759) Goodwill 2,463,071 Company’s carrying amount of the investment 2,417,312
Schedule of Contingent Liabilities	The associate had no contingent liabilities or capital commitments as at December 31, 2023. Nov 22, 2023 Revenue from contracts with customers 379 Cost of sales (33,967 ) Operating expenses (29,321 ) Finance costs (15,732 ) Profit before tax (78,641 ) Income tax expense (2,087 ) Profit after tax (80,728 ) Other comprehensive income 14,018 Total comprehensive income (66,710 ) Company’s share of loss of associate for the period (39,557 )

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2023
Investment [Abstract]
Schedule of Inventories	December 31, December 31, 2023 2022 Finished goods - 11,644 Total - 11,644

Other Receivables (Tables)

Other Receivables (Tables)	12 Months Ended
	Dec. 31, 2023
Other Receivables [Abstract]
Schedule of Other Receivables	December 31, December 31, 2023 2022 R&D tax credit receivable - 672,600 Value added tax receivable 22,036 78,650 Receivable from suppliers and other 52,787 4,737 Total other receivables 74,823 755,987

Prepayments (Tables)

Prepayments (Tables)	12 Months Ended
	Dec. 31, 2023
Prepayments [Abstract]
Schedule of Prepayments	December 31, December 31, 2023 2022 Advance payments to suppliers 212,579 659,861 Insurance 71,253 49,405 Total prepayments 283,832 709,266

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	12 Months Ended
	Dec. 31, 2023
Cash and Cash Equivalents [Abstract]
Schedule of Cash and Cash Equivalents	December 31, December 31, 2023 2022 Cash in bank accounts 617,409 15,395 Cash on hand - - Total cash and cash equivalents 617,409 15,395

Capital and Reserves (Tables)

Capital and Reserves (Tables)	12 Months Ended
	Dec. 31, 2023
Capital and Reserves [Abstract]
Schedule of Issued Share Capital	The issued share capital of the Company at December 31 consisted of: December 31, December 31, 2023 2022 Number USD Number CHF Common shares with par value of USD 0.002 each* 1,477,785 2,956 59,003 236,011 Total 1,477,785 2,956 59,003 236,011 * The par value of the common shares was reduced from CHF 4.00 and changed to USD 0.0001 following approval the Company’s special general meeting of October 31, 2023, and subsequently the board of directors in December 2023 consolidated the then common shares of par value $0.0001 each at a ratio of 20:1, into common shares of par value $0.002 each. In total the share capital was reduced by CHF 2,903,684 to CHF 2,646 (USD 2,956) and the amount of the reduction was credited to share premium.
Schedule of Common Shares	Common Shares (Number) 2023 2022 As of January 1 59,003 37,411 Exercise of warrants 81,274 - Public Offering 555,556 - LPC equity line 17,500 15,750 ATM program 104,147 5,842 Conversion convertible loans 660,345 - Fractional shares eliminated upon reverse split (40 ) - Total, as of December 31 1,477,785 59,003

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2023
Share Based Compensation [Abstract]
Schedule of Key Terms and Conditions Related to the Grants	The key terms and conditions related to the grants under these programs at December 31, 2023 are as follows: Number of Contractual options life of Plan outstanding Vesting conditions options Equity Incentive Plan Board 7,898 1 year service from grant date 6 years Equity Incentive Plan Management & Staff 68,713 2 years’ service from grant date (50%) 8 years Equity Incentive Plan Management & Staff 68,713 3 years’ service from grant date (50%) 8 years
Schedule of Fair Value of the Options Measured	The fair value of the options was measured based on the Black-Scholes formula. Stock Option Plan Equity Incentive Equity Incentive Equity Incentive Equity Incentive Plan 2023 Plan 2023 Plan 2022 Plan 2022 Fair value at grant date USD 1.72 (2 year vesting) 1) 1) USD 6.674 (1 year vesting) 2) USD 10.918 (2 year vesting) 2) 2) USD 86.94 (2 year vesting) 1) 1) USD 132.88 (1 year vesting) 2) 2) 2) Share price at grant date USD 2.92 USD 19.2 USD 149.6 USD 356 Exercise price USD 2.92 USD 19.2 USD 127.06 USD 415.60 Expected volatility 108.87% 111.23% 100.2% 99.1% Expected life 2 and 3 years 1, 2 and 3 years 2 and 3 years 1, 2 and 3 years Expected dividends — — — — Risk-free interest rate 4.90% 4.37% 4.45% 2.87% 1) October grants for the respective year 2) April grants for the respective year
Schedule of Exercise Prices for Outstanding Options	The range of exercise prices for outstanding options was CHF 2.46 to CHF 10,637 as of December 31, 2023 and CHF 117.6 to CHF 11,693.20 as of December 31, 2022. 2023 2022 Weighted Weighted Weighted Weighted average average average average Number of exercise remaining Number of exercise remaining options price term options price term Outstanding at January 1 7,884 385.60 6.22 3,324 660.00 6.56 Expired during the year - - - - - - Forfeited during the year (1,467 ) - - (325 ) - - Exercised during the year - - - - - Granted during the year 138,907 4.76 - 4,885 188.00 - Outstanding at December 31 145,324 22.17 5.62 7,884 385.60 6.22 Exercisable at December 31 2,630 - - 1,440 - -

Trade and Other Payables (Table

Trade and Other Payables (Tables)	12 Months Ended
	Dec. 31, 2023
Trade and Other Payables [Abstract]
Schedule of Trade and Other Payables	December 31, December 31, 2023 2022 Trade accounts payable - third parties 413,111 4,767,940 Other 27,303 146,464 Total trade and other payables 440,414 4,914,404

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2023
Accrued Expenses [Abstract]
Schedule of Accrued Expenses	December 31, December 31, 2023 2022 Accrued research and development costs including milestone payments 87,522 741,291 Professional fees 17,412 326,365 Accrued vacation & overtime 52,368 46,868 Employee benefits incl. share based payments 190,610 362,497 Accrued interest - 457,812 Other 929 42,781 Total accrued expenses 348,841 1,977,614

Deferred Income (Tables)

Deferred Income (Tables)	12 Months Ended
	Dec. 31, 2023
Deferred Income [Abstract]
Schedule of Deferred Income	December 31, December 31, 2023 2022 Upfront payment - 932,200 Total deferred income - 932,200

Other Operating Income (Tables)

Other Operating Income (Tables)	12 Months Ended
	Dec. 31, 2023
Other Operating Income [Abstract]
Schedule of Other Operating Income	2023 2022 2021 Income from Government grants 228,302 - - Other income 27,287 9,327 - Total other operating income 255,589 9,327 -

Research and Development Expe_2

Research and Development Expense (Tables)	12 Months Ended
	Dec. 31, 2023
Research and Development Expense [Abstract]
Schedule of Research and Development Expense	2023 2022 2021 Pre-clinical projects 505,031 389,673 96,840 Clinical projects 128,717 67,096 63,757 Product and process development 364,392 199,225 164,684 Employee benefits and expenses 1,429,564 1,426,299 934,577 Patents and trademarks 414,718 155,589 333,519 Regulatory projects 59,531 34,098 32,564 Impairment intangible assets - 12,338,837 1,529,929 Depreciation tangible assets - - 46,635 Other research and development expense 133,459 10,753 - Total research and development expense 3,035,413 14,621,570 3,202,505

General and Administrative Ex_2

General and Administrative Expenses (Tables)	12 Months Ended
	Dec. 31, 2023
General and Administrative Expenses [Abstract]
Schedule of General and Administrative Expenses	2023 2022 2021 Employee benefits and expenses 655,967 645,138 1,371,526 Business development 15,348 15,727 39,916 Travel expenses 43,055 95,503 75,829 Administration expenses 2,274,159 2,517,309 2,098,866 Lease expenses from short-term lease 15,705 6,001 52,280 Depreciation of Right-of-use assets 119,304 118,887 29,722 Depreciation of tangible assets - - - Capital tax expenses 12,738 3,110 706 Total general and administrative expenses 3,136,275 3,401,676 3,668,845

Employee Benefits (Tables)

Employee Benefits (Tables)	12 Months Ended
	Dec. 31, 2023
Employee Benefits [Abstract]
Schedule of Defined Benefit Plan Expense Recognized in Profit or Loss	2023 2022 2021 Salaries 2,145,943 2,815,411 1,865,633 Pension costs 172,460 266,256 165,801 Other social benefits 293,753 294,017 275,258 Share based payments costs 379,414 342,799 1,223,696 Other personnel expenditures 9,999 2,024 214,940 Total employee benefits 3,001,569 3,720,507 3,745,328 Employee benefits attributable to continuing operations 2,243,955 2,071,436 2,375,668 Employee benefits attributable to discontinued operations 757,614 1,649,071 1,369,660
Schedule of Defined Benefit Cost and Liability Assumptions	2023 2022 Defined benefit obligation at January 1 3,544,161 4,677,632 Service costs 163,101 256,336 Plan participants’ contribution 130,875 154,116 Interest cost 76,139 13,762 Actuarial losses 104,860 (931,636 ) Plan amendments - - Benefits paid through pension assets (78,957 ) (626,049 ) Defined benefit obligation at December 31 3,940,179 3,544,161 2023 2022 Fair value of plan assets at January 1 3,207,955 4,009,313 Interest income 71,813 12,187 Return on plan assets excluding interest income 136,023 (490,359 ) Employer contributions 130,875 154,116 Plan participants’ contributions 130,875 154,116 Benefits paid through pension assets (78,957 ) (626,049 ) Administration expense (5,033 ) (5,369 ) Fair value of plan assets at December 31 3,593,551 3,207,955 December 31, December 31, 2023 2022 Present value of funded defined benefit obligation 3,940,179 3,544,161 Fair value of plan assets (3,593,551 ) (3,207,955 ) Net defined benefit liability 346,628 336,206
Schedule of Defined Benefit Cost and Liability Assumptions	2023 2022 2021 Service cost 163,101 256,336 159,085 Net interest expense 3,270 1,575 1,878 Administration expense 4,259 5,369 6,030 Total defined costs for the year recognized in profit or loss 170,630 263,280 166,993 2023 2022 2021 Actuarial loss (gain) arising from changes in financial assumptions 247,262 (876,841 ) (74,284 ) Actuarial loss (gain) arising from experience adjustments (138,497 ) (54,795 ) 463,238 Actuarial gain arising from demographic assumptions (3,905 ) - (229,109 ) Return on plan assets excluding interest income (136,023 ) 490,359 (424,829 ) Total defined benefit cost for the year recognized in other comprehensive income (31,163 ) (441,277 ) (264,984 ) 2023 2022 2021 Discount rate 1.50 % 2.20 % 0.30 % Future salary increases 1.35 % 1.60 % 0.85 % Pension indexation 0.00 % 0.00 % 0.00 % BVG2020 BVG2020 BVG2020
Schedule of Sensitivity Analysis for Actuarial Assumptions	Reasonably possible changes at the reporting date to one of the relevant actuarial assumptions, holding other assumptions constant, would have affected the defined benefit obligation by the amounts shown below. 2023 2022 Change in assumption 0.25% increase 0.25% increase Discount rate (141,340 ) (177,546 ) Salary increase (22,950 ) 23,058 Pension indexation 78,491 63,916 Change in assumption +1 year +1 year Life expectancy 63,383 48,531

Finance Income and Finance Ex_2

Finance Income and Finance Expense (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure of finance income and finance expense [Abstract]
Schedule of Finance Income and Finance Expense	2023 2022 2021 Interest income 302,249 114,268 26,990 Net foreign currency exchange gain - - 47,161 Revaluation gain from derivative financial instruments 15,066 451,131 5,085 Gain on modification of financial instruments 36,778 - - Total finance income 354,093 565,399 79,236 Interest expense (incl. bank charges) 1,032,444 904,345 14,112 Net foreign currency exchange loss 447,456 305,560 - Revaluation loss from derivative financial instruments 181,258 - - Loss on modification of financial instruments 7,317 - - Transaction costs - 1,137 - Total finance expense 1,668,475 1,211,042 14,112 Finance expense, net (1,314,382 ) (645,643 ) 65,124

Taxation (Tables)

Taxation (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure of Taxation [Abstract]
Schedule of Income Tax Expense	The Group’s income tax expense recognized in the consolidated statement of profit or loss and other comprehensive loss was as follows: 2023 2022 2021 Deferred income tax expense from continuing operations - (11,604 ) (431,164 ) Deferred income tax gain from continuing operations - 19,524 549,109 Deferred income tax expense from discontinued operations - (52,004 ) (139,565 ) Deferred income tax gain from discontinued operations 99,847 54,413 - Income tax gain/(loss) 99,847 10,329 (21,620 )
Schedule of Effective Income Tax Expense Weighted Average Tax Rate	The Company’s effective income tax expense differed from the expected theoretical amount computed by applying the Company’s applicable weighted average tax rate of 15.8% in 2023 (2022: 13.7%, 2021: 13.5%) as summarized in the following table: Reconciliation 2023 2022 2021 Loss before income tax from continuing operations (7,270,038 ) (18,659,562 ) (6,806,226 ) Profit before income tax from discontinued operations 3,301,018 (7,879,178 ) (10,230,597 ) Accounting Profit before income tax (3,969,020 ) (26,538,740 ) (17,036,823 ) Income tax at statutory tax rates applicable to results in the respective countries 626,286 3,641,775 2,348,057 Effect of unrecognized temporary differences (5,423 ) (125,260 ) (632,031 ) Effect of unrecognized taxable losses (543,086 ) (3,015,088 ) (1,885,486 ) Effect of impact from application of different tax rates (43,534 ) (491,098 ) 223,215 Other effects 65,604 - (75,375 ) Income tax gain 99,847 10,329 (21,620 ) Income tax gain reported in the statement of profit or loss - 7,919 117,945 Income tax gain/(loss) attributable to discontinued operations 99,847 2,410 (139,565 )
Schedule of Unrecognized Tax Loss Carryforwards	The Company’s unrecognized tax loss carryforwards with their expiry dates are as follows: December 31, December 31, 2023 2022 Within 1 year 22,717,044 27,956,899 Between 1 and 3 years 13,625,930 31,668,498 Between 3 and 7 years 22,681,981 41,797,708 More than 7 years 1,581,616 1,691,572 Total 60,606,571 103,114,677
Schedule of Tax Effect Unrecognized Loss Carryforwards	The tax effect of the major unrecognized temporary differences and loss carryforwards is presented in the table below: December 31, December 31, 2023 2022 Deductible temporary differences Deferred income - 111,025 Employee benefit plan 45,200 43,841 Total potential tax assets 45,200 154,866 Potential tax assets from loss carry-forwards not recognized 7,936,946 13,297,723 Total potential tax assets from loss carry-forwards and temporary differences not recognized 7,982,146 13,452,589

Loss Per Share (Tables)

Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2023
Loss Per Share [Abstract]
Schedule of Loss Per Share	Loss per share 2023 2022 2021 Loss attributable to owners of the Company (3,869,173 ) (26,528,411 ) (17,058,443 ) Weighted average number of shares outstanding 491,258 45,536 33,116 Basic and diluted loss per share (7.88 ) (582.58 ) (515.11 ) Loss per share for continuing operations 2023 2022 2021 Loss attributable to owners of the Company (7,270,038 ) (18,651,643 ) (6,688,281 ) Weighted average number of shares outstanding 491,258 45,536 33,116 Basic and diluted loss per share (14.80 ) (409.60 ) (201.97 )

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2023
Discontinued Operations [Abstract]
Schedule of Gain on Disposal of Discontinued Operations	The gain on disposal of discontinued operations was determined as follows: November 21, Cash consideration received 2,040,000 Other consideration received 32,685 Total consideration received 2,072,685 Net assets disposed: Inventories (331,466 ) Prepaid expenses (218,395 ) Receivables and other assets (677,544 ) Cash and cash equivalents (115,676 ) Trade and other payables 1,104,399 Accrued liabilities 318,083 Deferred income 932,200 Foreign currency translation reserve, transfer to profit or loss 161,249 Total net assets disposed incl. currency translation reserve 1,172,850 Remeasurement of retained interest at fair value 1,960,000 Pre-tax gain on disposal of discontinued operation 5,205,535 Related tax expense - Gain on disposal of discontinued operation 5,205,535 Net cash inflow on disposal of discontinued operations Cash consideration received 2,040,000 Cash disposed of (115,676 ) Net cash inflow on disposal 1,924,324
Schedule of Discontinued Operations	Result of discontinued operations: 2023 2022 2021 Revenue 157,834 305,616 63,882 Cost of Sales (191,922 ) (1,443,855 ) (2,240,554 ) Other income 131,702 700,122 214,217 Operating expenses (1,870,939 ) (7,680,444 ) (7,934,264 ) Financial income/(expense), net (131,192 ) 239,383 (333,878 ) Tax (expense) / credit 99,847 2,410 (139,565 ) Gain on disposal of discontinued operation 5,205,535 - - Profit after tax from discontinued operations 3,400,865 (7,876,768 ) (10,370,162 )
Schedule of Earnings Per Share from Discontinued Operations	Earnings per share from discontinued operations: 2023 2022 2021 Basic and diluted earnings / (loss) per share from discontinued operations 6.92 (172.98 ) (313.15 )
Schdule of Statement of Cash Flows	Statement of cash flows: 2023 2022 2021 Operating activities (1,092,385 ) (1,104,053 ) (2,612,264 ) Investing activities 67 67,406 (116,330 ) Financing activities 1,056,532 859,610 2,000,000 Net cash from discontinued operations (35,786 ) (177,037 ) (728,594 )

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies [Abstract]
Schedule of Future Minimum Lease Payments Under Non-Cancellable Operating Leases	The future minimum lease payments under non-cancellable lease term that are not accounted for in the statement of financial position were as follows: December 31, December 31, 2023 2022 Within one year 3,946 3,450 Between one and five years - - Total 3,946 3,450

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2023
Related Party Transactions [Abstract]
Schedule of Related Party Transaction	In 2023, the compensation paid to management, excluding share bonuses and share-based payment charge, amounted to CHF 681,353 (2022: CHF 1,038,810; 2021: CHF 810,671). The fees paid to members of the Board of Directors in 2023 for their activities as board members totaled CHF 138,507 (2022: CHF 183,058; 2021: CHF 165,245). Executive Management Board of Directors Total 2023 2022 2021 2023 2022 2021 2023 2022 2021 Short term benefits 636,884 989,760 781,204 138,507 183,058 165,245 775,391 1,172,818 946,449 Post-employee benefits years 44,469 49,050 29,467 - - 44,469 49,050 29,467 Share bonuses - - 902,817 - - - - 902,817 Share-based payment 242,269 172,115 192,362 41,319 51,171 48,046 283,588 223,286 240,408 Total 923,622 1,210,925 1,905,850 179,826 234,229 213,291 1,103,448 1,445,154 2,119,141

Loans (Tables)

Loans (Tables)	12 Months Ended
	Dec. 31, 2023
Loans [Abstract]
Schedule of Loans	December 31, December 31, 2023 2022 Convertible loan February 2022 - 4,898,377 Loans with warrants - 871,420 Short-term loan from related party - 100,000 - 5,869,797
Schedule of Convertible Loan Agreement	Convertible loan agreements December 31, December 31, 2023 2022 As of January 1 4,898,377 - Gross proceeds at disbursement date 2,500,000 5,000,000 Embedded derivative, separated (435,023 ) (449,898 ) Transaction costs allocated to host - (10,236 ) Carrying amount at initial recognition 6,963,354 4,539,866 Repayment in cash (285,562 ) - Converted principal amount (7,214,438 ) - Accrued interest - 447,945 Amortization 536,646 358,511 Total - 5,346,322 Accrued interest balance of December 31 - 447,945 Convertible loan balance of December 31 - 4,898,377

Reporting Entity (Details)

Reporting Entity (Details)		12 Months Ended
	Nov. 21, 2023	Dec. 31, 2023 CHF (SFr)	Dec. 31, 2023 USD ($)	Dec. 31, 2023 EUR (€)	Dec. 31, 2023 AUD ($)	Dec. 31, 2022 CHF (SFr)
Reporting Entity [Line Items]
Ownership percentage in subsidiary	51%
Share capital of subsidiary		SFr 2,646	$ 2,956			SFr 236,011
Investment equity percentage	49%	49%	49%	49%	49%
Spinning off percentage		51%
Auris Medical AG [Member]
Reporting Entity [Line Items]
Ownership percentage in subsidiary		100%
Share capital of subsidiary		SFr 2,500,000
Otolanum AG [Member]
Reporting Entity [Line Items]
Ownership percentage in subsidiary		100%
Share capital of subsidiary		SFr 100,000
Zilentin AG [Member]
Reporting Entity [Line Items]
Ownership percentage in subsidiary		100%
Share capital of subsidiary		SFr 100,000
Altamira Therapeutics, Inc. [Member]
Reporting Entity [Line Items]
Ownership percentage in subsidiary		100%
Share capital of subsidiary | $			$ 100
Auris Medical Ltd. [Member]
Reporting Entity [Line Items]
Ownership percentage in subsidiary		100%
Share capital of subsidiary | €				€ 100
Auris Medical Pty Ltd [Member]
Reporting Entity [Line Items]
Ownership percentage in subsidiary		49%
Share capital of subsidiary | $					$ 100
Altamira Medica AG [Member]
Reporting Entity [Line Items]
Ownership percentage in subsidiary	51%
Auris Medical Pty Ltd [Member]
Reporting Entity [Line Items]
Ownership percentage in subsidiary	100%

Basis of Preparation (Details)

Basis of Preparation (Details) $ in Millions	12 Months Ended
	Dec. 31, 2023 CHF (SFr)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 CHF (SFr)
Basis of preparation [Line Items]
Total cash	SFr 617,409		SFr 15,395
Tax asset			SFr 41,430
Bottom of range [member]
Basis of preparation [Line Items]
Total cash	6,500,000
Top of range [member]
Basis of preparation [Line Items]
Total cash	SFr 7,500,000
Board of Directors [Member] | Bottom of range [member]
Basis of preparation [Line Items]
Total cash | $		$ 8
Board of Directors [Member] | Top of range [member]
Basis of preparation [Line Items]
Total cash | $		$ 10
Switzerland [Member]
Basis of preparation [Line Items]
Tax term	7 years
United States [Member]
Basis of preparation [Line Items]
Tax losses	80%

Material Accounting Policies (D

Material Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2023 CHF (SFr) SFr / shares shares	Dec. 31, 2023 USD ($) shares	Dec. 31, 2022 CHF (SFr)	Dec. 31, 2021 CHF (SFr)	Jun. 01, 2021
Significant Accounting Policies [Line items]
Share capital percentage					100%
Common shares (in Shares) | shares	1,911	1,911
Common shares per share (in Francs per share) | SFr / shares	SFr 4
Average closing price (in Dollars) | $		$ 1,500,000
Common trading days	15 days	15 days
Reference price (in Dollars) | $		$ 1,308
Expenses incurred (in Dollars) | $		$ 210,000
Cash paid	SFr 617,409		SFr 15,395
Minimum royalty term	12 years	12 years
Aggregate amount (in Dollars) | $		$ 4,375,000
Estimated fair value	SFr (29,461)
License acquired amounted	3,893,681		SFr 3,893,681
Attributable transaction costs	198,246	$ 728,728
Leases amount	SFr 5,000
Granted share option percentage	50%	50%
Granted term	2 years	2 years
Tax offset percentage	43.50%	43.50%
Research and development expenditures percentage	48.50%	48.50%
Equity Incentive Plan [Member]
Significant Accounting Policies [Line items]
Granted term	3 years	3 years
Remaining granted percentage	50%	50%
Common Shares [Member]
Significant Accounting Policies [Line items]
Average closing price (in Dollars) | $		$ 2,500,000
Cash paid	SFr 180,000
License [member]
Significant Accounting Policies [Line items]
Estimated useful life	10 years	10 years
Board of Directors [Member]
Significant Accounting Policies [Line items]
Granted term	1 year	1 year
Fair value [Member]
Significant Accounting Policies [Line items]
Estimated fair value	SFr 269,700

Material Accounting Policies _2

Material Accounting Policies (Details) - Schedule of Closing Rates for the Most Significant Foreign Currencies	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
CHF [Member]
Schedule of Closing Rates for the Most Significant Foreign Currencies [Line Items]
Reporting entities	5
Closing rate	1	1
Average exchange rate	1	1
USD [Member]
Schedule of Closing Rates for the Most Significant Foreign Currencies [Line Items]
Reporting entities	1
Closing rate	0.8451	0.9251
Average exchange rate	0.8985	0.955
EUR [Member]
Schedule of Closing Rates for the Most Significant Foreign Currencies [Line Items]
Reporting entities	1
Closing rate	0.9287	0.9901
Average exchange rate	0.9721	1.005
AUD [Member]
Schedule of Closing Rates for the Most Significant Foreign Currencies [Line Items]
Reporting entities	1
Closing rate	0.5735	0.6305
Average exchange rate	0.5971	0.6629

Material Accounting Policies _3

Material Accounting Policies (Details) - Schedule of Estimated Useful Lives	12 Months Ended
	Dec. 31, 2023
Production equipment [Member]
Schedule of Estimated Useful Lives [Line Items]
Useful life	5 years
Office furniture and electronic data processing equipment (“EDP”) [Member]
Schedule of Estimated Useful Lives [Line Items]
Useful life	3 years

Financial Instruments and Ris_3

Financial Instruments and Risk Management (Details) - CHF (SFr)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
USD [Member]
Financial instruments and risk management [Line Items]
Increase or decrease in exchange rate	5%
Impact of increase or decrease in rate on net result	SFr 57,870	SFr 10,913
EUR [Member]
Financial instruments and risk management [Line Items]
Increase or decrease in exchange rate	5%
Impact of increase or decrease in rate on net result	SFr 5,532	82,850
AUD [Member]
Financial instruments and risk management [Line Items]
Increase or decrease in exchange rate	5%
Impact of increase or decrease in rate on net result	SFr 0	SFr 43,977

Financial Instruments and Ris_4

Financial Instruments and Risk Management (Details) - Schedule of Carrying Amounts of Financial Assets and Financial Liabilities - CHF (SFr)	Dec. 31, 2023	Dec. 31, 2022
At amortized cost
Financial assets	SFr 963,405	SFr 486,359
At amortized cost
Financial liabilities	888,913	13,223,300
Trade And Other Payables [member]
At amortized cost
Financial liabilities	440,413	4,914,404
Accrued Expenses [Member]
At amortized cost
Financial liabilities	348,841	1,977,614
Loan [Member]
At amortized cost
Financial liabilities		5,869,797
Non-current lease liabilities [Member]
At amortized cost
Financial liabilities		343,629
Current lease liabilities [Member]
At amortized cost
Financial liabilities	99,659	117,856
Derivative Financial Instruments Liabilities [Member]
At amortized cost
Financial liabilities
Cash And Cash Equivalents [member]
At amortized cost
Financial assets	617,409	15,395
Other non-current financial assets [Member]
At amortized cost
Financial assets	80,001	194,263
Trade receivables [member]
At amortized cost
Financial assets		6,525
Other receivables [member]
At amortized cost
Financial assets	18,905
Derivative Financial Instruments Asset [Member]
At amortized cost
Financial assets	SFr 247,090	SFr 270,176

Financial Instruments and Ris_5

Financial Instruments and Risk Management (Details) - Schedule of Analysis the Remaining Contractual Maturities of Financial Liabilities - CHF (SFr)	Dec. 31, 2023	Dec. 31, 2022
Financial Instruments and Risk Management (Details) - Schedule of Analysis the Remaining Contractual Maturities of Financial Liabilities [Line Items]
Trade and other payables	SFr 440,413	SFr 4,914,404
Accrued expenses	348,841	1,977,614
Loan and borrowings		6,117,069
Non-current lease liabilities		358,050
Current lease liabilities	101,031	130,200
Total	890,285	13,497,337
Carrying amount [Member]
Financial Instruments and Risk Management (Details) - Schedule of Analysis the Remaining Contractual Maturities of Financial Liabilities [Line Items]
Trade and other payables	440,413	4,914,404
Accrued expenses	348,841	1,977,614
Loan and borrowings		5,869,797
Non-current lease liabilities		343,629
Current lease liabilities	99,659	117,856
Total	888,913	13,223,300
Less than 3 months [Member]
Financial Instruments and Risk Management (Details) - Schedule of Analysis the Remaining Contractual Maturities of Financial Liabilities [Line Items]
Trade and other payables	440,413	4,914,404
Accrued expenses	348,841	1,977,614
Loan and borrowings		5,759,877
Non-current lease liabilities
Current lease liabilities	33,677	32,550
Total	822,931	12,684,445
Between 3 months and 2 years [Member]
Financial Instruments and Risk Management (Details) - Schedule of Analysis the Remaining Contractual Maturities of Financial Liabilities [Line Items]
Trade and other payables
Accrued expenses
Loan and borrowings		357,192
Non-current lease liabilities		130,200
Current lease liabilities	67,354	97,650
Total	67,354	585,042
2 years and later [Member]
Financial Instruments and Risk Management (Details) - Schedule of Analysis the Remaining Contractual Maturities of Financial Liabilities [Line Items]
Trade and other payables
Accrued expenses
Loan and borrowings
Non-current lease liabilities		227,850
Current lease liabilities
Total		SFr 227,850

Financial Instruments and Ris_6

Financial Instruments and Risk Management (Details) - Schedule of Fair Value Measurement of Assets and Liabilities and Valuation Techniques - Level 3 [Member]	Dec. 31, 2023	Dec. 31, 2022
Derivative financial liabilities – Warrants from public offerings [Member]
Financial Instruments and Risk Management (Details) - Schedule of Fair Value Measurement of Assets and Liabilities and Valuation Techniques [Line Items]
Financial assets & liabilities
Derivative financial liabilities – Embedded derivatives of 2023 FiveT Convertible [Member]
Financial Instruments and Risk Management (Details) - Schedule of Fair Value Measurement of Assets and Liabilities and Valuation Techniques [Line Items]
Financial assets & liabilities
Derivative financial liabilities – Embedded derivatives of 2022 FiveT Convertible Loan [Member]
Financial Instruments and Risk Management (Details) - Schedule of Fair Value Measurement of Assets and Liabilities and Valuation Techniques [Line Items]
Financial assets & liabilities
Derivative Financial Asset - Option LPC Purchase Agreement [Member]
Financial Instruments and Risk Management (Details) - Schedule of Fair Value Measurement of Assets and Liabilities and Valuation Techniques [Line Items]
Financial assets & liabilities	Asset 247,090	Asset 270,176

Financial Instruments and Ris_7

Financial Instruments and Risk Management (Details) - Schedule of Fair Value Measurement of Derivative Financial Instrument - CHF (SFr)		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022
Financial Instruments and Risk Management (Details) - Schedule of Fair Value Measurement of Derivative Financial Instrument [Line Items]
Balance		SFr 6,331,282
Financing Cash Flows	[1]	1,029,731
Fair value revaluation		166,192
Other changes	[2]	(7,427,546)
Balance		99,659
Loans [Member]
Financial Instruments and Risk Management (Details) - Schedule of Fair Value Measurement of Derivative Financial Instrument [Line Items]
Balance		5,869,797
Financing Cash Flows	[1]	1,164,438	6,038,627
Fair value revaluation		166,192
Other changes	[2]	(7,200,427)	(168,830)
Balance			5,869,797
Lease liabilities [Member]
Financial Instruments and Risk Management (Details) - Schedule of Fair Value Measurement of Derivative Financial Instrument [Line Items]
Balance		461,485	575,736
Financing Cash Flows	[1]	(134,707)	(130,200)
Fair value revaluation
Other changes	[2]	(227,119)	15,949
Balance		SFr 99,659	461,485
Derivative financial instrument [Member]
Financial Instruments and Risk Management (Details) - Schedule of Fair Value Measurement of Derivative Financial Instrument [Line Items]
Balance			1,233
Financing Cash Flows	[1]
Fair value revaluation			(1,233)
Other changes	[2]
Balance
Total [Member]
Financial Instruments and Risk Management (Details) - Schedule of Fair Value Measurement of Derivative Financial Instrument [Line Items]
Balance			576,969
Financing Cash Flows	[1]		5,908,427
Fair value revaluation			(1,233)
Other changes	[2]		(152,881)
Balance			SFr 6,331,282
[1]The financing cash flows are from loan borrowings or loan and lease repayments.[2]Other non-cash changes include conversion of convertible loan including de-recognition of embedded derivative and remeasurement of lease liability.

Financial Instruments and Ris_8

Financial Instruments and Risk Management (Details) - Schedule of Carrying Amount of Each Financial Asset in the Consolidated Statement of Financial Position - CHF (SFr)	Dec. 31, 2023	Dec. 31, 2022
Financial assets
Maximum exposure to credit risk	SFr 716,315	SFr 216,183
Cash And Cash Equivalents [member]
Financial assets
Maximum exposure to credit risk	617,409	15,395
Other non-current financial assets [Member]
Financial assets
Maximum exposure to credit risk	80,001	194,263
Trade receivables [member]
Financial assets
Maximum exposure to credit risk		6,525
Other receivables [Member]
Financial assets
Maximum exposure to credit risk	SFr 18,905

Financial Instruments and Ris_9

Financial Instruments and Risk Management (Details) - Schedule of Quantitative Data about the Exposure of Financial Assets and Liabilities to Currency Risk	Dec. 31, 2023 USD ($)	Dec. 31, 2023 EUR (€)	Dec. 31, 2023 AUD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 EUR (€)	Dec. 31, 2022 AUD ($)
Financial Instruments and Risk Management (Details) - Schedule of Quantitative Data about the Exposure of Financial Assets and Liabilities to Currency Risk [Line Items]
Net statement of financial position exposure -asset/(liability)	$ 1,157,400	€ (110,632)		$ 218,261	€ (1,656,992)	$ 879,531
Trade and other payables [Member]
Financial Instruments and Risk Management (Details) - Schedule of Quantitative Data about the Exposure of Financial Assets and Liabilities to Currency Risk [Line Items]
Net statement of financial position exposure -asset/(liability)	(129,943)	(86,547)		(1,086,206)	(1,452,883)
Accrued expenses [Member]
Financial Instruments and Risk Management (Details) - Schedule of Quantitative Data about the Exposure of Financial Assets and Liabilities to Currency Risk [Line Items]
Net statement of financial position exposure -asset/(liability)	(91,355)	(26,737)		(220,616)	(299,435)
Cash and cash equivalents [Member]
Financial Instruments and Risk Management (Details) - Schedule of Quantitative Data about the Exposure of Financial Assets and Liabilities to Currency Risk [Line Items]
Net statement of financial position exposure -asset/(liability)	7,637	2,652		1,791	3,462
Trade and other receivables [Member]
Financial Instruments and Risk Management (Details) - Schedule of Quantitative Data about the Exposure of Financial Assets and Liabilities to Currency Risk [Line Items]
Net statement of financial position exposure -asset/(liability)	$ 1,371,060			$ 1,523,292	€ 91,864	$ 879,531

Segment Information (Details) -

Segment Information (Details) - Schedule of Non-Current Assets - CHF (SFr)	Dec. 31, 2023	Dec. 31, 2022
Schedule of Non-Current Assets [Line Items]
Non-current assets	SFr 3,973,792	SFr 4,339,509
Switzerland [Member]
Schedule of Non-Current Assets [Line Items]
Non-current assets	3,973,792	4,339,509
Australia [Member]
Schedule of Non-Current Assets [Line Items]
Non-current assets

Property and Equipment (Details

Property and Equipment (Details) - Schedule of Property and Equipment - CHF (SFr)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
At cost [Member]
Property and Equipment (Details) - Schedule of Property and Equipment [Line Items]
Property, plant and equipment	SFr 587,194	SFr 587,194
Property, plant and equipment	587,194	587,194
Additions
Disposals
At cost [Member] | Production equipment [Member]
Property and Equipment (Details) - Schedule of Property and Equipment [Line Items]
Property, plant and equipment	353,488	353,488
Property, plant and equipment	353,488	353,488
Additions
Disposals
At cost [Member] | Office furniture and EDP [Member]
Property and Equipment (Details) - Schedule of Property and Equipment [Line Items]
Property, plant and equipment	233,706	233,706
Property, plant and equipment	233,706	233,706
Additions
Disposals
Accumulated depreciation [Member]
Property and Equipment (Details) - Schedule of Property and Equipment [Line Items]
Property, plant and equipment	(587,193)	(587,193)
Property, plant and equipment	(587,193)	(587,193)
Charge for the year
Disposals
Accumulated depreciation [Member] | Production equipment [Member]
Property and Equipment (Details) - Schedule of Property and Equipment [Line Items]
Property, plant and equipment	(353,488)	(353,488)
Property, plant and equipment	(353,488)	(353,488)
Charge for the year
Disposals
Accumulated depreciation [Member] | Office furniture and EDP [Member]
Property and Equipment (Details) - Schedule of Property and Equipment [Line Items]
Property, plant and equipment	(233,705)	(233,705)
Property, plant and equipment	(233,705)	(233,705)
Charge for the year
Disposals
Net book value [Member]
Property and Equipment (Details) - Schedule of Property and Equipment [Line Items]
Property, plant and equipment	1
Property, plant and equipment	1	1
Net book value [Member] | Production equipment [Member]
Property and Equipment (Details) - Schedule of Property and Equipment [Line Items]
Property, plant and equipment
Property, plant and equipment
Net book value [Member] | Office furniture and EDP [Member]
Property and Equipment (Details) - Schedule of Property and Equipment [Line Items]
Property, plant and equipment	1
Property, plant and equipment	SFr 1	SFr 1

Right-of-Use Assets and Lease_3

Right-of-Use Assets and Lease Liabilities (Details) - CHF (SFr)	Dec. 31, 2023	Dec. 31, 2022
Right-of-use assets and lease liabilities [Abstract]
Lease payment amounted	SFr 101,031	SFr 130,200

Right-of-Use Assets and Lease_4

Right-of-Use Assets and Lease Liabilities (Details) - Schedule of Right-of-Use Assets and Lease Liabilities - CHF (SFr)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Right-of-Use Assets and Lease Liabilities (Details) - Schedule of Right-of-Use Assets and Lease Liabilities [Line Items]
Cost Beginning	SFr 594,436	SFr 594,436
Accumulated depreciation Beginning	(148,609)	(29,722)
Net Book Value Ending	445,827
Net Book Value Beginning	80,110	445,827
Additions
Remeasurement (revised lease term)	(246,413)
Disposals
Cost Ending	348,023	594,436
Charge for the year	(119,304)	(118,887)
Accumulated depreciation Ending	(267,913)	(148,609)
Office building [Member]
Right-of-Use Assets and Lease Liabilities (Details) - Schedule of Right-of-Use Assets and Lease Liabilities [Line Items]
Cost Beginning	594,436	594,436
Accumulated depreciation Beginning	(148,609)	(29,722)
Net Book Value Ending	445,827
Net Book Value Beginning	80,110	445,827
Additions
Remeasurement (revised lease term)	(246,413)
Disposals
Cost Ending	348,023	594,436
Charge for the year	(119,304)	(118,887)
Accumulated depreciation Ending	SFr (267,913)	SFr (148,609)

Right-of-Use Assets and Lease_5

Right-of-Use Assets and Lease Liabilities (Details) - Schedule of Low Value and Short-Term Lease Expenses - CHF (SFr)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Low Value and Short Term Lease Expenses [Abstract]
Expense related to short-term leases	SFr 6,600	SFr 6,001
Expense related to leases of low value assets
Total	SFr 6,600	SFr 6,001

Right-of-Use Assets and Lease_6

Right-of-Use Assets and Lease Liabilities (Details) - Schedule of Lease Liabilities - CHF (SFr)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Lease Liabilities [Abstract]
Beginning Balance	SFr 461,485	SFr 575,736
Additions
Interest expense	19,294	15,949
Repayment of lease liability	(134,707)	(130,200)
Remeasurement (revised lease term)	(246,413)
Ending Balance	99,659	461,485
thereof non-current		343,629
thereof current	SFr 99,659	SFr 117,856

Right-of-Use Assets and Lease_7

Right-of-Use Assets and Lease Liabilities (Details) - Schedule of Maturities of Lease Liabilities - CHF (SFr)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Maturities of Lease Liabilities [Abstract]
Year 1	SFr 101,030	SFr 130,200
Year 2		130,200
Year 3		130,200
Year 4		97,650
Year 5
Undiscounted lease payments	101,030	488,250
Less: unearned interest	(1,371)	(26,765)
Total	SFr 99,659	SFr 461,485

Intangible Assets (Details)

Intangible Assets (Details)	12 Months Ended
	Dec. 31, 2022 CHF (SFr)
Intangible Assets [Abstract]
Capitalized amount	SFr 275,281
Internal development costs	1,700,503
Impairment	SFr 12,397,148

Intangible Assets (Details) - S

Intangible Assets (Details) - Schedule of Intangible Assets - CHF (SFr)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Intangible Assets [Line Items]
At cost, Beginning Balance	SFr 17,820,590	SFr 15,844,806
At cost, Exchange differences	168
At cost, Additions		1,975,784
At cost, Ending Balance	17,820,758	17,820,590
Accumulated amortization and impairment losses, Beginning Balance		(1,529,929)
Accumulated amortization and impairment losses, Ending Balance	(13,927,077)	(13,927,077)
Net book value		3,893,681
Accumulated amortization and impairment losses, Impairment		(12,397,148)
Licenses [Member]
Schedule of Intangible Assets [Line Items]
At cost, Beginning Balance	5,376,201	5,376,201
At cost, Exchange differences
At cost, Additions
At cost, Ending Balance	5,376,201	5,376,201
Accumulated amortization and impairment losses, Beginning Balance		(1,482,520)
Accumulated amortization and impairment losses, Ending Balance	(1,482,520)	(1,482,520)
Net book value		3,893,681
Accumulated amortization and impairment losses, Impairment
IP & Data rights [Member]
Schedule of Intangible Assets [Line Items]
At cost, Beginning Balance	193,989	193,989
At cost, Exchange differences
At cost, Additions
At cost, Ending Balance	193,989	193,989
Accumulated amortization and impairment losses, Beginning Balance		(47,409)
Accumulated amortization and impairment losses, Ending Balance	(193,989)	(193,989)
Net book value
Accumulated amortization and impairment losses, Impairment		(146,580)
Patents [Member]
Schedule of Intangible Assets [Line Items]
At cost, Beginning Balance	748,435	473,154
At cost, Exchange differences
At cost, Additions		275,281
At cost, Ending Balance	748,435	748,435
Accumulated amortization and impairment losses, Beginning Balance
Accumulated amortization and impairment losses, Ending Balance	(748,435)	(748,435)
Net book value
Accumulated amortization and impairment losses, Impairment		(748,435)
Internally generated [Member]
Schedule of Intangible Assets [Line Items]
At cost, Beginning Balance	11,501,965	9,801,462
At cost, Exchange differences	168
At cost, Additions		1,700,503
At cost, Ending Balance	11,502,133	11,501,965
Accumulated amortization and impairment losses, Beginning Balance
Accumulated amortization and impairment losses, Ending Balance	(11,502,133)	(11,502,133)
Net book value
Accumulated amortization and impairment losses, Impairment		SFr (11,502,133)

Investment in an Associate (Det

Investment in an Associate (Details) - CHF (SFr)	Nov. 21, 2023	Dec. 31, 2023
Investment in an Associate [Line items]
Stake percentage of subsidiary	51%
Investment equity method	49%	49%
Transaction amount		SFr 1,000,000
Cash		SFr 490,000

Investment in an Associate (D_2

Investment in an Associate (Details) - Schedule of Financial Information of the Company’s Investment - Altamira Medica [Member]	12 Months Ended
	Dec. 31, 2023 CHF (SFr) shares
Investment in an Associate (Details) - Schedule of Financial Information of the Company’s Investment [Line Items]
Current assets	SFr 1,793,690
Non-current assets
Current liabilities	(897,665)
Non-current liabilities	(989,411)
Equity	SFr (93,386)
Company’s share in equity - 49% (in Shares) | shares	(45,759)
Goodwill	SFr 2,463,071
Company’s carrying amount of the investment	SFr 2,417,312

Investment in an Associate (D_3

Investment in an Associate (Details) - Schedule of Financial Information of the Company’s Investment (Parentheticals)	12 Months Ended
	Dec. 31, 2023
Altamira Medica [Member]
Investment in an Associate (Details) - Schedule of Financial Information of the Company’s Investment (Parentheticals) [Line Items]
Share in equity	49%

Investment in an Associate (D_4

Investment in an Associate (Details) - Schedule of Contingent Liabilities - CHF (SFr)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Contingent Liabilities [Abstract]
Revenue from contracts with customers	SFr 379
Cost of sales	(33,967)
Operating expenses	(29,321)
Finance costs	(15,732)
Profit before tax	(78,641)
Income tax expense	(2,087)
Profit after tax	(80,728)
Other comprehensive income	14,018
Total comprehensive income	(66,710)
Company’s share of loss of associate for the period	SFr (39,557)

Inventories (Details)

Inventories (Details) SFr in Millions	Dec. 31, 2022 CHF (SFr)
Stock Keeping Units [Member]
Inventories [Line Items]
Finished good inventories amount	SFr 0.9

Inventories (Details) - Schedul

Inventories (Details) - Schedule of Inventories - CHF (SFr)	Dec. 31, 2023	Dec. 31, 2022
Schedule of Inventories [Abstract]
Finished goods		SFr 11,644
Total		SFr 11,644

Other Receivables (Details)

Other Receivables (Details)	Dec. 31, 2023 CHF (SFr)
Other Receivables [Abstract]
Receivable from suppliers	SFr 18,905

Other Receivables (Details) - S

Other Receivables (Details) - Schedule of Other Receivables - CHF (SFr)	Dec. 31, 2023	Dec. 31, 2022
Schedule of Other Receivables [Abstract]
R&D tax credit receivable		SFr 672,600
Value added tax receivable	22,036	78,650
Receivable from suppliers and other	52,787	4,737
Total other receivables	SFr 74,823	SFr 755,987

Prepayments (Details) - Schedul

Prepayments (Details) - Schedule of Prepayments - CHF (SFr)	Dec. 31, 2023	Dec. 31, 2022
Schedule of Prepayments [Abstract]
Advance payments to suppliers	SFr 212,579	SFr 659,861
Insurance	71,253	49,405
Total prepayments	SFr 283,832	SFr 709,266

Cash and Cash Equivalents (Deta

Cash and Cash Equivalents (Details) - Schedule of Cash and Cash Equivalents - CHF (SFr)	Dec. 31, 2023	Dec. 31, 2022
Schedule of Cash and Cash Equivalents [Abstract]
Cash in bank accounts	SFr 617,409	SFr 15,395
Cash on hand
Total cash and cash equivalents	SFr 617,409	SFr 15,395

Capital and Reserves (Details)

Capital and Reserves (Details)

3 Months Ended

12 Months Ended

Dec. 15, 2023 CHF (SFr) SFr / shares shares

Dec. 07, 2023 SFr / shares shares

Jul. 10, 2023 SFr / shares shares

Jul. 10, 2023 $ / shares shares

May 31, 2023

May 04, 2023

May 01, 2023 SFr / shares shares

Dec. 05, 2022 USD ($) shares

Feb. 04, 2022 SFr / shares shares

Nov. 30, 2018 CHF (SFr) shares

Nov. 30, 2018 USD ($) shares

Mar. 08, 2023

Dec. 31, 2023 CHF (SFr) SFr / shares shares

Dec. 31, 2023 USD ($) shares

Dec. 31, 2022 CHF (SFr) shares

Dec. 31, 2022 USD ($) shares

Dec. 31, 2021 shares

Jan. 19, 2024 shares

Dec. 31, 2023 USD ($) $ / shares shares

Oct. 31, 2023 SFr / shares

Oct. 31, 2023 $ / shares

Dec. 28, 2022

Sep. 09, 2022

Capital and Reserves [Line items]

Common shares par value | (per share)

$ 0.0001

SFr 4

$ 0.0001

Reduction of share capital (in Francs) | SFr

Share capital

SFr 2,646

SFr 236,011

$ 2,956

Public offering

555,556

555,556

Pre-funded warrants

511,806

511,806

Common shares

81,274

555,556

555,556

81,274

81,274

Public offering price (in Francs per share) | (per share)

SFr 9

$ 9

Exercise price warrants (in Francs per share) | SFr / shares

SFr 8

Warrants granted

36,113

36,113

Strike price (in Francs per share) | SFr / shares

SFr 10

Exercise period

5 years

5 years

Pre-funded warrants were exercised | SFr

Gross proceeds

SFr 4,444,445

$ 5,000,000

Related transaction costs | $

$ 718,767

Fair value assumptions volatility

107.34%

107.34%

Annual risk free rate

4.25%

4.25%

Bears interest rate percentage

10%

5%

5%

Maturity month

22 months

Interest rate

10%

4.99%

4.90%

5%

Conversion price (in Francs per share) | SFr / shares

SFr 28.4

Cash plus percentage

3%

Volume weighted average price

90%

15.80%

15.80%

13.70%

13.70%

13.50%

Aggregate cash payments (in Francs) | SFr

SFr 387,045

Average price

443,294

443,294

Average price per shares (in Francs per share) | SFr / shares

SFr 5.07

Reduction of share premium (in Francs) | SFr

Exercise price (in Francs per share) | SFr / shares

SFr 6.656

SFr 30.76

Weighted average price percentage

90%

Share issued

1,477,785

59,003

637,460

1,477,785

Exercise of warrants

81,274

81,274

Conversion price (in Francs per share) | SFr / shares

SFr 28.95

Warrants issued (in Francs per share) | SFr / shares

SFr 0.5

Warrants maturity

2 years

Fair value warrants issued (in Francs) | SFr

SFr 165,041

Convertible loan (in Francs per share) | SFr / shares

SFr 5,000,000

Effective rate

90%

Common shares

491,258

491,258

45,536

45,536

33,116

Common shares par value | SFr / shares

SFr 25.73

Purchase agreement (in Dollars) | $

$ 10,000,000

Aggregate proceeds

$ 4,000,000

SFr 4,700,000

$ 5,100,000

SFr 776,198

$ 854,475

Common shares for agreement (in Dollars) | $

$ 10,000,000

Offering price (in Dollars) | $

$ 25,000,000

Sale of common stock

104,147

104,147

Common shares for an aggregate

123,512

123,512

Aggregate offering price (in Dollars) | $

$ 13.1

Common Shares [Member]

Capital and Reserves [Line items]

Common shares par value | $ / shares

$ 0.002

Common shares par value | $ / shares

$ 0.002

Common shares authorized

5,000,000

5,000,000

Top of Range [Member]

Capital and Reserves [Line items]

Fair value assumptions volatility

113.40%

Annual risk free rate

5.40%

Bottom of Range [Member]

Capital and Reserves [Line items]

Fair value assumptions volatility

115%

Annual risk free rate

4.70%

FiveT Loan [Member]

Capital and Reserves [Line items]

Common shares

217,051

Lincoln Park Capital Fund, LLC [Member]

Capital and Reserves [Line items]

Share issued

16,250

17,500

17,500

CHF [Member]

Capital and Reserves [Line items]

Warrants issued amount

3,921,647

3,921,647

Convertible loan agreement

2,500,000

Conversion price (in Francs per share) | SFr / shares

SFr 6.656

Warrants [Member]

Capital and Reserves [Line items]

Public offering

43,750

43,750

Warrants granted

36,113

36,113

Pre-funded warrants were exercised

SFr 102,361

$ 112,597

Related transaction costs | SFr

SFr 639,873

Share issued

81,274

Conversion price (in Francs per share) | SFr / shares

SFr 6.656

Warrants [Member] | CHF [Member]

Capital and Reserves [Line items]

Share issued

541,034

Exercise of warrants

15,066

Preference shares [member]

Capital and Reserves [Line items]

Common shares par value | $ / shares

$ 0.0001

Common shares authorized

20,000,000

20,000,000

Share premium [member]

Capital and Reserves [Line items]

Reduction of share capital (in Francs) | SFr

SFr 2,903,684

Pre-funded warrants were exercised | SFr

(4,086,688)

Reduction of share premium (in Francs) | SFr

(186,852,242)

Retained earnings [member]

Capital and Reserves [Line items]

Reduction of share capital (in Francs) | SFr

Reduction of share premium (in Francs) | SFr

SFr 186,852,242

Capital and Reserves (Details)

Capital and Reserves (Details) - Schedule of Issued Share Capital		Jan. 19, 2024 shares	Dec. 31, 2023 CHF (SFr) shares	Dec. 31, 2023 USD ($) shares	Dec. 31, 2022 CHF (SFr) shares
Schedule of Issued Share Capital [Line Items]
Number		637,460	1,477,785	1,477,785	59,003
Value (CHF) (in Francs and Dollars)			SFr 2,646	$ 2,956	SFr 236,011
Ordinary Shares Nominal Value [member]
Schedule of Issued Share Capital [Line Items]
Number	[1]		1,477,785	1,477,785	59,003
Value (CHF) (in Francs and Dollars)	[1]			$ 2,956	SFr 236,011
[1]The par value of the common shares was reduced from CHF 4.00 and changed to USD 0.0001 following approval the Company’s special general meeting of October 31, 2023, and subsequently the board of directors in December 2023 consolidated the then common shares of par value $0.0001 each at a ratio of 20:1, into common shares of par value $0.002 each. In total the share capital was reduced by CHF 2,903,684 to CHF 2,646 (USD 2,956) and the amount of the reduction was credited to share premium.

Capital and Reserves (Details_2

Capital and Reserves (Details) - Schedule of Issued Share Capital (Parentheticals)	Dec. 31, 2023 $ / shares	Dec. 31, 2022 SFr / shares
Ordinary Shares Nominal Value [member]
Schedule of Issued Share Capital [Line Items]
Nominal value of common shares | (per share)	$ 0.002	SFr 0.002

Capital and Reserves (Details_3

Capital and Reserves (Details) - Schedule of Common Shares - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Common Shares [Line Items]
Beginning balance	59,003	37,411
Exercise of warrants	81,274
Public Offering	555,556
LPC equity line	17,500	15,750
ATM program	104,147	5,842
Conversion convertible loans	660,345
Fractional shares eliminated upon reverse split	(40)
Ending balance	1,477,785	59,003

Share-Based Compensation (Detai

Share-Based Compensation (Details) - CHF (SFr)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-Based Compensation [Member]
Options granted (in Shares)	138,907	4,885
Share based payment (in Francs)	SFr 379,414	SFr 342,799	SFr 1,206,303
Bottom of range [member]
Share-Based Compensation [Member]
Stock options exercise price	SFr 2.46	SFr 117.6
Top of range [member]
Share-Based Compensation [Member]
Stock options exercise price	SFr 10,637	SFr 11,693.2

Share-Based Compensation (Det_2

Share-Based Compensation (Details) - Schedule of Key Terms and Conditions Related to the Grants	12 Months Ended
	Dec. 31, 2023
Share-Based Compensation (Details) - Schedule of Key Terms and Conditions Related to the Grants [Line Items]
Number of options outstanding	7,898
Vesting conditions	1 year service from grant date
Contractual life of options	6 years
Equity Incentive Plan Employees / Board [Member]
Share-Based Compensation (Details) - Schedule of Key Terms and Conditions Related to the Grants [Line Items]
Number of options outstanding	68,713
Vesting conditions	2 years’ service from grant date (50%)
Contractual life of options	8 years
Equity Incentive Plan Employees / Board One [Member]
Share-Based Compensation (Details) - Schedule of Key Terms and Conditions Related to the Grants [Line Items]
Number of options outstanding	68,713
Vesting conditions	3 years’ service from grant date (50%)
Contractual life of options	8 years

Share-Based Compensation (Det_3

Share-Based Compensation (Details) - Schedule of Fair Value of the Options Measured - USD ($)		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022
OneYear Vesting Period [Member] | Equity Incentive Plan 2023 [Member]
Share-Based Compensation (Details) - Schedule of Fair Value of the Options Measured [Line Items]
Fair value at grant date	[1]	USD 1.72 (2 year vesting) 1) USD 1.96 (3 year vesting) 1)
Share price at grant date		USD 2.92
Exercise price		USD 2.92
Expected volatility		108.87%
Expected life		2 and 3 years
Expected dividends
Risk-free interest rate		4.90%
OneYear Vesting Period [Member] | Equity Incentive Plan 2022 [Member]
Share-Based Compensation (Details) - Schedule of Fair Value of the Options Measured [Line Items]
Fair value at grant date	[2]		USD 132.88 (1 year vesting)  2) USD 175.2 (2 year  vesting) 2) USD 212.08 (3  year vesting) 2)
Share price at grant date			USD 356
Exercise price			USD 415.60
Expected volatility			99.10%
Expected life			1, 2 and 3 years
Expected dividends
Risk-free interest rate			2.87%
Two Year Vesting Period [Member] | Equity Incentive Plan 2023 [Member]
Share-Based Compensation (Details) - Schedule of Fair Value of the Options Measured [Line Items]
Fair value at grant date	[2]	USD 6.674 (1 year vesting)  2) USD 10.918 (2 year  vesting) 2) USD 12.82 (3  year vesting) 2)
Share price at grant date		USD 19.2
Exercise price		USD 19.2
Expected volatility		111.23%
Expected life		1, 2 and 3 years
Expected dividends
Risk-free interest rate		4.37%
Two Year Vesting Period [Member] | Equity Incentive Plan 2022 [Member]
Share-Based Compensation (Details) - Schedule of Fair Value of the Options Measured [Line Items]
Fair value at grant date	[1]		USD 86.94 (2 year vesting) 1) USD  100.22 (3 year vesting) 1)
Share price at grant date			USD 149.6
Exercise price			USD 127.06
Expected volatility			100.20%
Expected life			2 and 3 years
Expected dividends
Risk-free interest rate			4.45%
[1] October grants for the respective year April grants for the respective year

Share-Based Compensation (Det_4

Share-Based Compensation (Details) - Schedule of Exercise Prices for Outstanding Options - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Number And Weighted Average Exercise Prices Abstract
Number of options, Outstanding	7,884	3,324
Weighted average exercise price, Outstanding	$ 385.6	$ 660
Weighted average remaining term, Outstanding	6 years 2 months 19 days	6 years 6 months 21 days
Number of options, Expired during the year
Weighted average exercise price, Expired during the year
Weighted average remaining term, Expired during the year
Number of options, Forfeited during the year	(1,467)	(325)
Weighted average exercise price, Forfeited during the year
Weighted average remaining term, Forfeited during the year
Number of options, Exercised during the year
Weighted average exercise price, Exercised during the year
Weighted average remaining term, Exercised during the year
Number of options, Granted during the year	138,907	4,885
Weighted average exercise price, Granted during the year	$ 4.76	$ 188
Weighted average remaining term, Granted during the year
Number of options, Outstanding	145,324	7,884
Weighted average exercise price, Outstanding	$ 22.17	$ 385.6
Weighted average remaining term, Outstanding	5 years 7 months 13 days	6 years 2 months 19 days
Number of options, Exercisable	2,630	1,440
Weighted average exercise price, Exercisable
Weighted average remaining term, Exercisable

Trade and Other Payables (Detai

Trade and Other Payables (Details) - Schedule of Trade and Other Payables - CHF (SFr)	Dec. 31, 2023	Dec. 31, 2022
Schedule of Trade and Other Payables [Abstract]
Trade accounts payable - third parties	SFr 413,111	SFr 4,767,940
Other	27,303	146,464
Total trade and other payables	SFr 440,414	SFr 4,914,404

Accrued Expenses (Details) - Sc

Accrued Expenses (Details) - Schedule of Accrued Expenses - CHF (SFr)	Dec. 31, 2023	Dec. 31, 2022
Schedule of Accrued Expenses [Abstract]
Accrued research and development costs including milestone payments	SFr 87,522	SFr 741,291
Professional fees	17,412	326,365
Accrued vacation & overtime	52,368	46,868
Employee benefits incl. share based payments	190,610	362,497
Accrued interest		457,812
Other	929	42,781
Total accrued expenses	SFr 348,841	SFr 1,977,614

Deferred Income (Details)

Deferred Income (Details) SFr in Millions	12 Months Ended
	Dec. 31, 2022 CHF (SFr)	Dec. 31, 2022 USD ($)	Dec. 31, 2023 USD ($)
Deferred Income [Abstract]
Upfront payment amount	SFr 0.9	$ 1,000,000
Deferred income			$ 0

Deferred Income (Details) - Sch

Deferred Income (Details) - Schedule of Deferred Income - CHF (SFr)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Deferred Income [Abstract]
Upfront payment		SFr 932,200
Total deferred income		SFr 932,200

Other Operating Income (Details

Other Operating Income (Details) - Schedule of Other Operating Income - CHF (SFr)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Other Operating Income [Abstract]
Income from Government grants	SFr 228,302
Other income	27,287	9,327
Total other operating income	SFr 255,589	SFr 9,327

Research and Development Expe_3

Research and Development Expense (Details) - Schedule of Research and Development Expense - CHF (SFr)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Research and Development Expense [Abstract]
Pre-clinical projects	SFr 505,031	SFr 389,673	SFr 96,840
Clinical projects	128,717	67,096	63,757
Product and process development	364,392	199,225	164,684
Employee benefits and expenses	1,429,564	1,426,299	934,577
Patents and trademarks	414,718	155,589	333,519
Regulatory projects	59,531	34,098	32,564
Impairment intangible assets		12,338,837	1,529,929
Depreciation tangible assets			46,635
Other research and development expense	133,459	10,753
Total research and development expense	SFr 3,035,413	SFr 14,621,570	SFr 3,202,505

General and Administrative Ex_3

General and Administrative Expenses (Details) - Schedule of General and Administrative Expenses - CHF (SFr)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of General and Administrative Expense [Abstract]
Employee benefits and expenses	SFr 655,967	SFr 645,138	SFr 1,371,526
Business development	15,348	15,727	39,916
Travel expenses	43,055	95,503	75,829
Administration expenses	2,274,159	2,517,309	2,098,866
Lease expenses from short-term lease	15,705	6,001	52,280
Depreciation of Right-of-use assets	119,304	118,887	29,722
Depreciation of tangible assets
Capital tax expenses	12,738	3,110	706
Total general and administrative expenses	SFr 3,136,275	SFr 3,401,676	SFr 3,668,845

Employee Benefits (Details)

Employee Benefits (Details) - CHF (SFr)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Employee Benefits [Abstract]
Interest rate term	2 years
Benefit plans interest rate	1%	1%	1%
Weighted average duration defined benefit obligation	17 years 8 months 12 days	17 years 1 month 6 days
Expected employer plam	SFr 128,608

Employee Benefits (Details) - S

Employee Benefits (Details) - Schedule of Defined Benefit Plan Expense Recognized in Profit or Loss - CHF (SFr)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Defined Benefit Plan Expense Recognized in Profit or Loss [Abstract]
Salaries	SFr 2,145,943	SFr 2,815,411	SFr 1,865,633
Pension costs	172,460	266,256	165,801
Other social benefits	293,753	294,017	275,258
Share based payments costs	379,414	342,799	1,223,696
Other personnel expenditures	9,999	2,024	214,940
Total employee benefits	3,001,569	3,720,507	3,745,328
Employee benefits attributable to continuing operations	2,243,955	2,071,436	2,375,668
Employee benefits attributable to discontinued operations	SFr 757,614	SFr 1,649,071	SFr 1,369,660

Employee Benefits (Details) -_2

Employee Benefits (Details) - Schedule of Defined Benefit Obligation - CHF (SFr)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Defined Benefit Obligation [Abstract]
Defined benefit obligation at beginning	SFr 3,544,161	SFr 4,677,632
Service costs	163,101	256,336
Plan participants’ contribution	130,875	154,116
Interest cost	76,139	13,762
Actuarial losses	104,860	(931,636)
Plan amendments
Benefits paid through pension assets	(78,957)	(626,049)
Defined benefit obligation at ending	3,940,179	3,544,161
Fair value of plan assets at beginning	3,207,955	4,009,313
Interest income	71,813	12,187
Return on plan assets excluding interest income	136,023	(490,359)
Employer contributions	130,875	154,116
Plan participants’ contributions	130,875	154,116
Benefits paid through pension assets	(78,957)	(626,049)
Administration expense	(5,033)	(5,369)
Fair value of plan assets at ending	3,593,551	3,207,955
Present value of funded defined benefit obligation	3,940,179	3,544,161
Fair value of plan assets	(3,593,551)	(3,207,955)
Net defined benefit liability	SFr 346,628	SFr 336,206

Employee Benefits (Details) -_3

Employee Benefits (Details) - Schedule of Defined Benefit Cost and Liability Assumptions - CHF (SFr)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Defined Benefit Cost and Liability Assumptions [Abstract]
Service cost	SFr 163,101	SFr 256,336	SFr 159,085
Net interest expense	3,270	1,575	1,878
Administration expense	4,259	5,369	6,030
Total defined costs for the year recognized in profit or loss	170,630	263,280	166,993
Actuarial loss (gain) arising from changes in financial assumptions	247,262	(876,841)	(74,284)
Actuarial loss (gain) arising from experience adjustments	(138,497)	(54,795)	463,238
Actuarial gain arising from demographic assumptions	(3,905)		(229,109)
Return on plan assets excluding interest income	(136,023)	490,359	(424,829)
Total defined benefit cost for the year recognized in other comprehensive income	SFr (31,163)	SFr (441,277)	SFr (264,984)
Discount rate	1.50%	2.20%	0.30%
Future salary increases	1.35%	1.60%	0.85%
Pension indexation	0%	0%	0%
Mortality and disability rates	BVG2020	BVG2020	BVG2020

Employee Benefits (Details) -_4

Employee Benefits (Details) - Schedule of Sensitivity Analysis for Actuarial Assumptions - CHF (SFr)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Employee Benefits (Details) - Schedule of Sensitivity Analysis for Actuarial Assumptions [Line Items]
Percentage of reasonably possible increase in actuarial assumption	0.25% increase	0.25% increase
Discount rate [Member]
Employee Benefits (Details) - Schedule of Sensitivity Analysis for Actuarial Assumptions [Line Items]
Discount rate	SFr (141,340)	SFr (177,546)
Salary increase [Member]
Employee Benefits (Details) - Schedule of Sensitivity Analysis for Actuarial Assumptions [Line Items]
Discount rate	(22,950)	23,058
Pension indexation [Member]
Employee Benefits (Details) - Schedule of Sensitivity Analysis for Actuarial Assumptions [Line Items]
Discount rate	SFr 78,491	SFr 63,916
Change in assumption [Member]
Employee Benefits (Details) - Schedule of Sensitivity Analysis for Actuarial Assumptions [Line Items]
Life expectancy reasonably possible increase in actuarial assumption	+1 year	+1 year
Life expectancy {Member]
Employee Benefits (Details) - Schedule of Sensitivity Analysis for Actuarial Assumptions [Line Items]
Discount rate	SFr 63,383	SFr 48,531

Finance Income and Finance Ex_3

Finance Income and Finance Expense (Details)	12 Months Ended
	Dec. 31, 2023 CHF (SFr)	Dec. 24, 2023 CHF (SFr)	Dec. 31, 2022 CHF (SFr)	Dec. 31, 2022 CHE	Dec. 24, 2022 CHF (SFr)	Dec. 31, 2021 CHF (SFr)	Dec. 24, 2021 CHF (SFr)
Finance Income and Finance Expense [Line items]
Revaluation of outstanding warrants	SFr 15,066
Revaluation loss from derivative financial instruments	181,258
Gain on modification of financial instruments	36,778	SFr 36,778
Loss on modification of financial instruments	7,317	SFr 7,317
Gain from derivative financial instruments			SFr 451,131
Revaluation of the financial derivatives			449,898
Interest expense	SFr 1,007,437			CHE 892,005		SFr 4,991
Warrants [member]
Finance Income and Finance Expense [Line items]
Revaluation of outstanding warrants			SFr 1,233

Finance Income and Finance Ex_4

Finance Income and Finance Expense (Details) - Schedule of Finance Income and Finance Expense - CHF (SFr)	12 Months Ended
	Dec. 31, 2023	Dec. 24, 2023	Dec. 31, 2022	Dec. 24, 2022	Dec. 31, 2021	Dec. 24, 2021
Schedule of Finance Income and Finance Expense [Abstract]
Interest income		SFr 302,249		SFr 114,268		SFr 26,990
Net foreign currency exchange gain						47,161
Revaluation gain from derivative financial instruments		15,066		451,131		5,085
Gain on modification of financial instruments	SFr 36,778	36,778
Total finance income		354,093		565,399		79,236
Interest expense (incl. bank charges)		1,032,444		904,345		14,112
Net foreign currency exchange loss		447,456		305,560
Revaluation loss from derivative financial instruments	181,258	181,258
Loss on modification of financial instruments	7,317	7,317
Transaction costs	SFr 809,378		SFr 35,495	1,137	SFr 156,817
Total finance expense		1,668,475		1,211,042		14,112
Finance expense, net		SFr (1,314,382)		SFr (645,643)		SFr 65,124

Taxation (Details)

Taxation (Details) SFr in Millions		12 Months Ended
	May 04, 2023	Dec. 31, 2023 CHF (SFr)	Dec. 31, 2022 CHF (SFr)	Dec. 31, 2021	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Taxation [Line items]
Weighted average tax rate	90%	15.80%	13.70%	13.50%
Unrecognized tax loss carryforwards | $					$ 60,606,571	$ 103,114,677
Auris Medical AG [Member]
Taxation [Line items]
Unrecognized tax loss carryforwards		SFr 60.6	SFr 101.4
Otolanum AG [Member]
Taxation [Line items]
Unrecognized tax loss carryforwards			103.1
Altamira Therapeutics AG [Member]
Taxation [Line items]
Unrecognized tax loss carryforwards		59
Altamira Therapeutics Inc [Member]
Taxation [Line items]
Unrecognized tax loss carryforwards		SFr 1.6
Auris Medical Inc [Member]
Taxation [Line items]
Unrecognized tax loss carryforwards			SFr 1.7

Taxation (Details) - Schedule o

Taxation (Details) - Schedule of Income Tax Expense - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Income Tax Expense [Abstract]
Deferred income tax expense from continuing operations		$ (11,604)	$ (431,164)
Deferred income tax gain from continuing operations		19,524	549,109
Deferred income tax expense from discontinued operations		(52,004)	(139,565)
Deferred income tax gain from discontinued operations	99,847	54,413
Income tax gain/(loss)	$ 99,847	$ 10,329	$ (21,620)

Taxation (Details) - Schedule_2

Taxation (Details) - Schedule of Effective Income Tax Expense Weighted Average Tax Rate	12 Months Ended
	Dec. 31, 2023 CHF (SFr)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 CHF (SFr)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 CHF (SFr)	Dec. 31, 2021 USD ($)
Schedule of Effective Income Tax Expense Weighted Average Tax Rate [Abstract]
Loss before income tax from continuing operations	SFr (7,270,038)	$ (7,270,038)	SFr (18,659,562)	$ (18,659,562)	SFr (6,806,226)	$ (6,806,226)
Profit before income tax from discontinued operations		3,301,018		(7,879,178)		(10,230,597)
Accounting Profit before income tax		(3,969,020)		(26,538,740)		(17,036,823)
Income tax at statutory tax rates applicable to results in the respective countries		626,286		3,641,775		2,348,057
Effect of unrecognized temporary differences		(5,423)		(125,260)		(632,031)
Effect of unrecognized taxable losses		(543,086)		(3,015,088)		(1,885,486)
Effect of impact from application of different tax rates		(43,534)		(491,098)		223,215
Other effects		65,604				(75,375)
Income tax gain		99,847		10,329		(21,620)
Income tax gain reported in the statement of profit or loss			SFr (7,919)	7,919	SFr (117,945)	117,945
Income tax gain/(loss) attributable to discontinued operations		$ 99,847		$ 2,410		$ (139,565)

Taxation (Details) - Schedule_3

Taxation (Details) - Schedule of Unrecognized Tax Loss Carryforwards - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Taxation (Details) - Schedule of Unrecognized Tax Loss Carryforwards [Line Items]
Total tax loss carry-forwards	$ 60,606,571	$ 103,114,677
Within 1 year [Member]
Taxation (Details) - Schedule of Unrecognized Tax Loss Carryforwards [Line Items]
Total tax loss carry-forwards	22,717,044	27,956,899
Between 1 and 3 years [Member]
Taxation (Details) - Schedule of Unrecognized Tax Loss Carryforwards [Line Items]
Total tax loss carry-forwards	13,625,930	31,668,498
Between 3 and 7 years [Member]
Taxation (Details) - Schedule of Unrecognized Tax Loss Carryforwards [Line Items]
Total tax loss carry-forwards	22,681,981	41,797,708
More than 7 years [Member]
Taxation (Details) - Schedule of Unrecognized Tax Loss Carryforwards [Line Items]
Total tax loss carry-forwards	$ 1,581,616	$ 1,691,572

Taxation (Details) - Schedule_4

Taxation (Details) - Schedule of Tax Effect Unrecognized Loss Carryforwards - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Schedule of Tax Effect Unrecognized Loss Carryforwards [Abstract]
Deferred income		$ 111,025
Employee benefit plan	45,200	43,841
Total potential tax assets	45,200	154,866
Potential tax assets from loss carry-forwards not recognized	7,936,946	13,297,723
Total potential tax assets from loss carry-forwards and temporary differences not recognized	$ 7,982,146	$ 13,452,589

Loss Per Share (Details)

Loss Per Share (Details) - shares		12 Months Ended
	Jan. 01, 2023	Dec. 31, 2023	Dec. 31, 2022
Loss Per Share [Abstract]
Antidilutive securities excluded from computation of earnings per share, Amount		145,324
Average number of options outstanding	41,803	45,536
Warrants to purchase		759,167
Warrant to purchase of common stock			4,958

Loss Per Share (Details) - Sche

Loss Per Share (Details) - Schedule of Loss Per Share - CHF (SFr)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Loss Per Share [Abstract]
Loss attributable to owners of the Company	SFr (3,869,173)	SFr (26,528,411)	SFr (17,058,443)
Weighted average number of shares outstanding	491,258	45,536	33,116
Basic loss per share	SFr (7.88)	SFr (582.58)	SFr (515.11)
Loss attributable to owners of the Company	SFr (7,270,038)	SFr (18,651,643)	SFr (6,688,281)
Weighted average number of shares outstanding	491,258	45,536	33,116
Basic loss per share	SFr (14.8)	SFr (409.6)	SFr (201.97)

Loss Per Share (Details) - Sc_2

Loss Per Share (Details) - Schedule of Loss Per Share (Parentheticals) - SFr / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Loss Per Share [Abstract]
Diluted loss per share	SFr (7.88)	SFr (582.58)	SFr (515.11)
Diluted loss per share	SFr (14.80)	SFr (409.60)	SFr (201.97)

Discontinued Operations (Detail

Discontinued Operations (Details)		12 Months Ended
	Nov. 21, 2023	Dec. 31, 2023
Discontinued Operations [Abstract]
Selling rate	51%
Percentage of reatined shares		49%

Discontinued Operations (Deta_2

Discontinued Operations (Details) - Schedule of Gain on Disposal of Discontinued Operations - Discontinued operations [Member]	Nov. 21, 2023 CHF (SFr)
Discontinued Operations (Details) - Schedule of Gain on Disposal of Discontinued Operations [Line Items]
Cash consideration received	SFr 2,040,000
Cash disposed of	(115,676)
Net cash inflow on disposal	1,924,324
Other consideration received	32,685
Total consideration received	2,072,685
Net assets disposed:
Inventories	(331,466)
Prepaid expenses	(218,395)
Receivables and other assets	(677,544)
Cash and cash equivalents	(115,676)
Trade and other payables	1,104,399
Accrued liabilities	318,083
Deferred income	932,200
Foreign currency translation reserve, transfer to profit or loss	161,249
Total net assets disposed incl. currency translation reserve	1,172,850
Remeasurement of retained interest at fair value	1,960,000
Pre-tax gain on disposal of discontinued operation	5,205,535
Related tax expense
Gain on disposal of discontinued operation	SFr 5,205,535

Discontinued Operations (Deta_3

Discontinued Operations (Details) - Schedule of Discontinued Operations - Discontinued operations [member] - CHF (SFr)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Discontinued Operations (Details) - Schedule of Discontinued Operations [Line Items]
Revenue	SFr 157,834	SFr 305,616	SFr 63,882
Cost of Sales	(191,922)	(1,443,855)	(2,240,554)
Other income	131,702	700,122	214,217
Operating expenses	(1,870,939)	(7,680,444)	(7,934,264)
Financial income/(expense), net	(131,192)	239,383	(333,878)
Tax (expense) / credit	99,847	2,410	(139,565)
Gain on disposal of discontinued operation	5,205,535
Profit after tax from discontinued operations	SFr 3,400,865	SFr (7,876,768)	SFr (10,370,162)

Discontinued Operations (Deta_4

Discontinued Operations (Details) - Schedule of Earnings Per Share from Discontinued Operations - SFr / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Earnings Per Share from Discontinued Operations [Abstract]
Basic and diluted earnings / (loss) per share from discontinued operations	SFr 6.92	SFr (172.98)	SFr (313.15)

Discontinued Operations (Deta_5

Discontinued Operations (Details) - Schedule of Earnings Per Share from Discontinued Operations (Parentheticals) - SFr / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Earnings Per Share from Discontinued Operations [Abstract]
Diluted earnings / (loss) per share from discontinued operations	SFr 6.92	SFr (172.98)	SFr (313.15)

Discontinued Operations (Deta_6

Discontinued Operations (Details) - Schdule of Statement of Cash Flows - CHF (SFr)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schdule of Statement of Cash Flows [Abstract]
Operating activities	SFr (1,092,385)	SFr (1,104,053)	SFr (2,612,264)
Investing activities	67	67,406	(116,330)
Financing activities	1,056,532	859,610	2,000,000
Net cash from discontinued operations	SFr (35,786)	SFr (177,037)	SFr (728,594)

Commitments and Contingencies_2

Commitments and Contingencies (Details) - CHF (SFr)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Commitments and contingencies [Line Items]
Office lease expenses	SFr 6,600	SFr 6,001

Commitments and Contingencies_3

Commitments and Contingencies (Details) - Schedule of Future Minimum Lease Payments Under Non-Cancellable Operating Leases - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Schedule of Future Minimum Lease Payments Under Non-Cancellable Operating Leases [Line Items]
Minimum finance lease payments payable	$ 3,946	$ 3,450
Within one year [Member]
Schedule of Future Minimum Lease Payments Under Non-Cancellable Operating Leases [Line Items]
Minimum finance lease payments payable	3,946	3,450
Between one and five years [Member]
Schedule of Future Minimum Lease Payments Under Non-Cancellable Operating Leases [Line Items]
Minimum finance lease payments payable

Related Party Transactions (Det

Related Party Transactions (Details) - CHF (SFr)					3 Months Ended	12 Months Ended
	May 31, 2023	May 01, 2023	Sep. 09, 2022	Feb. 04, 2022	Mar. 08, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Related Party Transactions (Details) [Line Items]
Interest receivable						SFr 18,905
Agreement amount			SFr 600,000
Short term loan					SFr 100,000
Bearing interest rate	10%	4.99%		4.90%	5%
Share based payment charge amounted						283,588	SFr 223,286	SFr 240,408
Share based payments						283,588	223,286	240,408
Stock option amount						99,318	5,355	2,474
Gremaud GmbH [Member]
Related Party Transactions (Details) [Line Items]
Fees paid						251,110	195,988
Fees payment for other services						0	0
Dr Wickline [Member]
Related Party Transactions (Details) [Line Items]
Fees paid							172,512
Loan Agreement [Member]
Related Party Transactions (Details) [Line Items]
Agreement amount			SFr 200,000
Board of Directors Chairman [Member]
Related Party Transactions (Details) [Line Items]
Fees paid							138,507
Share based payment charge amounted						681,353
Payroll charge							1,038,810	810,671
Fees amount							183,058	165,245
Board of Directors [Member]
Related Party Transactions (Details) [Line Items]
Share based payment charge amounted						SFr 41,319	51,171	48,046
Pension amount							SFr 44,469	SFr 49,050	SFr 29,467

Related Party Transactions (D_2

Related Party Transactions (Details) - Schedule of Related Party Transaction - CHF (SFr)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Related Party Transactions (Details) - Schedule of Related Party Transaction [Line Items]
Short term benefits	SFr 775,391	SFr 1,172,818	SFr 946,449
Post-employee benefits years	44,469	49,050	29,467
Share bonuses			902,817
Share-based payment	283,588	223,286	240,408
Total	1,103,448	1,445,154	2,119,141
Executive Management [Member]
Related Party Transactions (Details) - Schedule of Related Party Transaction [Line Items]
Short term benefits	636,884	989,760	781,204
Post-employee benefits years	44,469	49,050	29,467
Share bonuses			902,817
Share-based payment	242,269	172,115	192,362
Total	923,622	1,210,925	1,905,850
Board of Directors [Member]
Related Party Transactions (Details) - Schedule of Related Party Transaction [Line Items]
Short term benefits	138,507	183,058	165,245
Post-employee benefits years
Share bonuses
Share-based payment	41,319	51,171	48,046
Total	SFr 179,826	SFr 234,229	SFr 213,291

Loans (Details)

Loans (Details)

1 Months Ended

12 Months Ended

Dec. 15, 2023 shares

Dec. 07, 2023 SFr / shares

Jul. 10, 2023 shares

May 12, 2023 SFr / shares

May 12, 2023 $ / shares

May 12, 2023 SFr / shares

May 04, 2023

May 01, 2023 CHF (SFr) SFr / shares

Sep. 09, 2022 CHF (SFr) SFr / shares shares

Feb. 08, 2022 CHF (SFr)

Mar. 04, 2021 CHF (SFr)

Dec. 28, 2022 CHF (SFr) SFr / shares shares

Dec. 31, 2023 CHF (SFr) SFr / shares shares

Dec. 24, 2023 CHF (SFr)

Dec. 31, 2022 CHF (SFr)

Dec. 24, 2022 CHF (SFr)

Dec. 24, 2021 CHF (SFr)

Loan [Line items]

Pricing of conversion description

the 2022 FiveT Loan (see below), which amended the conversion price of the 2022 FiveT Loan to a fixed price equal to the lower of (a) the mean daily trading volume weighted average price (“VWAP”) of the Company’s common shares on the Nasdaq Stock Market on the 20 trading days preceding the effective date of the FiveT Loan Amendment or (b) 90% of the VWAP on the effective date of the FiveT Loan Amendment. From April 13, 2023 to April 17, 2023, FiveT IM converted the entire 2022 FiveT Loan into an aggregate of 217,050 common shares at an average conversion price of $28.95 per share (CHF 25.69 per share). As a result, the 2022 FiveT Loan is no longer outstanding and has been terminated. The fair value of the embedded derivative in the 2022 FiveT Loan as of December 31, 2022, was zero.

Derivative financial instruments

SFr 181,258

SFr 181,258

Convertible loan agreement amount

SFr 2,500,000

SFr 600,000

SFr 350,000

Interest rate

10%

5%

5%

Convertible Loan Agreement

22 months

Percentage of convertible loan

4.99%

Conversion price per share (in Francs per share) | SFr / shares

SFr 28.4

Common shares (in Shares) | shares

81,274

555,556

81,274

Exercise price per common share (in Francs per share) | SFr / shares

SFr 6.656

SFr 30.76

Cash Plus

3%

Weighted average percentage

90%

90%

90%

90%

Purchase of warrants (in Shares) | shares

2,085

2,359

warrants exercise share (in Francs per share) | SFr / shares

SFr 144

SFr 89.02

Issuance term

5 years

5 years

Outstanding loan amount

SFr 17.62

Equity amount

SFr 86,744

SFr 48,185

Carrying amount

561,062

SFr 305,873

SFr 4,898,377

Convertible loan per share (in Francs per share) | SFr / shares

SFr 22.4

Percentage of weighted average price (in Dollars per share) | $ / shares

$ 120

Common share per value (in Francs per share) | SFr / shares

SFr 17.62

Convertible loan description

The convertible loan of CHF 5.0 million, as amended (the “2022 FiveT Loan”) carried interest at the rate of 10% per annum and was to mature on May 31, 2023. FiveT IM had the right to convert all or part of the 2022 FiveT Loan, including accrued and unpaid interest, at its option, into common shares, subject to the limitation that FiveT IM own no more than 4.9% of the common shares at any time. On April 13, 2023, the Company and FiveT IM entered into an amendment to the 2022 FiveT Loan (the “2022 FiveT Loan Amendment”), which amended the conversion price of the 2022 FiveT Loan to a fixed price equal to the lower of (a) the mean daily trading volume weighted average price (“VWAP”) of the Company’s common shares on the Nasdaq Stock Market on the 20 trading days preceding the effective date of the FiveT Loan Amendment or (b) 90% of the VWAP on the effective date of the FiveT Loan Amendment. From April 13, 2023 to April 17, 2023, FiveT IM converted the entire FiveT Loan into an aggregate of 217,051 common shares at an average conversion price of $28.95 per share.

Expected volatility

90.70%

Derivative amount

SFr 449,898

SFr 0

Fair value measurement

SFr 449,898

Transaction costs

SFr 807,593

Mr. Meyer lent [Member]

Loan [Line items]

Principal amount

SFr 200,000

Loans (Details) - Schedule of L

Loans (Details) - Schedule of Loans - CHF (SFr)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule Of Loans Abstract
Convertible loan February 2022		SFr 4,898,377
Loans with warrants		871,420
Short-term loan from related party		100,000
Total		SFr 5,869,797

Loans (Details) - Schedule of C

Loans (Details) - Schedule of Convertible Loan Agreement - CHF (SFr)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule Of Convertible Loan Agreement Abstract
As of January 1	SFr 4,898,377
Gross proceeds at disbursement date	2,500,000	SFr 5,000,000
Embedded derivative, separated	(435,023)	(449,898)
Transaction costs allocated to host		(10,236)
Carrying amount at initial recognition	6,963,354	4,539,866
Repayment in cash	(285,562)
Converted principal amount	(7,214,438)
Accrued interest		447,945
Amortization	536,646	358,511
Total		5,346,322
Accrued interest balance of December 31		447,945
Convertible loan balance of December 31		SFr 4,898,377

Warrants from Public Offering (

Warrants from Public Offering (Details)				12 Months Ended
	Dec. 15, 2023 shares	Jul. 10, 2023 SFr / shares shares	Jul. 10, 2023 $ / shares shares	Dec. 31, 2023 CHF (SFr) shares	Dec. 31, 2023 USD ($) shares	Dec. 31, 2022 shares
Warrants from Public Offering [Line items]
Public offering				555,556	555,556
Pre funded warrants		511,806	511,806
Common shares	81,274	555,556	555,556	81,274	81,274
Public offering price (in Dollars per share) | (per share)		SFr 9	$ 9
Exercise price warrants (in Francs per share) | SFr / shares		SFr 8
Warrants granted		36,113	36,113
Strike price (in Francs per share) | SFr / shares		SFr 10
Exercise period		5 years	5 years
Pre-funded warrants were exercised (in Dollars) | $					$ 112,597
Value of warrants and prefunded warrants (in Francs) | SFr
Gross proceed offering cost				4,444,445	5,000,000
Attributable transaction costs				SFr 198,246	$ 728,728
Fair value assumptions volatility				107.34%	107.34%
Annual risk-free rate				4.25%	4.25%
CHF [Member]
Warrants from Public Offering [Line items]
Warrants issued				3,921,647	3,921,647
Warrants [Member]
Warrants from Public Offering [Line items]
Public offering		43,750	43,750
Warrants granted		36,113	36,113
Value of warrants and prefunded warrants (in Francs)				SFr 102,361	$ 112,597
Attributable transaction costs | SFr				SFr 639,873

Events After the Balance Shee_2

Events After the Balance Sheet Date (Details) $ in Thousands		12 Months Ended
	Jan. 19, 2024 USD ($) shares	Dec. 31, 2023 CHF (SFr) shares	Dec. 31, 2022 shares
Basis of Preparation [Abstract]
Share issued	637,460	1,477,785	59,003
Gross proceeds	$ 1,660	SFr 4,444,445